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Introduction from the Director of National Shared Services
The Health Service Reform Programme is driving 
unprecedented change in our healthcare system with 
the new Health Service Executive (HSE) in place 
since 1st January 2005. As the single largest reform 
project undertaken in the State, this programme 
offers an unparalleled opportunity to modernise and 
improve service provision to our clients, stakeholders 
and partners. By modernising our processes, 
technology and communication structures we can 
achieve economies of scale and strive to deliver value 
in the services we provide.
The former General Medical Services (Payments) 
Board is now known as the Primary Care 
Reimbursement Service (PCRS) and is part of the 
HSE’s National Shared Services Directorate. 
The PCRS is one of six Business Units within 
National Shared Services (NSS); other services to 
be provided by NSS are Finance, Human Resources, 
Information & Communication Technology, 
Procurement and Legal Services. The vision for 
National Shared Services is to deliver a customer-
focused National Shared Service to support health 
service delivery.
The core business of NSS PCRS is the processing 
and payment of claims on a national basis to 
key customers including General Practitioners, 
Pharmacists, Dentists and Optometrists/
Ophthalmologists for services they provide to 
members of the public. NSS PCRS captures large 
volumes of data from which it compiles statistics 
and we provide this information to our customers, 
stakeholders and the public. 
During 2005 we have worked with our customers 
to improve the service provided by combining the 
appropriate technology, with a professional service 
and efficient delivery. NSS PCRS processed more 
than 56 million transactions in 2005 and expenditure 
throughput amounted to e1.9 billion. Expenditure 
will grow to an estimated e2.1 billion in 2006. 
During 2005 NSS PCRS played an important role 
in providing a range of information to support the 
management of the various schemes, which are 
becoming increasingly complex. This Statistical 
Analysis Book reflects the many and varied Schemes 
and Payment Systems in operation.
The goodwill and cooperation received from all of 
our customers, General Practitioners, Pharmacists, 
Dentists, Optometrists/Ophthalmologists and our 
colleagues in the HSE, in a period of major change 
is very much appreciated. It is our aim to serve the 
interests of our customers in a professional and 
efficient manner. 
The ongoing commitment and dedication of our 
staff throughout the year to achieve targets and 
reach deadlines is acknowledged and appreciated. As 
Director of National Shared Services I look forward 
to further developing the business relationship and 
striving to continuously improve the services to our 
customers.
Laverne McGuinness 
Director of National Shared Services
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Community Based Services – Payment Arrangements
Almost all payments for services provided in the 
community by General Practitioners, Community 
Pharmacies, Dentists and Optometrists/
Ophthalmologists are made by the Primary Care 
Reimbursement Service. Payments in the Year 2005 
were in excess of 1.88bn. Estimated payments by 
the Primary Care Reimbursement Service for 2006 
are 2.07bn.
Claim data is processed and payments are made by 
the Primary Care Reimbursement Service under the 
following Schemes/Payment Arrangements:
General Medical Services (GMS)
Persons who are unable without undue hardship to 
arrange general practitioner medical and surgical 
services for themselves and their dependants and all 
persons aged 70 years and over receive a free general 
medical service.
Drugs, medicines and appliances supplied under the 
Scheme are provided through retail pharmacies. In 
most cases the Doctor gives a completed prescription 
form to a person, who takes it to any pharmacy that 
has an agreement with the Health Service Executive 
to dispense GMS prescription forms. In rural areas 
the Doctor may dispense for those persons who opt 
to have their medicines dispensed by him/her. All 
GMS claims are processed and paid by the Primary 
Care Reimbursement Service. 
Drugs Payment Scheme (DPS)
Under the Drugs Payment Scheme persons who are 
ordinarily resident in the State and who do not have 
a current medical card can benefit – an individual 
or family has now to pay no more than 85 in 
a calendar month for approved drugs, medicines 
and appliances for themselves or their families. In 
order to benefit under this Scheme a person must 
register themselves and their dependants with their 
Local Health Office. Items currently reimbursable 
under the Drugs Payment Scheme are those listed 
in the GMS Code Book. Other items which were 
reimbursable under the DCS and Refund of Drugs 
Schemes continue, in certain circumstances, to be 
reimbursable under the Drugs Payment Scheme. 
DPS claims are processed and paid by the Primary 
Care Reimbursement Service. 
Long Term Illness Scheme (LTI)
On approval by the Health Service Executive 
persons who suffer from one or more of a schedule 
of illnesses are entitled to obtain, without charge, 
irrespective of income, necessary drugs/medicines 
and/or appliances under the LTI Scheme. All LTI 
claims are processed and paid by the Primary Care 
Reimbursement Service.
Dental Treatment Services Scheme (DTSS)
Under the Dental Treatment Services Scheme GMS 
eligible adults have access to a range of treatments 
and clinical procedures comprised of Routine 
Treatments and Full Upper and Lower Dentures. 
Routine Treatments are now available for all eligible 
persons. Dentists may also prescribe a range of 
medicines to eligible persons. All claims under the 
DTSS are processed and paid by the Primary Care 
Reimbursement Service. 
European Economic Area (EEA)
Residents from one of the other states of the 
European Economic Area, with established eligibility, 
who require emergency general practitioner services 
while on a temporary visit to the State are entitled 
to receive from a General Practitioner a GMS 
prescription form for necessary medication and 
to have such medication dispensed in a Pharmacy 
that has entered into an agreement with the Health 
Service Executive within the State. Students, posted 
workers and their dependants are entitled to full 
services on presentation of a valid Form E128. EEA 
claims are paid by the Primary Care Reimbursement 
Service. 
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High Tech Drugs (HTD)
Arrangements are in place for the supply and 
dispensing of High Tech medicines through 
Community Pharmacies. Such medicines are 
generally only prescribed or initiated in hospital 
and would include items such as anti-rejection 
drugs for transplant patients or medicines used 
in conjunction with chemotherapy or growth 
hormones. The medicines are purchased by the 
Health Service Executive and supplied through 
Community Pharmacies for which Pharmacists are 
paid a patient care fee: the cost of the medicines 
and patient care fees are paid by the Primary Care 
Reimbursement Service.
Primary Childhood Immunisation Scheme
A National Primary Childhood Immunisation 
Scheme provides for immunisation of the total 
child population with the aim of eliminating, as 
far as possible, such conditions as Diphtheria, 
Polio, Measles, Mumps, Rubella and more recently 
Meningococcal C Meningitis. Payments under this 
Scheme to Doctors in the Midland, Mid-Western, 
Southern and Western HSE Areas are made by the 
Primary Care Reimbursement Service.
Health (Amendment) Act 1996
Under the Health (Amendment) Act 1996 certain 
health services are made available without charge to 
persons who have contracted Hepatitis C directly or 
indirectly from the use of Human Immunoglobulin 
– Anti D or the receipt within the State of another 
blood product or blood transfusion. General 
Practitioner services, pharmaceutical services, 
dental services and optometric/ophthalmic services 
provided under the Act are paid for by the Primary 
Care Reimbursement Service.
Methadone Treatment Scheme
Methadone is prescribed and dispensed by Doctors 
and Pharmacists for approved clients under the 
Methadone Treatment Scheme – capitation fees 
payable to participating Doctors and Community 
Pharmacists and claims by pharmacies for the 
ingredient cost of the Methadone dispensed and the 
associated dispensing fees are processed and paid by 
the Primary Care Reimbursement Service.
Health Service Executive Community 
Ophthalmic Services Scheme (HSE-COS)
Under the Health Service Executive Community 
Ophthalmic Services Scheme, adult medical card 
holders and their dependants are entitled, free 
of charge, to eye examinations and necessary 
spectacles/appliances. Claims by Optometrists/
Ophthalmologists are paid by the Primary Care 
Reimbursement Service. Claims for spectacles 
provided under the Children’s Scheme are also paid 
by the Primary Care Reimbursement Service.
Immunisations for certain GMS Eligible 
Persons
Agreement was reached between the Department 
of Health & Children and the Irish Medical 
Organisation on fee rates to be applied to certain 
immunisations for GMS eligible persons. The 
immunisations encompassed by the agreement 
are: Pneumococcal, Influenza, Hepatitis B and the 
combined Pneumococcal/Influenza. The Health 
Service Executive facilitated claiming for any of 
these immunisations by extending the range of codes 
for ‘Special Items of Service’.
General Practitioner Visit Card (GPVC)
Certain people in Ireland who do not qualify for 
a medical card may apply to the Health Service 
Executive for a GP Visit Card. GP Visit Cards 
allow individuals and families who qualify, to 
visit their General Practitioner for free. All GP 
claims are processed and paid by the Primary Care 
Reimbursement Service.
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Summary Statement of Activity During the Year
● Payments in the Year were in excess  
of €1,881.3m.
● Claim data is processed and payments are made 
by the PCRS under the following Schemes:
■ General Medical Services (GMS);
■ Drugs Payment (DP); 
■ Long Term Illness (LTI);
■ Dental Treatment Services (DTS);
■ European Economic Area (EEA);
■ High Tech Drugs (HTD);
■ Primary Childhood Immunisation;
■ Health (Amendment) Act 1996;
■ Methadone Treatment;
■ Health Service Executive Community 
Ophthalmic Services (HSE-COS).
● At year end there were more than 2.73m 
persons registered as being eligible to benefit 
under the General Medical Services, Drugs 
Payment, Long Term Illness, Dental Treatment 
and Health Service Executive Community 
Ophthalmic Services Schemes.
● More than 95% of eligible GMS persons 
availed of GP, Pharmaceutical, Dental or 
Ophthalmic services provided by more than 
5,612 Doctors, Pharmacists, Dentists and 
Optometrists/Ophthalmologists.
● More than 50.5m prescription items were  
paid for by the PCRS – an increase of over 
3.3m items on 2004.
● Fees and allowances paid to Doctors totalled 
€414.03m.
● Payments to Pharmacies totalled €1,198.14m;
■ GMS €831.44m;
■ DP €246.68m;
■ LTI €100.55m;
■ EEA €1.88m;
■ Patient Care Fees under the HTD Scheme 
€8.73m;
■ The Health (Amendment) Act 1996, 
Methadone Treatment Scheme and DTS 
prescriptions €8.86m.
● Payments to Dentists under the DTS totalled 
€54.46m.
● Payments to Optometrists/Ophthalmologists 
under the HSE-COS totalled €17m.
● Payments to Wholesalers under the HTD 
Scheme totalled €168.76m.
● Administration costs in the accounting period 
of 2005 were €17.01m.
● Claims processed are in respect of services 
provided in the community and availed  
of by almost 51.3% of the population.
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The Year 2005
Doctors Fees 291.33m 
 Allowances 122.70m
Pharmacists Fees and Mark-Up 283.82m 
 Drugs and Medicines 905.59m
Dentists  54.46m
High Tech Drugs Scheme Payment to Wholesalers 168.76m 
Patient Care Fees paid to Pharmacists 8.73m
Optometrists/Ophthalmologists 17.00m
Administration  17.01m
Investment in General Practice Development 11.93m
Total of Payments for the year €1,881.3m
● Fees to Doctors include an amount of 
€4.80m in respect of the Primary Childhood 
Immunisation Scheme, €0.23m in respect of 
the Health (Amendment) Act 1996, €4.08m in 
respect of the Methadone Treatment Scheme.
● Allowances paid to Doctors include an amount 
of €6.25m paid as superannuation to Retired 
District Medical Officers and their dependants.
● Payments to Pharmacists include an amount 
of €1.48m in respect of drugs/medicines 
dispensed under the Health (Amendment) Act 
1996, an amount of €6.78m in respect of the 
cost of Methadone dispensed under the 
 Methadone Treatment Scheme and an amount 
of €0.6m in respect of DTS prescriptions.
● Payments to Dentists include an amount of 
€55,922 in respect of treatments under the 
Health (Amendment) Act 1996.
● Payments to Optometrists/Ophthalmologists 
include an amount of €44,541 in respect of 
treatments under the Health (Amendment)  
Act 1996.
● The corresponding figures for 2004 are-
■ Total of Payments €1,652.83m.
■ Doctors’ Fees €220.91m and Doctors’ 
Allowances €96.59m.
■ Pharmacists’ Fees and Mark-Up €272.34m, 
Drugs and Medicines €813.56m.
■ Payments to Dentists under the DTS 
Scheme were €52.49m.
■ Payments to Optometrists/
Ophthalmologists €17.44m.
■ Investment in General Practice 
Development was €15.79m.
■ High Tech Drugs Scheme – Payment to 
Wholesalers €141.41m, Patient Care  
Fees €6.8m.
■ Administration €15.50m.
0 
Number of Agreements
2,257 Doctors 1,394 Dentists 531 Optometrists1,430 Pharmacists
The number of agreements between Health Service Executive and General Practitioners for the provision of services to GMS 
persons reflects the policy position agreed between the Department of Health & Children and the Irish Medical Organisation on 
entry to the GMS. In December 2005 there were 2,257 such agreements. 
Number of Agreements as at 31st December 2005
* 239 GPs who do not hold GMS agreements and who were registered as providing services under the Primary Childhood Immunisation Scheme, the Health 
(Amendment) Act 1996, Heartwatch, Palliative Care and the Methadone Treatment Scheme at year end are included above.
# 11 Pharmacies who do not hold GMS agreements and who were registered as providing services under non GMS Schemes at year end are included above.
+ 198 Dentists who are employees of the Health Service Executive and who provide services under the Dental Treatment Services Scheme are included above.
Health Service Executive Doctors Pharmacists Dentists Optometrists
East Coast Area 22 26 02 45
South Western Area 0 96 205 78
Northern Area 242 6 54 42
Midland 26 82 68 4
Mid-Western 24 7 02 42
North Eastern 62 26 0 50
North Western 4 79 64 0
South Eastern 222 5 2 5
Southern 89 227 04 79
Western 25 4 60 69
National *2,257 #1,430 +1,394 531
Corresponding Figures for 2004 2,20 , ,40 489
0 
Persons Eligible for Services
Persons who are unable without undue hardship to arrange General 
Practitioner medical and surgical services plus dental and optometric 
services for themselves and their dependants are provided with such 
services free of charge under the GMS Scheme. An eligible person 
is entitled to select a Doctor of his/her choice, from among those 
Doctors who have entered into agreements with the Health Service 
Executive. Drugs, medicines and appliances prescribed by participating 
Doctors for their GMS patients are provided through Community 
Pharmacies. Dental and ophthalmic services are provided by Dentists 
and Optometrists/Ophthalmologists who have contracted with the 
Health Service Executive. GMS prescription forms may be dispensed in 
any Pharmacy that has an agreement with the Health Service Executive 
to dispense GMS prescription forms. In rural areas, where a Doctor has 
a centre of practice three miles or more from the nearest retail Pharmacy 
participating in the Scheme, the Doctor dispenses for those persons 
served from the centre who opt to have their medicines dispensed by 
him/her. The number of eligible GMS persons at year end included 
53,808 persons who were entitled and had opted to have their medicines 
dispensed by their GPs.
Under the terms of the Drugs Payment Scheme persons who do not 
have a medical card may apply for a Drugs Payment Scheme card on 
an individual or on a family unit basis. Prescribed medicines, which are 
reimbursable under the GMS, costing in excess of a specified amount per 
month, currently €85 per family, is claimed by the Pharmacy and is paid 
by the Primary Care Reimbursement Service.
On approval by the Health Service Executive persons who suffer from 
one or more of a schedule of illnesses are entitled to obtain, without 
charge, irrespective of income, necessary drugs/medicines and/or 
appliances under the LTI Scheme. The Primary Care Reimbursement 
Service makes payments on behalf of the Health Service Executive for 
LTI claims submitted by Pharmacies.
GMS  1,155,727 
Number of Eligible Persons as at 31st December 2005
Health Service Executive
Eastern Areas  9,647 767  508,9  52,044
Midland 70,2 65  9,9  5,40
Mid-Western 00,688 26  5,566  7,00
North Eastern 99,566 648  0,9  7,888
North Western 98,95 72  64,25  5,492
South Eastern 9,620 96  5,560  9,96
Southern 7,586 ,245  248,02  6,852
Western ,582 07  0,9  4,657
National 1,155,727 5,079  1,478,650  99,280
% of Population 29.50%  0.13%  36.57%  2.46%
Corresponding Figures for 2004  ,48,94  - ,469,25 9,504
GMS - General Medical Services Scheme. GPVC - GP Visit Card Scheme. DP - Drugs Payment Scheme. LTI - Long Term Illness Scheme.
GPVC  5,079 DP  1,478,650 LTI  99,280
GMS GPVC DP LTI
2 
Payments to Doctors
Payments to General Practitioners are categorised as fees and/or 
allowances. For the majority of GPs who operate under the 1989 
agreement the principle fee is the capitation per person which is weighted 
for gender, age and distance from Doctor’s centre of practice – capitation 
fees totalled €206,098,590 in 2005 – an increase of €48,731,232 over 
2004. Fees totalling €1,803,460 were paid to 17 GPs who continue to 
provide services under the Fee-Per-Item of service agreements.
Apart from ‘Out-of-Hours’ fees and fees for a range of special services 
the cost of services provided in normal hours by GPs for GMS persons, 
including the prescribing of necessary medicines, is encompassed by the 
capitation fee. All GMS persons can avail of full GP services and in many 
cases they can benefit from specialist clinics provided by GPs for issues 
such as Women’s Health, Family Planning and Asthma.
In addition to a capitation fee an outside normal hours fee is payable for 
non routine consultations when an eligible GMS person is seen by their 
GP or another GP acting on his/her behalf from 5pm in the evening 
to 9am on the following morning (Monday to Friday) and all hours on 
Saturdays, Sundays and Bank Holidays. The number of ‘Out-of-Hours’ 
claims increased to 576,885 in 2005 compared with 547,001 in 2004 – 
and the cost of such claims increased to €33,506,917 from €24,354,181 
in 2004. Special fees are payable for a range of 18 services such as 
excisions, suturing, vaccinations, catheterization, family planning etc. the 
most frequent claimed special service in 2005 was Influenza Vaccination 
(299,094) followed by Excisions (68,152) and E.C.G treatments (49,929) 
– there was a total of more than 580,722 special services provided in 
2005 – special fees totalling €18,499,824 were paid in 2005.
Annual and Study Leave together with locum, nursing and secretarial 
support plus other practice support payments account for most of the 
€122,697,221 allowances paid in the year. The total paid in 2004 was 
€96,591,919.
 Fees 291.33m Allowances 122.70m
Total of Payments to Doctors by Health Service Executive
Health Service Executive 2005
East Coast Area €0,440,924
South Western Area €47,55,70
Northern Area €40,66,965
Midland €26,55,87
Mid-Western €5,695,
North Eastern €4,87,408
North Western €2,650,49
South Eastern €49,92,757
Southern €65,986,796
Western €50,7,07
National 414,025,306
Corresponding Figure for 2004 €7,499,98
The total of payments to Doctors includes payments of: €4,804,366 under the Primary Childhood Immunisation Scheme; €227,523 to Doctors who provided services 
under the Health (Amendment) Act 1996; Heartwatch €1,841,690; Trainers/Trainee Grants €1,808,360 and €4,080,640 under the Methadone Treatment Scheme.
The above figures include the arrears paid resulting from the implementation of the 2005 LRC Agreement.
2 
Volume of Claims by Doctors
Fee-Per-Item 101,608
Special Type 196,443
Special Service 580,722
Out-of-Hours 576,885
National – Number of Claims – 2005
Number of Claims in each Health Service Executive Area
Health Service Executive Fee-Per-Item Special Type Special Service Out-of-Hours
East Coast Area – 8,769 7,809 2,779
South Western Area 24,06 7,984 54,57 55,608
Northern Area 25,5 4,9 47,45 4,76
Midland – 8,425 9,559 7,70
Mid-Western 9,674 2,69 46,479 4,87
North Eastern – 9,678 45,768 9,254
North Western – 2,864 5,27 47,054
South Eastern 0,9 7,578 78,69 8,075
Southern 2,574 44,545 96,256 4,694
Western – 0,842 80,95 95,09
National 101,608 196,443 580,722 576,885
Corresponding figures for 2004 02,462 86,460 52,80 547,00
A majority of Doctors are paid an annual capitation fee for each eligible 
person – the rate of payment is determined by the age/gender of the 
person and distance between each person’s residence and the centre of 
practice of their Doctor-of-Choice. A minority of Doctors (17) who 
have continued to provide services under the Fee-Per-Item of Service 
agreement are paid a fee for each Doctor/Patient contact.
A Special Type Consultation (STC) fee is payable when a GMS eligible 
person is unable to contact their registered Doctor and is seen as an 
emergency case by another. General Practitioners qualify for payment of 
‘special fees’ for the special items of service separately identified under 
the Capitation agreement and the Fee-Per-Item agreement.
4 5
Payments to Pharmacies
A GMS person who is provided with a properly completed GMS 
prescription form by his/her GP can choose to have such prescription 
forms dispensed in any of the Pharmacies who have entered into 
agreements with the Health Service Executive for the provision of 
services under Section 59 of the Health Act, 1970.
In 2005 there were 13.2m prescription forms containing 37m prescription 
items dispensed at a cost of over €816,303,561 i.e. an average cost of 
€21.81 per dispensed item. More than 95% of all eligible GMS persons 
were prescribed for in the year. The average cost of medicines per GMS 
person in 2005 was €750.04.
Payments made to Pharmacies under the GMS and DTS Schemes are 
inclusive of the ingredient cost of medicines, dispensing fees and VAT.
Under DP, LTI and EEA Schemes Pharmacies are reimbursed the 
ingredient cost of items dispensed; dispensing fees and VAT; a markup of 
up to 50% on the ingredient cost of items dispensed is also paid.
The cost of the High Tech Drugs Scheme was €177.48m – at year end 
there were 31,510 persons registered under this Scheme – Patient Care 
Fees totalled €8.7m and payments for drugs and medicines totalled 
€168.76m.
In the year the Primary Care Reimbursement Service processed claims 
valued at e318.6m on drugs acting on the ‘cardiovascular system’ (GMS 
e200.68m, DP e97.72m, LTI e20.20m). The second highest cost 
category was drugs acting on the ‘nervous system’ e237.01m (GMS 
e164.84m, DP e58.16m, LTI e14.01m). The third highest amount 
paid was for drugs acting on the alimentary tract and metabolism system 
e212.85m (GMS e126.64m, DP e57.83m, LTI e28.38m).
 GMS €831.44m DP €246.68m LTI €100.55m EEA €1.88m
Total of Payments to Pharmacies by Health Service Executive
Health Service Executive GMS  DP  LTI  *EEA 
East Coast Area 59,006,09 2,4,2 2,4,274 64,0
South Western Area 94,74,86 4,200,688 7,784,470 2,07
Northern Area 9,89,00 5,95,992 5,62,47 62,92
Midland 57,9,2 4,05, 5,940,055 77,502
Mid-Western 76,58,70 20,726,49 6,557,278 84,670
North Eastern 72,27,28 20,564,876 8,928,228 9,68
North Western 5,75,449 8,422,499 5,54,647 249,9
South Eastern 02,86,94 2,996,49 0,267,489 27,992
Southern ,06,75 7,7,22 ,597,622 42,790
Western 90,894,45 8,84,555 6,660,4 8,257
National 831,442,623 244,485,938 100,546,643 1,879,609
Corresponding Figures for 2004 e76,8,07 e22,958,894 e85,55,069 e,79,527
* EEA – Payment to Pharmacies to cover the cost of GMS prescriptions dispensed for residents from the European Economic Area.
Pharmacies were also paid in respect of the drugs/medicines dispensed under: Health (Amendment) Act 1996 – €1,483,077; Methadone Treatment Scheme 
– €6,780,362; DTS Scheme – €598,687 and Patient Care Fees totalling €8,726,632 under the High Tech Drugs Scheme. (Payments to Wholesalers under the High 
Tech Drugs Scheme amounted to €168,757,201).
In 2005 The National Maternity Hospital was paid €496,813 and The Rotunda Hospital was paid €1,700,415 in respect of Fertility Treatment. These figures are not 
included in the above table.
4 5
Volume of Claims by Pharmacies
EEA 0.08m
HTD 0.21m
Other 0.33m
LTI 1.93m
DP 10.58m
GMS 37.43m
National – Number of Items – 2005
GMS prescription forms processed for payment in the year totalled 13.2m 
– the total of prescribed items was more than 37m – these accounted 
for approximately 74% of all items paid for by the Primary Care 
Reimbursement Service in 2005.
Approximately 38.83% of GMS forms contained a single item; more 
than 20.15% contained 2 items – the average number of items per form 
was 2.83 (2004 – 2.74).
GMS dispensed items paid for by the Primary Care Reimbursement 
Service in 2005 increased by more than 2,397,521 – the increase in 
the number of DP items was more than 649,055 – the overall increase 
in the number of pharmacy claims processed by the Primary Care 
Reimbursement Service in the year was more than 3.3m.
Number of Items in each Health Service Executive Area
Health Service Executive GMS DP LTI EEA HTD *Other
East Coast Area 2,700,20 ,05,67 27,76 ,9 6,72 2,657
South Western Area 4,47,74 ,627,75 ,906 4,742 27,824 0,9
Northern Area 4,066,787 ,47,69 29,09 2,77 22,8 85,562
Midland 2,5,68 648,992 ,245 ,94 ,074 9,66
Mid-Western ,508,6 9,744 9,286 8,46 6,058 4,86
North Eastern ,256,4 946,459 70,74 4,95 9,647 4,984
North Western 2,67,62 65,789 06,485 ,2 5,29 6,66
South Eastern 4,629, ,22,97 205,67 9,88 22,75 7,548
Southern 6,080,556 ,622,59 225,90 9,02 28,842 22,868
Western ,869,66 806,922 2,664 4,70 24,057 ,94
National 37,427,774 10,581,689 1,929,111 81,965 206,641 328,119
Corresponding Figures for 2004 5,00,25 9,92,64 ,674,707 80,50 77,97 29,625
* This group includes: 48,975 claim items in respect of the Health (Amendment) Act 1996; 203,385 items under the Methadone Treatment Scheme and 75,759 prescription items under the DTS Scheme.
GMS – General Medical Services Scheme. DP – Drugs Payment Scheme. LTI – Long Term Illness Scheme. EEA – European Economic Area. HTD – High Tech Drugs Scheme. 
Other – Methadone Treatment Scheme, Health (Amendment) Act 1996 and Dental Treatment Services Scheme.
6 7
Payments to Dentists
Dentists were paid a total of €54,402,901 in 2005, in respect of 
treatments provided for more than 242,865 GMS persons under the 
DTS Scheme.
The following treatments were available to all eligible GMS persons.
ROUTINE: Routine treatments are categorised as either ‘Above the 
Line’ or ‘Below the Line’: 
 ‘Above the Line’ treatments are uncomplicated 
procedures viz. Amalgam; Extractions; 
 ‘Below the Line’ treatments are advanced procedures 
viz. Protracted Periodontal; Prosthetics.
‘Below the Line’ treatments – prior Health Service Executive approval 
for a specific course of treatment under this category is required. Full 
denture treatment is available, with prior Health Service Executive 
approval, to all edentulous GMS persons over 16 years. 
 Above the line €35.63m Below the line €18.77m
Payments to Dentists in each Health Service Executive Area
Health Service Executive 2005
Eastern Areas €4,472,
Midland €,00,007
Mid-Western €4,787,246
North Eastern €4,448,08
North Western €,808,98
South Eastern €6,774,99
Southern €9,689,962
Western €7,420,460
National €54,402,901
Corresponding Figure for 2004 e 52,42,828
Dentists were also paid a total of €55,922 in 2005 in respect of treatments under the Health (Amendment) Act 1996.
6 7
Volume of Claims by Dentists
Above the Line  962,936
Below the Line 106,466
National – Volume of Treatments – 2005
Volume of Treatments by Dentists in each Health Service Executive Area
Health Service Executive +Above the Line +Below the Line No. of persons treated  
   under DTS 
Eastern Areas 264,54 26,094 6,982
Midland 5,924 6,728 ,64
Mid-Western 82,458 0,8 22,26
North Eastern 77,27 9,795 20,40
North Western 75,7 5,29 8,87
South Eastern 5,584 4,822 29,7
Southern 78,04 7,445 44,929
Western 8,22 5,420 29,594
National 962,936 106,466 242,865
Corresponding Figures for 2004 968,665 04,850 27,828
ROUTINE –  Routine treatments are categorised as either ‘Above the Line’ or ‘Below the Line’:
 ‘Above the Line’ (ATL) treatments are uncomplicated procedures;
 ‘Below the Line’ (BTL) treatments are advanced procedures.
+ The most frequently used ATL service was Amalgam Restoration, which was used by 94,187 patients followed by Oral Examination.  
In the BTL category the most frequently used service was Prosthetics followed by Radiographs and Protracted Periodontal.
8 9
Under the Health Service Executive Community Ophthalmic Services 
Scheme, Optometric/Ophthalmic services are provided to adult 
medical cardholders, which include free eye examinations and necessary 
spectacles/appliances.
Payments in respect of spectacles provided under the Children’s Scheme 
are also made by the Primary Care Reimbursement Service on behalf of 
the majority of Health Service Executive Areas.
Payments in respect of eye examinations and necessary spectacles/
appliances are provided under the Teenager’s Scheme for eligible medical 
card holders on behalf of certain Health Service Executive Areas.
In the 12-month period to the end of December 2005 claims were 
received on behalf of eligible persons for 175,093 treatments costing 
€15,833,940. 
Eye examinations by Optometrists/Ophthalmologists totalled 168,400 
- complete spectacles (distance, reading and bi-focals) provided under 
the Scheme totalled 249,133. The balance of treatments included 
replacement lenses and frames, tinted lenses, prisms and contact lenses. 
A breakdown of treatments and payments in each Health Service 
Executive area is shown hereunder.
Payments to Optometrists/Ophthalmologists in each Health Service Executive Area
Health Service Executive 2005
Eastern Areas €4,77,686
Midland €,075,79
Mid-Western €,409,20
North Eastern €,225,70
North Western €,28,706
South Eastern €2,98,744
Southern €2,48,926
Western €,40,759
National €15,833,940
Corresponding Figure for 2004 e6,27,620
Opticians were also paid in respect of: Health (Amendment) Act 1996 €44,541; Optical services for Teenagers €83,210; Optical services for Children €1,038,488.
Payments to Optometrists/Ophthalmologists
8 9
Volume of Treatments by Optometrists/Ophthalmologists
Eye Exams 168,400
Appliances 249,133
GMS %1,093.39
LTI %1,896.89
DP %464.76
DTS %215.89
HSE-COS %90.43
C - 25.19%
N - 14.99%
A - 14.90%
R - 11.49%
V - 3.60%
Other - 29.83%
C - 24.14%
N - 19.83%
A - 15.23%
R - 8.95%
V - 7.73%
Other - 24.12%
V - 30.77%
A - 28.23%
C - 20.10%
N - 13.93%
Other - 6.97%
National – Volume of Treatments – 2005 
Volume of Treatments by Optometrists/Ophthalmologists in each Health Service Executive Area
Health Service Executive Eye Exams Appliances Volume of  No. of Persons 
   Treatments  Treated 
Eastern Areas 50,666 72,555 2,22 52,00
Midland 0,7 5,804 26,4 ,49
Mid-Western 4,044 2,474 7,58 5,648
North Eastern ,66 20,054 ,420 ,50
North Western 4,902 20,490 5,92 5,00
South Eastern 2,26 6,8 59,79 24,695
Southern 26,48 7,722 64,070 26,744
Western 5,476 22,96 8,92 6,024
National 168,400 249,133 417,533 175,093
Corresponding Figures for 2004 65,526 248,658 44,84 7,55
20 2
Cost per Person in each Health Service Executive Area
   GMS  LTI DP DTS HSE-COS
Health Service  Doctor Pharmacy Total Pharmacy Net Cost Per Person Per Adult
Executive Cost Cost Cost Cost Per Claimant Treated Treated
        
Eastern Areas 2.9 727.2 ,060.05 2,000.94 54.26 224.64 9.7
Midland  5.48 8.55 ,87.0 ,927.96 429.47 200.25 94.79
Mid-Western  2.44 776.40 ,08.84 ,6.90 425.0 200.9 90.06
North Eastern 8.74 775.9 ,.9 ,877.65 4.02 207.5 90.7
North Western 22.96 629.0 95.97 ,80.85 442.68 84.09 85.0
South Eastern 49.6 764.57 ,4.8 ,84.7 48.76 26.82 89.04
Southern 6.87 789.96 ,5.8 ,854.7 47.85 20.44 9.20
Western 60.7 79.60 ,00. ,78.7 40.45 248.7 89.29
National 343.35 750.04 1,093.39 1,896.89 464.76 215.89 90.43
Corresponding  
Figures for 2004 €26.5 €692.7 €954.26 €,69.2 €448.22 €220.47 €9.98
The Doctor cost above does not include superannuation paid to retired DMOs.
The above table shows the actual cost per person in respect of those who availed of services under each Scheme in 2005.
Medical and pharmaceutical services delivered to GMS persons increased in cost from 6954.26 in 2004 to 61,093.39 in 2005 an increase of 6139.13 per person - the cost of  
medical services per person increased in cost from 6261.53 in 2004 to 6343.35 in 2005 an increase of 31.29% as did the cost per person of pharmaceutical services 6692.73  
in 2004 to 6750.04 in 2005 an increase of 8.27%.
Cost per Person
National 2005
Eye Exams 168,400
Appliances 249,133
GMS %1,093.39
LTI %1,896.89
DP %464.76
DTS %215.89
HSE-COS %90.43
C - 25.19%
N - 14.99%
A - 14.90%
R - 11.49%
V - 3.60%
Other - 29.83%
C - 24.14%
N - 19.83%
A - 15.23%
R - 8.95%
V - 7.73
Other - 24.12%
V - 30.77%
A - 28.23%
C - 20.10%
N - 13.93%
Other - 6.97%
20 2
Major Therapeutic Classification     m   %
A Alimentary Tract and Metabolism 126.64  15.23 
B Blood and Blood Forming Organs  7.9  4.50 
C Cardiovascular System 200.68  24.14
D Dermatologicals  6.84  2.0
G Genito Urinary System and Sex Hormones  .7  .8
H Systemic Hormonal Preps. excl. Sex Hormones and Insulins 7.26  0.87
J Anti-infectives for Systemic Use  .07  .74
L Antineoplastic and Immunomodulating Agents  7.4  0.88
M Musculo-Skeletal System  5.08  6.8
N Nervous System 164.84  19.83
P Antiparasitic Products, Insecticides and Repellents  0.6  0.07
R Respiratory System  74.44  8.95
S Sensory Organs  5.27  .84
V Clinical Nutritional Products  0.64  .69  
 Diagnostic Products  4.5  .75 
 Ostomy Appliances  9.5  .0 
 Urinary Appliances  .26  0.9  
 Needles/Syringes/Lancets  2.48  0.0 
 Other Therapeutic Products  .65  0.20 
 Dressings  .5  0.8 
 Miscellaneous  .0  0.2
 Total 831.44m 100%
Major Therapeutic Classification of Drugs, Medicines and Appliances - General Medical Services Scheme
National 2005
Eye Exams 168,400
Appliances 249,133
GMS %1,093.39
LTI %1,896.89
DP %464.76
DTS %215.89
HSE-COS %90.43
C - 25.19%
N - 14.99%
A - 14.90%
R - 11.49%
V - 3.60%
Other - 29.83%
C - 24.14%
N - 19.83%
A - 15.23%
R - 8.95%
V - 7.73%
Other - 24.12%
V - 30.77%
A - 28.23%
C - 20.10%
N - 13.93%
Other - 6.97%
22 2
Major Therapeutic Classification     m   %
A Alimentary Tract and Metabolism 57.83 14.90 
B Blood and Blood Forming Organs 2.5  .8
C Cardiovascular System 97.72 25.19
D Dermatologicals 8.82  4.85
G Genito Urinary System and Sex Hormones  28.88  7.44 
H Systemic Hormonal Preps. excl. Sex Hormones and Insulins 2.87  0.74
J Anti-infectives for Systemic Use 8.00  4.64
L Antineoplastic and Immunomodulating Agents 5.5  .8
M Musculo-Skeletal System 24.8  6.40
N Nervous System 58.16 14.99
P Antiparasitic Products, Insecticides and Repellents 0.55  0.4 
R Respiratory System 44.58 11.49
S Sensory Organs 4.2  .06
V Clinical Nutritional Products 6.0  .56 
 Ostomy Appliances 4.4  .4 
 Urinary Appliances .29  0. 
 Diagnostic Products 0.87  0.22 
 Dressings 0.46  0.2 
 Needles/Syringes/Lancets 0.9  0.05 
 Other Therapeutic Products 0.40  0.0 
 Miscellaneous 0.  0.08
 Total 388.02m  100%
Major Therapeutic Classification of Drugs, Medicines and Appliances - Drugs Payment Scheme
National 2005
Note: The above costs are inclusive of the monthly payment of €85 payable to the Pharmacy by the individual or family. 
Eye Exams 168,400
Appliances 249,133
GMS %1,093.39
LTI %1,896.89
DP %464.76
DTS %215.89
HSE-COS %90.43
C - 25.19%
N - 14.99%
A - 14.90%
R - 11.49%
V - 3.60%
Other - 29.83%
C - 24.14%
N - 19.83%
A - 15.23%
R - 8.95%
V - 7.73%
Other - 24.12%
V - 30.77%
A - 28.23%
C - 20.10%
N - 13.93%
Other - 6.97%
22 2
Major Therapeutic Classification     m   %
A Alimentary Tract and Metabolism 28.38 28.23 
B Blood and Blood Forming Organs .95 .94
C Cardiovascular System 20.20 20.10 
D Dermatologicals 0.6 0.5
G Genito Urinary System and Sex Hormones 0.92 0.92
H Systemic Hormonal Preps. excl. Sex Hormones and Insulins 0.72  0.72
J Anti-infectives for Systemic Use .85 .84
L Antineoplastic and Immunomodulating Agents 0.09 0.09
M Musculo-Skeletal System 0.6 0.62
N Nervous System 14.01 13.93
P Antiparasitic Products, Insecticides and Repellents 0.00 0.00
R Respiratory System 0.5 0.5
S Sensory Organs 0.6 0.6
V Diagnostic Products 20.40 20.28 
 Clinical Nutritional Products 4.80 4.78 
 Needles/Syringes/Lancets/Swabs .65 .6 
 Urinary Appliances 0.78 0.77 
 Nutritional/Ancillary Devices 0.65 0.65 
 Dressings 0. 0. 
 Ostomy Appliances 0.6 0.6 
 Other Therapeutic Products 0.05 0.05 
 Miscellaneous 0.2 0.2
 Total 100.54m 100%
Major Therapeutic Classification of Drugs, Medicines and Appliances – Long Term Illness Scheme
National 2005
Eye Exams 168,400
Appliances 249,133
GMS %1,093.39
LTI %1,896.89
DP %464.76
DTS %215.89
HSE-COS %90.43
C - 25.19%
N - 14.99%
A - 14.90%
R - 11.49%
V - 3.60%
Other - 29.83%
C - 24.14%
N - 19.83%
A - 15.23%
R - 8.95%
V - 7.73%
Other - 24.12%
V - 30.77%
A - 28.23%
C - 20.10%
N - 13.93%
Other - 6.97%
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Summary of Statistical Information relating to the GMS Scheme for each of the five years 2001-2005
2005 2004 2003 2002 2001
Number of Eligible Persons in December ,55,727 ,48,94 ,58,4 ,68,745 ,99,454
Doctors (000’s) (000’s) (000’s) (000’s) (000’s)
Total Payments €40,07 €06,250 €286,80 €27,99 €20,86
Doctors’ Payment per Person €4.5 €26.5 €247.66 €22.5 €69.46
Pharmacies (000’s) (000’s) (000’s) (000’s) (000’s)
Total Cost of Prescriptions €86,04 €747,905 €66,566 €57,874 €422,464
Ingredient Cost €65,25 €585,22 €50,578 €42,269 €29,497
Dispensing Fee €47,860 €49,08 €2,5 €04,827 €85,4
VAT €5,9 €,702 €,87 €9,778 €7,554
Number of Forms ,227 2,794 2,24 ,55 0,454
Number of Items 7,428 5,00 2,24 29,500 25,52
Cost per Form €6.7 €58.46 €5.99 €46.57 €40.4
Cost per Item €2.8 €2.5 €9.74 €8.24 €6.55
Ingredient Cost per Item €7.45 €6.70 €5.62 €4.5 €2.9
Items per Form 2.8 2.74 2.6 2.55 2.44
(000’s) (000’s) (000’s) (000’s) (000’s)
Total Cost of Stock Orders €5,9 €5,4 €4,096 €,08 €,555
Ingredient Cost €,74 €,944 €0,904 €0,059 €8,945
Pharmacy Fees €2,927 €2,986 €2,726 €2,55 €2,222
VAT €498 €48 €466 €444 €88
(000’s) (000’s) (000’s) (000’s) (000’s)
Overall Cost of Medicines €8,44 €76,8 €650,662 €550,892 €44,09
*Pharmacy Payment per Person €750.04 €692.7 €595.6
Overall Payments €1,234,514 €1,069,568 €937,493 €822,831 €637,882
*Overall Payment per Person €1,093.39 €954.26 €842.82
Doctors’ payment per person is exclusive of superannuation paid to retired DMOs.
*Since 2003 these figures are based on the actual number of persons who availed of services.
24 25
Summary of Statistical Information relating to the LTI/DP Schemes for each of the five years 2001-2005
*Since 2003 these figures are based on the actual number of persons who availed of services under each Scheme.
2005 2004 2003 2002 2001
LTI Scheme
Number of Eligible Persons in December 99,280 9,504 97,84 92,745 87,988
*Number of Claimants 5,006 50,526 48,05
(000’s) (000’s) (000’s) (000’s) (000’s)
Number of Items ,929 ,675 ,464 ,280 ,57
Total Cost €00,547 €85,55 €7,48 €6,66 €52,08
Cost per Item €52.2 €5.08 €50. €48.5 €44.98
*Cost per Claimant €,896.89 €,69.2 €,526.40
DP Scheme
Number of Eligible Persons in December ,478,650 ,469,25 ,96,8 ,9,95 ,56,86
*Number of Claimants 526,052 499,664 474,4
(000’s) (000’s) (000’s) (000’s) (000’s)
Number of Items 0,582 9,9 9, 9,06 8,985
Gross Cost €88,02 €5,44 €5,82 €287,489  €262,87
Net Cost €244,486 €22,959 €204,422 €92,66 €77,67
Gross Cost per Item €6.67 €5.5 €.92 €.72 €29.8
*Net Cost per Claimant €464.76 €448.22 €40.90
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Fees and Allowances under Capitation Agreement as at 31st December 2005
Above rates inclusive of supplementary Out-of-Hours Fee.
Up to 3 Miles 3-5 Miles 5-7 Miles 7-10 Miles  Over 10 Miles
Ages Male € Female € Male € Female € Male € Female € Male € Female €  Male € Female €
Under 5 years 77.57 75.75 8.50 79.70 87.0 85.54 9.04 9.28 00.5  98.8
5 – 5 46.54 47.0 48.7 48.65 50.56 5. 52.88  5.9 55.80  56.25
6 – 44 58.40 9.2 60.52 95. 6.64 98.4  66.7 0.00 70.47 05.26
45 – 64 .05 2.86 8.2  28.9  25.60 6.40 2.98 4.8 42.6 52.94
65 – 69 8.90 2.2 .00  46.4  5.94  67.26 74.48 87.82 200.04 2.4
70 and over 29.62 4.6 44.4  57.92  65.78  79.5 87.00 200.77 2.8 227.8
The Capitation rate is €594 per annum for persons aged 70 years and over in the community issued with a medical card for the first time regardless 
of income. A Capitation rate of €861 per annum will apply to anyone aged 70 years and over in a private nursing home (approved by the Health 
Service Executive) for continuous periods in excess of five weeks. 
Out-of-Hours Payment  
Surgery €44.76 
Domiciliary
Up to  miles €44.76
 - 5 miles €59.7
5 - 7 miles €67.24
7 - 0 miles €74.6
Over 0 miles €89.58 
Additional Fee €4.94
*Special Items of Service
(i) to (ix) €27.99
(x) and (xi) €42.0
(xii) €70.02
(xiii) €47.
(xiv) €75.4
(xv) and (xvi) €7.78 
(xvii) €56.67
(xviii) €6.24
 +Mileage
Temporary Residents 
Surgery €44.76
Domiciliary
Up to  miles €44.76
 - 5 miles €59.7
5 - 7 miles €67.24
7 - 0 miles €74.6
Over 0 miles €89.58 
Rural Dispensing Fee €.62
Fee for Second Medical Opinion €29.87
Practice Payments for Rural Areas
Rural Practice Allowance  
Per Annum €8,07.08
Practice Support
Allowance for Practice Secretary  
up to a maximum Per Annum of €24,586.82 
Allowance for Practice Nurse up  
to a maximum Per Annum of €8,66.45
Contributions to Locum Expenses
(Subject to the conditions of the Agreement)
Annual Leave  Up to a maximum of 
Sick Leave €,558.66 per week
Study Leave  Up to a maximum of 
Maternity Leave  €222.67 per day
Paternity Leave
Contributions to Medical  
Indemnity Insurance
Calculation of contribution is related  
to GMS panel numbers and net premium.
Asylum Seekers
A one off superannuable registration fee of
€72.2 per relevant patient will be paid to
Doctors in respect of each such patient on 
their GMS Scheme panels.
* Special Items of Service. 
(i) Excisions/Cryotherapy/ 
Diathermy of Skin Lesions.
(ii) Suturing of Cuts and Lacerations.
(iii) Draining of Hydroceles.
(iv) Treatment and Plugging  
of Dental and Nasal 
Haemorrhages.
(v) Recognised Vein Treatment.
(vi) ECG Tests and their 
Interpretation.
(vii) Instruction in the fitting 
of a Diaphragm.
(viii) Removal of Adherent 
Foreign Bodies from the 
Conjunctival Surface of the Eye.
(ix) Removal of Lodged or Impacted 
Foreign Bodies from the Ear, 
Nose and Throat.
(x) Nebuliser Treatment  
in the case of Acute Asthmatic 
Attack. 
(xi) Bladder Catheterization.
(xii) Attendance at case conferences 
(in cases where such are 
convened by the HSE).
(xiii) Advice and Fitting  
of a Diaphragm.
(xiv) Counselling and  
Fitting of an IUCD.
(xv) Pneumococcal Vaccination.
(xvi) Influenza Vaccination.
(xvii) Pneumococcal/Influenza 
Vaccination.
(xviii) Hepatitis B Vaccination.
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Fees and Allowances under the Fee-Per-Item Agreement and Fees under the Immunisation Scheme, 
Health (Amendment) Act 1996 and Methadone Treatment Scheme as at 31st December 2005
Surgery Consultations
Day Normal Hours €2. 
Late Outside Normal Hours other than (Night) €7.5 
Night Midnight to 8.00 a.m. €4.68
Domiciliary Consultations
Day Normal Hours  
 Urban €8.9 
 Up to  miles €8.9 
  - 5 miles €2.82 
 5 - 7 miles €2.00 
 7 - 0 miles €40.2 
 Over 0 miles €50.7
Late Outside Normal Hours  
 Urban €2.82 
 Up to  miles €2.82 
  - 5 miles €0.82 
 5 - 7 miles €40.2 
 7 - 0 miles €5.0 
 Over 0 miles €62.50
Night Midnight to 8.00 a.m.  
 Urban €46.7 
 Up to  miles €46.7 
  - 5 miles €60.0 
 5 - 7 miles €75.94 
 7 - 0 miles €84.7 
 Over 0 miles €9.99
Emergency Fee/EEA Fee (Additional to Standard Fee) €.49
Dispensing Fee €.49
Rural Practitioner’s Allowance 
Per Annum €7,95.07
Locum and Practice Expense Allowance 
Per Annum €,547.86
Sessional Rate - Homes for the Aged 
Per  Hour Session €82.62
* Special Items of Service 
(i) to (vii) €25.2 
(viii) and (ix) €7.78 
(x) €56.67 
(xi)  €6.24
Immunisation Fees 
(i) Registration of child with a GP €6.0 
(ii) Complete course of immunisation   
 against PT/DT; Hib; Polio and MMR  €20.28 
(iii) 95% uptake bonus €57.9
Health (Amendment) Act 1996 
Surgery Fee €4.46 
Domiciliary Fee €45.45
Methadone Treatment Scheme 
Level  Contractor €4.40 
Level 2 Contractor €55.94
* Special Items of Service. 
(i) Excisions/Cryotherapy/ 
Diathermy of Skin Lesions.
(ii) Suturing of Cuts and 
Lacerations.
(iii) Draining of Hydroceles.
(iv) Treatment and Plugging 
of Dental and Nasal 
Haemorrhages.
(v) Recognised Vein Treatment.
(vi) ECG Tests and their 
Interpretation.
(vii) Instruction in the fitting of a 
Diaphragm.
(viii) Pneumococcal Vaccination.
(ix) Influenza Vaccination.
(x) Pneumococcal/Influenza 
Vaccination.
(xi) Hepatitis B Vaccination.
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Scale of Fees Payable to Participating Pharmacists as at 31st December 2005
High Tech Medicines Scheme
Reimbursement of ingredient cost plus 50% mark-up on ingredient cost plus Standard Fee - €2.86 (Note 1)
20% mark-up on Incontinence Products and Dressings under DP Scheme
Extemporaneously dispensed preparations are reimbursed at current private prescription rates. In the case of the Drugs Payment Scheme  
the PCRS makes payments to Pharmacies in respect of authorised Patients whose monthly costs of prescribed drugs and medicines are  
in excess of the specified monthly amount (currently 85) payable to the Pharmacy by an individual or family.
Note 1 The standard fee is an all inclusive fee which includes container and broken bulk allowance.
Patient Care Fee: 54.82 per month.
Methadone Treatment Scheme 
Patient Care Fee: Up to a Maximum of 54.80 per month.
DP/LTI/EEA Schemes and Health (Amendment) Act 1996
GMS Scheme E
Standard Fee-Per-Item (Note 1) .26
Extemporaneous Fee 6.28
Extemporaneous dispensing and compounding of 
- Powders  8.8 
- Ointments and Creams 2.56
Controlled Drugs 5.07
Non-Dispensing - exercise of professional judgement .4
Phased Dispensing - each part of phased dispensing .4
Urgent/Late Dispensing 
Additional fee for Urgent/Late dispensing other than between midnight and 8.00 a.m. (Note 2) 8.8
Additional fee for Urgent/Late dispensing between midnight and 8.00 a.m. 8.24
Note 1 e2.78 basic fee and e0.48 allowance for containers, obsolescence etc.
Note 2 Urgent fee prescriptions are those so specified by the prescriber and necessarily dispensed outside normal hours. Late fee prescriptions are 
  those which, though not marked urgent, are in exceptional circumstances necessarily dispensed outside normal hours by the Pharmacist, 
  having regard to the person’s requirements.
Note 3 A Standard Fee-Per-Item is also payable on prescription forms issued by Dentists under the DTS Scheme.
Note 4 A Fee-Per-Item of €4.21 is also payable on prescription forms in respect of persons aged 70 years and over issued with a medical card for 
  the first time regardless of income.
Supplies to Dispensing Doctors 
Pharmacies supplying Dispensing Doctors are reimbursed on the basis of the basic trade price with the addition of 25% on cost.
28 29
Scale of Fees Payable under the Dental Treatment Services Scheme as at 31st December 2005
Treatment Type Routine 
  E
Oral Examination 29.9
Prophylaxis  28.0
Restoration (Amalgam) 45.2
Restoration (Composite) 6 anterior teeth only 46.86
Exodontics (Extraction under local anaesthetic) 5.72
Surgical Extraction - Maximum  units:  
 Fee payable for each 5 minute unit  .8
 Maximum 95.4
st Stage Endodontic Treatment (Anterior teeth only) 5.75
Denture Repairs 
 st Item of Repair 4.5
 Each Subsequent Item  .9
 Maximum 67.5
Apicectomy/Amputation of Roots  *Dentist Estimate
Endodontics (Anterior teeth only) *Dentist Estimate
Protracted Periodontal Treatment *Dentist Estimate
Radiographs  
  Film 22.8
 2 or more Films .8
 Panoramic 7.46
Miscellaneous   
 (e.g. Abcess, Haemorrhage, Dressings etc.)  20.46
Prosthetics 
 Full Upper or Lower Denture  280.50
 (Other than Edentulous Persons) 
 Partial Upper or Lower Acrylic Denture  205.74
 Complete Upper or Lower Reline 2.29
 Complete Upper and Lower Reline 86.9
Full Upper and Lower Denture (Edentulous Persons Only)  4.64
* Dentist Estimates are subject to agreement between a Dentist and the Health Service Executive Area.
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Scale of Fees Payable under the Health Service Executive Community Ophthalmic Services Scheme
As as 31st December 2005 E
Examinations  
Eye Examination Ophthalmic Optician 2.57 
Eye Examination Ophthalmologist/  
 Ophthalmic Medical Practitioner 24.48 
Medical Eye Examination by Ophthalmologist 48.96 
Eye Examination for Contact Lenses (Grant) 67.7 (H)
Eye Examination Ophthalmic (Dilation) 4.4 
Appliances  
Single Vision Complete Appliances  
Spectacles – Distance 4.2 
Spectacles - Reading 4.2 
Spectacles - Uncollected 28.6 
Contact Lenses (Pair) 4.2 
Contact Lenses Standard or Disposable per pair (Grant) 6.89 (H)
Single Vision Spectacles - with Glass Lenses Distance 2.25 (H)
Single Vision Spectacles - with Glass Lenses Reading 2.25 (H)
Single Vision Spectacles - with Plastic Lenses Distance 0.28 (H)
Single Vision Spectacles - with Plastic Lenses Reading 0.28 (H)
Single Vision Lenses to Own Frame  
Replacement Distance Lens () to own frame 6.02 
Replacement Distance Lenses (2) to own frame 2.04 
Replacement Reading Lens () to own frame 6.02 
Replacement Reading Lenses (2) to own frame 2.04 
Single Vision Lenses to Non-Standard Frame  
Single Vision Lens () (Glass) Distance 2.8 (H)
Single Vision Lenses (2) (Glass) Distance 46.77 (H)
Single Vision Lens () (Glass) Reading 2.8 (H)
Single Vision Lenses (2) (Glass) Reading 46.77 (H)
Single Vision Lens () (Plastic) Distance  26.66 (H)
Single Vision Lenses (2) (Plastic) Distance 5.2 (H)
Single Vision Lens () (Plastic) Reading 26.66 (H)
Single Vision Lenses (2) (Plastic) Reading 5.2 (H)
Additional Specification for Lenses to All Spectacle Types
Special grant towards additional specification for lens () 
– applies to all spectacle types 8.8 (H)
Special grant towards additional specification for lenses (2) 
– applies to all spectacle types  62.75 (H)
Other Items - Single Vision  
Lenticular Lens ( Surface) .50 
Lenticular Lenses (2 Surfaces) 2.00 
Lenticular Lenses ( Surfaces) 4.50 
Lenticular Lenses (4 Surfaces) 46.00 
Tinted Lens () 7.0 
Tinted Lenses (2) 4.59 
Tinted Lenses () 2.89 
Tinted Lenses (4) 29.8 
Prism () 6.2
Prisms (2) 2.45 
Prisms () 8.68 
Prisms (4) 24.9 
Prisms (5) .4 
Prisms (6) 7.6 
Prisms (7) 4.59 
Prisms (8) 49.82 
Dioptric powers higher than 8.00 () Lens 6.5 
Dioptric powers higher than 8.00 (2) Lenses 2.29 
Dioptric powers higher than 8.00 () Lenses 8.44 
Dioptric powers higher than 8.00 (4) Lenses 24.59 
Anti-Reflective Coating on Plastic Lens () 8.05 (H)
  E
(H) Denotes fees payable in respect of services under the Health (Amendment) Act 1996 only.
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Scale of Fees Payable under the Health Service Executive Community Ophthalmic Services Scheme continued
As as 31st December 2005 E
Anti-Reflective Coating on Plastic Lenses (2) 6.09 (H)
Dioptric powers higher than 6.00 (Plastic) () Lens 5.7 
Dioptric powers higher than 6.00 (Plastic) (2) Lenses 0.7 
Dioptric powers higher than 6.00 (Plastic) () Lenses 46.0 
Dioptric powers higher than 6.00 (Plastic) (4) Lenses 6.47 
Plastic Lens () for children as prescribed 4.52 
Plastic Lenses (2) for children as prescribed 9.0 
Plastic Lens () Adult 4.52 (H)
Plastic Lenses (2) Adult 9.0 (H)
Bifocals  
Spectacles Bifocal Complete 8.72 
Fused Bifocal Spectacles 6.77 (H)
Varifocals Spectacles - Glass or Plastic  249.8 (H)
  
Bifocal Lenses  
Replacement Bifocal Lens () to own frame 6. 
Replacement Bifocal Lenses (2) to own frame 72.62 
Bifocal Lens () to Non-Standard Frames 47.5 (H)
Bifocal Lenses (2) to Non-Standard Frames 95.06 (H)
Varifocal Lens () (Grant) 94.2 (H)
Varifocal Lenses (2) (Grant) 88.47 (H)
Other Items - Bifocals 
Sphere over 6.00 and up to 9.00 extra charge () Lens 4.5 
Sphere over 6.00 and up to 9.00 extra charge (2) Lenses 8.0 
Sphere over 9.00 extra charge () Lens 9.22 
Sphere over 9.00 extra charge (2) Lenses 8.44 
Tinted Lens () 8.07 
Tinted Lenses (2) 6. 
Prism () 8.6 
Prisms (2) 7.25 
Repairs  
Replacement Frame to own lenses .8 
Replacement Front to own lenses 5.8 
Replacement Side () to own frame 2.45 
Replacement Sides (2) to own frame 4.90 
Complete New Frames 90.00 (H)
  E
(H) Denotes fees payable in respect of services under the Health (Amendment) Act 1996 only.
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DETAILED STATISTICAL ANALYSIS OF CLAIMS AND PAYMENTS
2005
4 5
Table 1 GMS: Summary of Statistical Information for each of the Five Years 2001 - 2005
Year ended December:- 2005 2004 2003 2002 2001 Year ended December:- 2005 2004 2003 2002 2001
Number of Eligible  ,55,727 ,48,94 ,58,4 ,68,745 ,99,454 Number of Doctor Contracts 2,257 2,20 2,8 2,4 ,86
Persons in December      Number of Pharmacist Contracts ,40 , ,292 ,249 ,20
DOCTORS (000’s) (000’s) (000’s) (000’s) (000’s)   (000’s) (000’s) (000’s) (000’s) (000’s)
           
Total Payments 8403,071 8306,250 8286,830 8271,939 8203,863 Total Cost of Stock Orders 815,139 815,413 814,096 813,018 811,555
        Ingredient Cost 8,74 8,944 80,904 80,059 88,945
Doctors’ Payment  8343.35 8261.53 8247.66 8221.15 8169.46  Pharmacy Fees 82,927 82,986 82,726 82,55 82,222
per Person       VAT 8498 848 8466 8444 888
PHARMACIES
Total Cost of  8816,304 8747,905 8636,566 8537,874 8422,464 Overall Cost of Medicines 8831,443 8763,318 8650,662 8550,892 8434,019
Prescriptions
 Ingredient Cost 865,25 8585,22 850,578 842,269 829,497 *Pharmacy Payment  8750.04 8692.73 8595.16
 Dispensing Fee 847,860 849,08 82,5 804,827 885,4 per Person
 VAT 85,9 8,702 8,87 89,778 87,554
Number of Forms ,227 2,794 2,24 ,55 0,454
Number of Items 7,428 5,00 2,24 29,500 25,52 Overall Payments 81,234,514 81,069,568 8937,493 8822,831 8637,882
Cost per Form 86.7 858.46 85.99 846.57 840.4 *Overall Payment  81,093.39 8954.26 8842.82
       per Person
Cost per Item 82.8 82.5 89.74 88.24 86.55
Ingredient Cost per Item 87.45 86.70 85.62 84.5 82.9
Items per Form 2.8 2.74 2.6 2.55 2.44
Note: Doctors payment per person is exclusive of superannuation paid to retired DMOs.
*Since 2003 these figures are based on the actual number of persons who availed of services. 
4 5
Table 1.1 LTI/DP: Summary of Statistical Information for each of the Five Years 2001 - 2005
Year ended December:- 2005 2004 2003 2002 2001 Year ended December:- 2005 2004 2003 2002 2001
LTI Scheme      DP Scheme
Number of Eligible       Number of Eligible Persons  
Persons in December 99,280 9,504 97,84 92,745 87,988 in December ,478,650 ,469,25 ,96,8 ,9,95 ,56,86
*Number of Claimants 5,006 50,526 48,05   *Number of Claimants 526,052 499,664 474,4
  (000’s)  (000’s) (000’s) (000’s)  (000’s)   (000’s) (000’s) (000’s) (000’s) (000’s)
Number of Items ,929 ,675 ,464 ,280 ,57 Number of Items 0,582 9,9 9, 9,06 8,985
            
Total Cost 800,547 885,55 87,48 86,66 852,08 Gross Cost 888,02 85,44 85,82 8287,489 8262,87
            
Cost per Item 852.2 85.08 850. 848.5 844.98 Net Cost 8244,486 822,959 8204,422 892,66 877,67
*Cost per Claimant 8,896.89 8,69.2 8,526.40   Gross Cost per Item 86.67 85.5 8.92 8.72 829.8
       *Net Cost per Claimant 8464.76 8448.22 840.90
*Since 2003 these figures are based on the actual number of persons who availed of services under each Scheme.
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Table 2 Number of Agreements
Note:  (i) Where Doctors have panels numbers drawn from more than one HSE Area, the Area wherein the majority of such persons reside is deemed to be the Doctors HSE Area.
 (ii) 239 Doctors who do not have agreements under the GMS Scheme and who provide services under the Primary Childhood Immunisation Scheme,  
 the Health (Amendment) Act 1996, Heartwatch, Palliative Care and the Methadone Treatment Scheme are included in the above.
 (iii) 198 Dentists (184 - 2004) who are employees of the Health Service Executive and who provide services under the Dental Treatment Services Scheme are included above.
 (iv) 11 Pharmacies who do not hold GMS agreements and who were registered as providing services under the non GMS Schemes at year end are included above. 
 (v) Above figures relate to the position as at 31st December 2005.
Health Service  
Executive
Doctors Pharmacists Dentists Optometrists
2005  2004 2005 2004  2005  2004  2005  2004  
East Coast Area 22 209 26 4 02 99 45 44 
South Western Area 0 00 96 85 205 79 78 74 
Northern Area 242 240 6 5 54 47 42 4 
Midland 26 2 82 75 68 77 4 40 
Mid-Western 24 204 7 26 02 00 42 8 
North Eastern 62 6 26 5 0 2 50 50 
North Western 4  79 75 64 60 0 24 
South Eastern 222 22 5 44 2 22 5 49 
Southern 89 72 227 2 04 290 79 7 
Western 25 256 4 5 60 4 69 56 
National 2,257 2,210 1,430 1,333 1,394 1,340 531 489 
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Table 3 GMS: Payments to Doctors 
   2005 2004
   2 2
FEES - Item of Service Contract ,80,460 ,20,542
 - Capitation 206,098,590 57,67,58
 - Special Claims/Services 4,64,854 2,249,824
 - Out-of-Hours ,506,97 24,54,8
 - Dispensing 2,75,426 ,8,55
 - Asylum Seekers ,484,255 ,64,02
 - GP Visit Cards 92,65 -
ALLOWANCES -  Annual Leave 8,508,7 6,75,482
 - Locum and Practice Expenses ,25 6,57
 -  Sick Leave ,54,79 ,72,059
 -  Maternity Leave 52,758 7,4
 -  Rural Practice 4,974,708 2,929,286
 -  Secretarial/Nursing 59,48,7 42,69,
 -  Study Leave ,560,225 ,25,82
 -  Medical Indemnity Insurance ,99,026 2,67,78
 -  Rostering/Out-of-Hours 6,548,29 6,528,544
 -  Practice Development 4,65,469 4,52,25
 -  Practice Support Grant 2,668,68 2,67,547
 -  IMO Agreements:  
   One-in-One rotas 64,869 64,869
    Third year Trainees 28,882 247,599
    Trainer Grants 89,60 774,60
SALARIES -  Former District Medical Officers ,807,47 2,06,679
 -  Benefits to retired DMOs and their dependants 6,249,48 5,779,920
SUPERANNUATION FUND -  Contribution 20,807,94 6,095,40 
TOTAL   €403,071,088 €306,250,280  
Note:  The above figures include the arrears paid resulting from the implementation of the 2005 LRC Agreement.
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Table 4 GMS: Cost of Prescriptions 
Health 
Service  
Executive
Ingredient Cost Dispensing Fee VAT Total
2005  

2004  

2005  

2004  

2005  

2004  

2005  

2004  

East Coast Area 46,496,56 4,52,478 ,6,95 ,8,87 ,4,29 998,926 58,772,807 55,704,275 
South Western 
Area 75,4,20 68,750,06 7,289,04 8,645,657 ,864,426 ,7,029 94,586,690 89,28,749 
Northern Area 7,247,60 65,07,099 6,70,06 8,00,57 ,689,822 ,520,82 9,07,58 84,60,798 
Midland 45,478,996 40,45,464 0,096,069 9,544,860 ,047,9 927,892 56,622,978 50,888,26 
Mid-Western 60,5,877 5,04,44 ,66,854 ,20,452 ,9,282 ,222,566 75,207,0 67,77,452 
North Eastern 56,5,85 5,08,799 2,84,200 2,604,709 ,08,787 ,92,968 70,656,822 65,06,476 
North Western 40,948,98 7,088,659 9,40,657 8,520,4 944,60 866,708 5,04,24 46,475,50 
South Eastern 79,072,272 70,542,70 8,258,25 7,594,976 ,945,504 ,755,670 99,276,0 89,89,56 
Southern 06,,4 95,50,59 2,8,500 2,466,655 2,68,59 2,44,72 2,492,99 20,76,97 
 Western 69,57,87 6,90,977 5,254,274 4,08,567 ,58,77 ,9,508 86,46,468 77,579,052 
National €653,250,513 €585,122,276 €147,859,882 €149,081,398 €15,193,166 €13,702,172 €816,303,561 €747,905,846
Note: Cost of medicines supplied by pharmacies to Dispensing Doctors is given in Table 5.
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Health 
Service 
Executive
Ingredient Cost *Pharmacy Fee VAT Total
2005  

2004  

2005  

2004  

2005  

2004  

2005  

2004  

East Coast Area 60,88 54,065 40,22 8,59 2,08 2,79 2,22 225,77 
South Western 
Area 04,04 22,40 26,004 0,608 27, 27,9 57,7 80,4 
Northern Area 54,250 6,9 ,568 9,26 ,944 9,5 8,762 55,464 
Midland 47,946 68,90 09,495 70,982 22,9 2, 570,54 878,045 
Mid-Western 88,22 85,685 220,799 22,97 47,686 44,4 ,5,77 ,08,76 
North Eastern ,206,28 ,054,79 0,566 26,677 52,459 5,674 ,560,06 ,72,070 
North Western 2,098,402 2,,9 52,98 527,985 58,82 59,88 2,68,208 2,699,04 
South Eastern 2,797,52 2,92,6 699,284 70,77 90,747 92,6 ,587,8 ,746,58 
Southern 407,894 425,55 0,978 06,84 58,0 52,648 568,82 584,585 
Western ,564,090 ,579,62 890,05 894,8 9,772 87,52 4,547,967 4,56,78 
National €11,714,162 €11,943,684 €2,927,005 €2,985,932 €497,895 €482,612 €15,139,062 €15,412,228
Table 5 GMS: Cost of Stock Order Forms 
Note:  (i) Stock Order Forms are provided by HSE Areas for use by Dispensing Doctors to obtain Medicines and Appliances from retail pharmacies for dispensing to persons who  
 are entitled to be dispensed to.
 (ii) *Pharmacies are reimbursed for stock order items on the basis of the basic trade price, with the addition of 25% on cost.
 (iii) The above figures include needles, syringes and dressings which are available for Doctors use.
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Table 6 DTS: Payments to Dentists
Note: Dentists were also paid a total €55,922 in 2005 (€55,587 in 2004) in respect of fees under Health (Amendment) Act 1996.
Health Service  
Executive
Above the Line Below the Line Total
2005 
€
2004 
€
2005 
€
2004 
€
2005 
€
2004 
€
Eastern Areas 9,899,747 9,925,4 4,572,584 4,447,76 4,472, 4,7,97 
Midland ,874,45 ,7,905 ,26,662 ,02,26 ,00,007 2,726,68 
Mid-Western ,02,569 2,897,09 ,76,677 ,558,725 4,787,246 4,455,86 
North Eastern 2,840,442 2,765,727 ,607,576 ,469,489 4,448,08 4,25,26 
North Western 2,698,869 2,425,977 ,0,069 958,895 ,808,98 ,84,872 
South Eastern 4,22,062 ,999,529 2,55,877 2,442,847 6,774,99 6,442,76 
Southern 6,59,095 6,554,96 ,096,867 2,900,02 9,689,962 9,454,969 
Western 4,477,946 4,62,98 2,942,54 2,76,20 7,420,460 7,60,24 
National €35,629,075 €34,906,581 €18,773,826 €17,526,244 €54,402,901 €52,432,828 
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Table 7 GMS: Payment per Person 
Health Service 
Executive
2005 2004
Doctors

Pharmacies

Total

Doctors

Pharmacies

Total

Eastern Areas 2.9 727.2 ,060.05 25.46 687.2 98.69
Midland 5.48 8.55 ,87.0 267.82 766.76 ,04.58
Mid-Western 2.44 776.40 ,08.84 254.57 702.08 956.65
North Eastern 8.74 775.9 ,.9 272.06 705.20 977.26
North Western 22.96 629.0 95.97 244.2 58.7 827.40
South Eastern 49.6 764.57 ,4.8 264.59 704.59 969.8
Southern 6.87 789.96 ,5.8 275.04 724.2 999.6
Western 60.7 79.60 ,00. 27.5 669.5 942.68
National €343.35 €750.04 €1,093.39 €261.53 €692.73 €954.26
Note:  The payment per person is inclusive of total payments to Doctors (Table 3) excluding superannuation benefits to retired DMOs and their dependants and total payments to pharmacies 
(Tables 4 and 5) in respect of the actual cost per person who availed of services.
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Table 8 GMS: Number of Doctors in Eligible Person Cost Categories
Number of Doctors with an annual cost per eligible person of:-
Health Service 
Executive Up to 300 301-350 351-400 401-450 451-500 501-550 551-600 601-650 651-700 701&Over
Eastern Areas 7 (5) 8 ()  (5) 5 (5) 0 (22) 2 (0) 6 (9) 0 (5)  (2) 49 (469)
Midland  (-) -  (-) -  (-) - - (2)  (2)  (4) 96 (96)
Mid-Western  (-)  (-) -  ()  (-) 2 ()  (4) 2 (4) 7 (8) 47 (8)
North Eastern 4 (2) 2 () 2 ()  ()  (-)  () 2 (0) 5 (6) 2 (-)  (7)
North Western 2 (2) 2 (-) - 2 (4) 2 () 4 (4)  (4) 6 (8) 9 () 00 (76)
South Eastern 2 ()  (-) - 2 (-) - ()  (4) 4 (2) 2 () 4 (4) 94 (88)
Southern 2 () - () - ()  (-)  () 4 (4) 4 (2) 2 (5) 5 (6) 0 (287)
Western 5 () 2 (-) - () - (2)  () 4 ()  (8)  (4) 7 (9) 202 (9)
National 36 (12) 18 (5) 6 (8) 22 (23) 21 (28) 28 (27) 29 (61) 31 (47) 46 (73) 1,668 (1,564)
Note:  (i) Doctors not in the GMS Scheme for the full year have been excluded from this table.
 (ii) The annual cost per eligible person is the total payment for the Doctor and the total prescribing/dispensing costs in respect of the number of persons on the panel as at December 2005.
 (iii) Doctors payment is exclusive of superannuation paid to retired DMOs.
2005 (2004 in brackets)
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Table 9 GMS: Number of Eligible Persons
Health Service 
Executive
Number of persons (including dependants)  
and % of population* eligible in Health Service 
Executive
Number of persons (including dependants)  
and % of population* eligible in
December 2005 December 2004 December 2005 December 2004
No.          % No.          % No.          % No.          %
EASTERN AREAS NORTH WESTERN
Dublin 274,245 24.47 274,272 24.4 Donegal 68,80 50.09 67,229 48.87
Kildare 7,790 2.0 7,95 22.69 Leitrim ,044 4.26 ,69 4.9
Wicklow 27,62 24.9 27,62 24.08 Sligo 9,49 .67 9,4 .24
TOTAL 9,647 24.29 9,079 24.20 TOTAL 98,95 44.7 97,74 4.88
MIDLAND SOUTH EASTERN
Laois 6,99 29.00 7, 29.5 Carlow 5,44 .9 5,404 .48
Longford 2,545 40.46 2,84 9.86 Kilkenny 9,802 24.85 9,506 24.28
Offaly 9,597 0.88 9,09 29.9 Tipperary S.R. 28,6 6.7 28,8 5.79
Westmeath 20,990 29.24 2,059 29. Waterford 5,744 5.40 4,98 4.4
TOTAL 70,2 .9 69,65 0.89 Wexford 40,020 4.55 8,5 2.89
TOTAL 9,620 .9 6,59 2.2
MID-WESTERN
Clare ,55 0.49 0,896 29.92 SOUTHERN
Limerick 49,92 28.55 49,767 28.9 Cork 2,65 29.76 0,955 29.24
Tipperary N.R. 9,40 .8 8,95 .00 Kerry 4,22 .5 40,924 0.88
TOTAL 00,688 29.7 99,578 29.2 TOTAL 7,586 0.2 7,879 29.62
NORTH EASTERN WESTERN
Cavan 8,958 4.45 8,68 .67 Galway 65,758 .5 66,502 .8
Louth 5,4 4.69 5,0 4.9 Mayo 47,588 40.67 47,590 40.52
Meath 29,69 22.07 0, 22.64 Roscommon 20,26 7.64 20,066 7.2
Monaghan 6,05 0.89 6,6 . TOTAL ,582 5.2 4,58 5.28
TOTAL 99,566 29.5 00,45 29.9 National 1,155,727 29.50 1,148,914 29.33 
Note:  (i) *The population figures for each county are taken from the Census of Population 2003. The most recent Official C.S.O. estimate of national population as at April 2005 is 4,130,700.
 (ii) As at December 2005 – 5,079 people on GP Visit Only Cards are excluded.
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Table 9.1 GMS: Number of Eligible Persons by Gender within Age Groups
Health 
Service 
Executive
Age Classification
As at December 2005
Under 5 Years 5-11 Years 12-15 Years 16-24 Years 25-34 Years 35-44 Years
Female Male Total Female Male Total Female Male Total Female Male Total Female Male Total Female Male Total
Eastern Areas ,44 ,992 27,426 6,77 7,205 ,82 8,27 8,57 6,844 5,502 9,525 25,027 20,849 ,26 ,975 6,98 2,477 29,458
Midland 2,7 2,447 4,820 ,266 ,466 6,72 ,876 ,942 ,88 ,647 2,449 6,096 ,597 2,070 5,667 ,50 2,574 6,084
Mid-Western ,062 ,025 6,087 4,257 4,504 8,76 2,498 2,575 5,07 5,5 ,766 8,90 5,075 ,285 8,60 4,800 ,92 8,72
North Eastern ,090 ,48 6,48 4,55 4,784 9,7 2,552 2,62 5,75 5,567 ,720 9,287 5,66 ,087 8,25 4,856 ,795 8,65
North Western 2,87 ,6 5,989 4,578 4,925 9,50 2,674 2,94 5,588 6,074 4,442 0,56 5,0 ,5 8,82 5,8 4,427 9,745
South Eastern 4,262 4,62 8,874 5,857 6,40 2,258 ,405 ,569 6,974 7,740 5,292 ,02 7,22 4,7 ,594 6,990 5,5 2,4
Southern 4,879 5,7 0,26 6,809 7,55 4,64 ,92 4,24 8,056 8, 5,52 ,654 8,756 5,50 4,266 8,574 6,6 5,85
Western ,5 ,752 7,28 5,55 5,844 ,95 ,509 ,52 7,00 6,822 5,67 ,989 6,48 ,99 0,087 6,74 5,6 ,77
National 7,504 9,629 77, 5,048 54,484 05,52 28,77 29,84 58,558 58,68 9,884 98,502 6,84 6,74 98,584 57,40 44,50 0,9
% of Eligible 
Persons .25% .4% 6.67% 4.42% 4.7% 9.% 2.48% 2.58% 5.07% 5.07% .45% 8.52% 5.5% .8% 8.5% 4.97% .85% 8.82%
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Table 9.1 GMS: Number of Eligible Persons by Gender within Age Groups continued
Health 
Service 
Executive
Age Classification
As at December 2005
45-54 Years 55-64 Years 65-69 Years 70-74 Years 75 Years and Over All
Female Male Total Female Male Total Female Male Total Female Male Total Female Male Total Female Male Total
Eastern Areas 4,0 ,24 25,254 6,286 2,89 29,05 0,45 7, 7,748 20,628 6,988 7,66 4,945 2,868 65,8 94,68 45,00 9,648
Midland ,05 2,859 6,64 4,089 ,248 7,7 2,26 ,786 4,022 ,502 ,89 6,89 7,42 5,060 2,492 8,8 ,290 70,2
Mid-Western 4,796 4,29 9,05 5,89 5,00 0,99 ,24 2,759 6,000 5,07 4,984 0,29 ,64 7, 8,477 55,226 45,462 00,688
North Eastern 4,62 4,087 8,708 5,72 4,788 0,509 ,6 2,470 5,606 4,979 4,59 9,572 0,97 7,09 8,00 55,78 44,88 99,566
North Western 5,76 4,909 0,085 5,72 5,5 ,24 2,859 2,62 5,49 ,67 ,700 7,7 8,86 6,4 5,002 52,827 46,088 98,95
South Eastern 6,78 5,948 2,7 8,75 7,22 5,607 4,78 4,028 8,746 7,4 6,564 ,678 4,92 9,59 2,785 76,657 62,96 9,620
Southern 8,56 7,59 6,27 0,59 8,86 9,5 6,65 5,05 ,28 9,70 8,70 8,4 20,044 2,90 2,954 96,055 77,5 7,586
Western 6,885 6,522 ,407 7,820 7,588 5,408 4,06 ,885 8,9 6,9 6,95 2,88 4,647 0,020 24,667 7,786 6,796 ,582
National 54,22 47,279 0,5 64,4 55,22 9,55 7,096 29,926 67,022 6,04 55,4 6,28 29,222 8,998 2,220 64,200 54,528 ,55,728
% of Eligible 
Persons
4.69% 4.09% 8.78% 5.57% 4.77% 0.4% .2% 2.59% 5.80% 5.29% 4.77% 0.06% .8% 7.09% 8.28% 55.48% 44.52% 00.00%
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Table 9.2 GPVC: Number of Eligible Persons by Gender within Age Groups
Health 
Service 
Executive
Age Classification
As at December 2005
Under 5 Years 5 - 11 Years 12 - 15 Years 16 - 24 Years 25 - 34 Years 35 - 44 Years
Female Male Total Female Male Total Female Male Total Female Male Total Female Male Total Female Male Total
Eastern Areas 9 42 8 50 66 6 29  60 25 2 46 68 0 98 65 57 22
Midland   22 8 2 0 5 7 2 5 2 7 4 4 8 2 5 8
Mid-Western 4  25 24 5 9 7 8 25 2  2 9 8 27 27 8 45
North Eastern 4 47 90 42 48 90 20 9 9 44 24 68 5 2 74 54 46 00
North Western 40 2 72 5 6 6 45  78   66 47 0 77 72 59 
South Eastern 5 42 95 70 79 49 5 47 00 54 9 9 86 46 2 86 62 48
Southern 56 65 2 84 9 77 5 44 97 76 4 7 95 49 44 26 95 22
Western 27 4 6 26 2 47 0 8 8 5 4 9 2 4 7 27  60
National 283 284 567 367 397 764 232 197 429 254 175 429 405 202 607 480 385 865
% of Eligible 
Persons 5.57% 5.59% 11.16% 7.23% 7.82% 15.04% 4.57% 3.88% 8.45% 5.00% 3.45% 8.45% 7.97% 3.98% 11.95% 9.45% 7.58% 17.03%
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Table 9.2 GPVC: Number of Eligible Persons by Gender within Age Groups continued
Health Service Executive
Age Classification
As at December 2005
45 - 54 Years 55 - 64 Years 65 - 69 Years All
Female Male Total Female Male Total Female Male Total Female Male Total
Eastern Areas 52  8 6 45 08 2 0 5 44 5 767
Midland 5 7 2  0 2 2  5 94 7 65
Mid-Western 7 9 6 5  26 4  5 49 2 26
North Eastern  27 60 55 4 96 0 2  54 294 648
North Western 52 46 98 29 7 66 6  9 77 46 72
South Eastern 6 54 5 55 5 06 0 5 25 528 45 96
Southern 92 6 55 76 77 5 0 0 60 688 557 ,245
Western 4  27 6 7  8 7 5 56 5 07
National 326 260 586 320 289 609 93 130 223 2,760 2,319 5,079
% of Eligible Persons 6.42% 5.12% 11.54% 6.30% 5.69% 11.99% 1.83% 2.56% 4.39% 54.34% 45.66% 100.00%
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Table 9.3 GMS: Percentage of Eligible Persons by Mileage Allocation
Health Service 
Executive
Mileage Classification
As at December 2005
Up to 3 Miles 3 - 5 Miles 5 - 7 Miles 7 - 10 Miles Over 10 Miles
Female Male Total Female Male Total Female Male Total Female Male Total Female Male Total
Eastern Areas 5.27 7.96 89.2 .2 2.5 5.74 .82 .42 .24 0.64 0.52 .6 0.4 0.28 0.6
Midland .57 26.64 60.2 6.95 5.85 2.80 .4 0.92 24.4 .42 .7 2.59 0.0 0.04 0.07
Mid-Western 6.6 29.52 65.68 6.9 5.7 2.62 0.46 8.78 9.24 .08 0.92 2.00 0.24 0.2 0.46
North Eastern 4.77 27.42 62.9 8.0 6.75 4.78 . 9.2 20.65 .0 0.92 2.02 0.9 0.8 0.7
North Western 26.9 22.4 48.2 9.60 8.67 8.27 2.6 .07 2.4 .88 .4 7.28 .9 . 2.70
South Eastern 6.0 29.29 65.0 7.4 6.07 .20 9.99 8.28 8.26 .55 .29 2.84 0.22 0.7 0.9
Southern 5. 27.95 6.28 7.2 5.9 .0 9.49 7.8 7.29 2.02 .78 .80 .8 .22 2.60
Western 27.58 22.70 50.28 8.72 7.74 6.46 .24 0.0 2.25 4.49 4.20 8.69 .7 .62 .2
National 38.34 29.96 68.30 6.43 5.43 11.85 8.22 6.92 15.15 1.80 1.58 3.39 0.69 0.62 1.31
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Table 10 GMS: Size of Panels of Doctors
Health Service 
Executive
 Number of Doctors with panels of:-
Up to 250 251 - 500 501 - 1,000 1,001 - 1,500 1,501 - 2,000 2,001 - 2,500
East Coast Area 59 (62) 49 (47) 6 (60)  () - -
South Western Area 64 (64) 47 (4) 8 (85) 42 (40) 4 ()  (2) 
Northern Area 5 () 42 (44) 7 (68) 28 (28) 0 (0)  () 
Midland  (4) 22 (7) 47 (49) 2 (2) - -
Mid-Western 7 (2)  (0) 77 (78) 8 (7) 4 (4) -
North Eastern 24 (0) 0 (26) 8 (80) 9 (20)  () -
North Western 7 (6) 2 (20) 47 (5) 6 () 7 (6) -
South Eastern 26 (27) 9 (8)  (0) 28 (26) 5 (5) -
Southern 75 (7) 79 (79) 6 (7) 0 (0) 2 (2)  ()
Western 44 (48) 55 (5) 0 (92) 29 ()  (2) -
National 394 (399) 417 (397) 815 (810) 254 (251) 34 (33) 5 (4) 
 As at December 2005 (2004 in brackets)
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Table 11  GMS: Payments to Doctors in each Health Service Executive Area
Health Service  
Executive
2005

2004

East Coast Area 29,687,792 2,954,859
South Western Area 45,029,29 4,487,50
Northern Area 9,92,489 29,725,829
Midland 25,206,856 9,026,820
Mid-Western 4,22,427 26,008,407
North Eastern 4,409,257 27,906,452
North Western 2,470,288 24,44,07
South Eastern 49,75,964 6,950,000
Southern 6,954,440 48,28,554
Western 49,8,284 7,49,8
National €403,071,088 €306,250,280 
Note:  The above figures include the arrears paid resulting from the implementation of the 2005 LRC Agreement.
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Table 12 GMS: Number of Special Type Consultations and Out-of-Hours Claims
Health Service 
Executive
No. of  Temporary 
Resident Claims
No. of EEA  
Visitor Claims
No. of Emergency 
Claims
Second Medical 
Opinion Claims
No. of Out-of-
Hours Claims
Total No. of 
Claims
2005 2004 2005 2004 2005 2004 2005 2004 2005 2004 2005 2004
East Coast Area ,29 ,056 2,850 2,954 2,588 ,876 2 2 2,779 2,598 2,548 ,486 
South Western 
Area
7,959 6,992 4,470 4,449 5,542 5,784  4 55,608 50,956 7,592 68,95 
Northern Area 6,545 5,944 2,26 2,249 5, 4,578  -  - 4,76 4,00 57,902 55,772 
Midland 8,26 9,595 2,88 2,70 7,908 7,407   7,70 5,479 56,55 54,652 
Mid-Western ,248 0,682 5,97 5,74 ,05 2,868 9 76 4,87 4,92 6,456 60,92 
North Eastern* 5,202 4,62 ,0 2,96 ,442 ,59  2 9,254 0,227 8,92 9,4 
North Western ,226 ,22 7,9 7,880 ,67 ,895 2 25 47,054 44,955 59,98 57,987 
South Eastern 8,04 7,7 5,902 6,208 ,629 ,044 6  8,075 75,595 98,65 92,22 
Southern 24,96 2,92 ,6 2,920 5,666 5,28 ,052 794 4,694 ,75 86,29 72,6 
Western 5,04 4,97 0,0 0,484 5,440 5,296 29 9 95,09 90,28 25,9 20,989 
National 95,115 88,335 57,795 57,651 42,254 39,548 1,279 926 576,885 547,001 773,328 733,461
* HSE North Eastern Area figures do not include statistics from North East Doc.
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Table 12.1 GMS: Payment to Doctors for Special Type Consultations and Out-of-Hours Claims 
* HSE North Eastern Area figures do not include statistics from North East Doc.
Health 
Service 
Executive
Cost of  Temporary 
Resident Claims
Cost of EEA  
Visitor Claims
Cost of Emergency 
Claims
Cost of Second Medical 
Opinion Claims
Cost of Out-of-Hours 
Claims
Total Cost of  
Claims
2005 
€
2004 
€
2005 
€
2004 
€
2005 
€
2004 
€
2005 
€
2004 
€
2005 
€
2004 
€
2005 
€
2004 
€
East Coast Area 9,52 9,204 0,29 0,8 04,8 7,284 50 50 94,094 902,872 ,295,298 ,204,22 
South Western 
Area
9,992 268,425 7,628 66,95 226,568 226,77 28 48 2,276,275 ,997,762 2,994,79 2,659,70 
Northern Area 254,06 220,90 87,002 84,09 204,96 70,902  -  - ,698,684 ,620,4 2,244,665 2,096,8 
Midland 29,697 65,2 8,722 8,0 06,24 279,74 84 25 ,540,667 ,406,485 2,260,84 2,2,495 
Mid-Western 55,529 405,56 99,258 200,25 7,96 08,8 ,659 ,882 ,707,605 ,64,688 2,54,987 2,57,864 
North Eastern * 22,675 84,67 6,2 0,655 57,8 57,49 75 50 7,07 97,8 759,27 750,22 
North Western 25,577 22,92 04,88 296,00 65,668 7,64 84 622 ,9,68 ,778,48 2,40,55 2,268,896 
South Eastern 0,472 277,00 225,544 2,992 40,528 5,0 50 75 ,26,288 2,945, ,97,982 ,569,79 
Southern ,005,042 897,826 524,74 484,945 22,9 200,75 26,9 9,749 5,740,09 5,75,52 7,520,085 6,778,78 
Western 594,490 564,07 95,88 9,920 2,902 202,40 7 222 ,898,54 ,568,567 5,0,547 4,727,90 
National €,807,060 €,424,47 €2,29,02 €2,58,099 €,660,792 €,504,85 €2,822 €2,02 €2,70,850 €2,44,587 €,090,545 €28,545,06
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Table 13 GMS: Analysis of Special Items of Service
 Type of Service Number of Claims Cost of Claims
2005 2004 2005
€
2004
€
(i) Excisions/Cryotherapy/Diathermy: Skin Lesions 68,52 64,02 ,65,049 ,490,956 
(ii) Suturing: Cuts and Lacerations 27,574 26,249 662,6 6,70 
(iii) Hydroceles: Draining of ,005 ,08 24,26 25,788 
(iv) Haemorrhages: Dental/Nasal ,587 ,46 8,20 4,074 
(v) Veins: Recognised treatment 2,74 2,08 65,59 49,8 
(vi) ECG: Tests and interpretation 49,929 45,94 ,98,888 ,070,69 
(vii) Diaphragm: Instruction in the fitting of 85 74 20,454 7,094 
(viii) Eye: Removal of Adherent foreign body 7,929 7,207 90,06 67,87 
(ix) Ear/Nose/Throat: Removal of foreign body 8,78 6,46 44,448 76,52 
(x) Nebuliser: Treatment in the case of acute asthmatic attack 47,775 42,27 ,726,807 ,472,67 
(xi) Bladder: Catheterization 5,47 5,0 97,4 75,88 
(xii) Case Conference: Convened by HSE 70 48 0,6 8,60 
(xiii) Diaphragm: Advice and fitting of 56 42 2,44 7,49 
(xiv) IUCD: Counselling and fitting of 4,94 4,6 26,024 268,669 
(xv) Pneumococcal: Vaccination 20,7 ,267 699,646 60,098 
(xvi) Influenza: Vaccination 299,094 292,476 9,989,8 9,72,468 
(xvii) Pneumococcal/Influenza: Vaccination 2,885 ,900 ,204,778 570,802 
(xviii) Hepatitis B: Vaccination 90 269 46,2 ,047 
National 580,722 532,803 €18,499,824 €16,119,775
54 55
Table 13.1 GMS: Analysis of Special Items of Service by HSE Area
 Type of Service East Coast Area South Western Area
Number  
of Claims
Cost of Claims
€
Number of 
Claims
Cost of Claims
€
(i) Excisions/Cryotherapy/Diathermy: Skin Lesions ,790 9,089 7,009 68,58
(ii) Suturing: Cuts and Lacerations 689 6,604 ,84 44,086 
(iii) Hydroceles: Draining of 4 80 52 ,2 
(iv) Haemorrhages: Dental/Nasal 8 924 86 2,060 
(v) Veins: Recognised treatment 0 708  8,00 
(vi) ECG: Tests and interpretation 2,520 60,628 ,25 77,80 
(vii) Diaphragm: Instruction in the fitting of 56 ,5 6 8,678 
(viii) Eye: Removal of Adherent foreign body 77 4,229 20 7,702 
(ix) Ear/Nose/Throat: Removal of foreign body 760 8,257 ,99 47,646 
(x) Nebuliser: Treatment in the case of acute asthmatic attack ,077 8,90 ,59 27,944 
(xi) Bladder: Catheterization 48 5, 72 6,246 
(xii) Case Conference: Convened by HSE 2 78 5 886 
(xiii) Diaphragm: Advice and fitting of 7 ,526  4,658 
(xiv) IUCD: Counselling and fitting of 259 7,444 596 9,479 
(xv) Pneumococcal: Vaccination ,687 58,45 2,06 69,50 
(xvi) Influenza: Vaccination 24,0 80,026 0,429 ,09,2 
(xvii) Pneumococcal/Influenza: Vaccination 2,460 25,686 2,406 2,788 
(xviii) Hepatitis B: Vaccination 4 46 0 ,557 
Total 37,809 €1,253,046 54,537 €1,758,295
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Table 13.1 GMS: Analysis of Special Items of Service by HSE Area continued
Type of Service Mid-Western North Eastern
Number  
of Claims
Cost of Claims
€
Number  
of Claims
Cost of Claims
€
(i) Excisions/Cryotherapy/Diathermy: Skin Lesions 4,48 99,282 4,75 4,44
(ii) Suturing: Cuts and Lacerations ,9 46, ,686 40,50 
(iii) Hydroceles: Draining of 8 ,948 7 ,740 
(iv) Haemorrhages: Dental/Nasal 95 2,270 48 ,78 
(v) Veins: Recognised treatment 577 ,920 6 ,985 
(vi)  ECG: Tests and interpretation ,529 84,985 ,550 84,956 
(vii) Diaphragm: Instruction in the fitting of 25 600 79 ,872 
(viii) Eye: Removal of Adherent foreign body 407 9,748 25 7,706 
(ix) Ear/Nose/Throat: Removal of foreign body 88 2,4 ,68 2,97 
(x) Nebuliser: Treatment in the case of acute asthmatic attack 2,402 87,22 ,24 2,944 
(xi) Bladder: Catheterization 52 9,90 495 7,857 
(xii) Case Conference: Convened by HSE 9 556 7 409 
(xiii) Diaphragm: Advice and fitting of 5 ,450 0 4,05 
(xiv) IUCD: Counselling and fitting of 27 2,7 526 4,785 
(xv) Pneumococcal: Vaccination ,962 67,42 ,662 56,565 
(xvi) Influenza: Vaccination 27,6 92,6 25,452 852,72 
(xvii) Pneumococcal/Influenza: Vaccination 2,68 09,248 2,45 8,299 
(xviii) Hepatitis B: Vaccination 25 ,04  ,28 
Total 46,479 €1,501,888 45,768 €1,487,802
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Table 13.1 GMS: Analysis of Special Items of Service by HSE Area continued
Type of Service Northern Area Midland
Number  
of Claims
Cost of Claims
€
Number  
of Claims
Cost of Claims
€
(i) Excisions/Cryotherapy/Diathermy: Skin Lesions 4,086 97,844 ,526 84,247
(ii) Suturing: Cuts and Lacerations ,456 5,004 2,29 56,02 
(iii) Hydroceles: Draining of 2 55 9 94 
(iv) Haemorrhages: Dental/Nasal 7 ,28 05 7,40 
(v) Veins: Recognised treatment 2 57 6 7 
(vi)  ECG: Tests and interpretation ,649 9,750 4,492 07,727 
(vii) Diaphragm: Instruction in the fitting of 22 542 6 76 
(viii) Eye: Removal of Adherent foreign body 68 6,0 666 5,960 
(ix) Ear/Nose/Throat: Removal of foreign body ,2 ,792 ,97 ,525 
(x) Nebuliser: Treatment in the case of acute asthmatic attack ,20 47,954 5,076 82,908 
(xi) Bladder: Catheterization 64 2,09 6 ,25 
(xii) Case Conference: Convened by HSE 7 409 2 7 
(xiii) Diaphragm: Advice and fitting of 2 ,5 4 587 
(xiv) IUCD: Counselling and fitting of 5 ,982 42 27,94 
(xv) Pneumococcal: Vaccination ,87 62,48 ,548 54,20 
(xvi) Influenza: Vaccination ,27 ,049,28 8,040 604,474 
(xvii) Pneumococcal/Influenza: Vaccination 2,9 46,80 ,285 65,462 
(xviii) Hepatitis B: Vaccination 26 ,090 22 2,655 
Total 47,415 €1,573,059 39,559 €1,258,236
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Table 13.1 GMS: Analysis of Special Items of Service by HSE Area continued
Type of Service North Western South Eastern
Number  
of Claims
Cost of Claims
€
Number  
of Claims
Cost of Claims
€
(i) Excisions/Cryotherapy/Diathermy: Skin Lesions 7,4 77,696 8,795 2,589
(ii) Suturing: Cuts and Lacerations ,004 7,944 5,04 20,876 
(iii) Hydroceles: Draining of 0 ,70 8 2,87 
(iv) Haemorrhages: Dental/Nasal 9 ,79 20 4,922 
(v) Veins: Recognised treatment 9 472 78 7,688 
(vi)  ECG: Tests and interpretation 7,7 84,88 7,662 8,846 
(vii) Diaphragm: Instruction in the fitting of 4 ,045  744 
(viii) Eye: Removal of Adherent foreign body ,000 2,999 79 8,984 
(ix) Ear/Nose/Throat: Removal of foreign body 2,8 57,05 2,26 5,2 
(x) Nebuliser: Treatment in the case of acute asthmatic attack 6,527 24,847 8,0 290,06 
(xi) Bladder: Catheterization 786 28,202 868 ,82 
(xii) Case Conference: Convened by HSE 4 848 6 2,42 
(xiii) Diaphragm: Advice and fitting of 5 2,5 4 ,722 
(xiv) IUCD: Counselling and fitting of 75 24,95 82 5,87 
(xv) Pneumococcal: Vaccination ,470 5,279 2,40 82,96 
(xvi) Influenza: Vaccination 20,454 68,970 8,485 ,279,28 
(xvii) Pneumococcal/Influenza: Vaccination ,727 86,40 2,472 24,2 
(xviii) Hepatitis B: Vaccination 27 ,288 58 6,687 
Total 53,271 €1,637,261 78,693 €2,485,122
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Table 13.1 GMS: Analysis of Special Items of Service by HSE Area continued
Type of Service Southern Western
Number  
of Claims
Cost of Claims
€
Number  
of Claims
Cost of Claims
€
(i) Excisions/Cryotherapy/Diathermy: Skin Lesions 2,84 297,09 2,252 29,692
(ii) Suturing: Cuts and Lacerations 5,47 28,647 4,27 02,40 
(iii) Hydroceles: Draining of 56 ,75 299 7,24 
(iv) Haemorrhages: Dental/Nasal 5 ,626 85 9,247 
(v) Veins: Recognised treatment 722 7,58 9 2,252 
(vi)  ECG: Tests and interpretation 7,0 69,06 8,548 205,24 
(vii) Diaphragm: Instruction in the fitting of 64 ,95 56 ,29 
(viii) Eye: Removal of Adherent foreign body 2,442 58,542 ,8 26,88 
(ix) Ear/Nose/Throat: Removal of foreign body ,605 86,686 2,546 6,20 
(x) Nebuliser: Treatment in the case of acute asthmatic attack 7,958 288,2 8,74 5,857 
(xi) Bladder: Catheterization 894 2,26 ,5 4,527 
(xii) Case Conference: Convened by HSE 46 2,774 22 ,284 
(xiii) Diaphragm: Advice and fitting of 05 4,86 2 ,58 
(xiv) IUCD: Counselling and fitting of 797 52,85 288 9,060 
(xv) Pneumococcal: Vaccination 2,795 96,66 2,977 0,26 
(xvi) Influenza: Vaccination 47,650 ,584,66 5,865 ,96,02 
(xvii) Pneumococcal/Influenza: Vaccination ,847 9,729 2,264 ,29 
(xviii) Hepatitis B: Vaccination 62 8,949 25 ,092 
 Total 96,256 €3,042,763 80,935 €2,502,352
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Table 14 GMS: Visiting Rate Categories for Doctors on Fee-Per-Item of Service
NATIONAL
2005 (2004 in brackets)
Doctors with 
panels of:-
 Visiting Rate:-*
6 - 6.9 7 - 7.9 8 - 8.9 9 - 9.9 10 - 10.9 11 - 11.9 12 and Over
 00-249 -  (-) - - () - ()  (-)  (2)
 250-499 - -  ()  (-) - (2) - ()  (-)
 500-999 2 () - - () - -  (-) - ()
 ,000-,499 -  (-) - - - -  ()
 Over ,500 - - () - - -  () -
 TOTAL 2 (1) 2 (1) 1 (2) 1 (1) - (3) 3 (2) 3 (4)
Note: (i) The overall visiting rate in 2005 of the Doctors who continued on a Fee-Per-Item of service contract was 10.56 (Surgery: 9.50 Domiciliary: 1.06),  
    (2004 - Total: 10.77 Surgery: 9.82 Domiciliary: 0.95).
 (ii) Only Doctors with panels of 100 persons or over are included in the above table.
 (iii) *Visiting Rate is the total number of consultations divided by the total number of persons on panel.
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Table 15 GMS: Cost of Medicines by Gender within Age Groups 
Health 
Service 
Executive
Age Classification
Under 5 Years 5-11 Years 12-15 Years 16-24 Years 25-34 Years 35-44 Years
Female

Male

Total

Female

Male

Total

Female

Male

Total

Female

Male

Total

Female

Male

Total

Female

Male

Total

Eastern Areas 78.88 92.25 85.70 59.70 69.72 64.87 68.96 65.4 67.6 2.5 2.25 224.56 04.62 54.65 22.02 447.62 450.8 448.79 
Midland 97.75 96.90 97.2 74.0 74.78 74.55 74.77 90.28 82.67 288.8 290.97 289.69 60.0 462.56 97.48 54.6 590.4 56.99 
Mid-Western 25.87 26.26 26.06 87.65 0.8 99.22 97. .8 04.25 269.86 25.92 262.26 85.90 447.5 40.0 5.9 588.75 557.02 
North Eastern 87.7 90.76 89.0 65.4 72.82 69.2 9.6 64.95 78. 26. 98. 208.99 29.84 79.89 48.52 44.75 44.7 442.46 
North Western 56.90 74.9 66.27 56.07 6.59 58.9 58.00 65.66 6.98 6.54 59.07 6.65 249.6 250.75 250.08 26.04 26.62 26.0 
South Eastern 9.95 0.5 97.95 6.87 87.94 76.44 78.80 0.78 90.55 226.4 2.06 228. 2.40 422.48 60.74 495.8 486.67 49.85 
Southern 6. 24. 20.9 92.74 99.25 96.2 9.92 2.24 0.28 269.28 28.85 274.6 7.88 477.06 4.68 5.58 575.69 550.78 
Western 04. 06.94 05.67 6.5 68.84 66.07 6.6 86.2 7.92 2.9 224.47 229.4 55.75 454.9 94.47 448.62 487.2 466.27 
National €9.7 €00.65 €96.0 €68.4 €78.97 €7.87 €76.49 €84.27 €80.45 €24.69 €227.55 €2.80 €29.24 €98.86 €55.7 €467.0 €485.2 €474.97
% of National 
Average 2.80% 4.05% .44% 9.55% .0% 0.% 0.68% .77% .2% 2.77% .77% 2.6% 45.97% 55.69% 49.59% 65.2% 67.7% 66.%
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Health 
Service 
Executive
Age Classification
45-54 Years 55-64 Years 65-69 Years 70-74 Years 75 Years & Over Total
Female

Male

Total

Female

Male

Total

Female

Male

Total

Female

Male

Total

Female

Male

Total

Female

Male

Total

Eastern Areas 779.25 78.89 76.48 ,07.88 ,07.98 ,088.90 ,20.00 ,268.79 ,246.00 ,45.40 ,44.2 ,449.74 ,206.7 ,66.42 ,88.52 756.5 69.27 729.4
Midland 89.4 84.84 866.24 ,4.8 ,22.57 ,74.25 ,5.2 ,47.9 ,90.85 ,676.92 ,659.8 ,669.99 ,6.85 ,0.5 ,47.27 842.58 89.4 82.24
Mid-Western 76.75 744.9 75.60 ,056.62 ,02.6 ,045.27 ,52.7 ,70.82 ,60.76 ,9.76 ,4.24 ,40.47 ,20.8 ,57.8 ,85.6 768.52 79.48 755.4
North Eastern 686.99 679.46 68.46 98.20 975.8 944.44 ,2.46 ,67.85 ,6.94 ,60.2 ,4.92 ,88.49 ,67.8 ,72.25 ,69.72 695.8 680.70 688.7
North Western 508.2 490.4 499.57 787.09 7.90 759.92 925. 94.40 9.90 ,92.9 ,57.50 ,78.4 ,040.85 ,04.4 ,07.6 54.78 50.4 527.
South Eastern 77.4 765.5 750.56 ,0.2 ,09.4 ,05.0 ,89.60 ,77.4 ,8.98 ,42.9 ,407.4 ,46.9 ,2.06 ,20.5 ,20.80 76.74 78.06 728.2
Southern 80.50 778.57 79.78 ,066.5 ,068.0 ,067.20 ,88.2 ,22. ,98.99 ,5.8 ,4.95 ,48.78 ,27.49 ,202.86 ,22.2 790.8 760.26 776.9
Western 665.72 64.86 654. 858.7 85.6 847.2 ,02.59 994.8 ,009.64 ,250.29 ,242.50 ,247.2 ,06.59 ,058.00 ,082.29 674.9 647.66 66.9
National €75.0 €70.5 €72.6 €,004.62€,004.95€,004.77 €,6.5€,75.9€,67.52 €,9.50 €,86.90 €,90.94 €,98.6 €,66.5 €,82.98 €7.9 €695.7 €76.26
% of National 
Average 02.62% 99.20% 0.0% 40.26% 40.% 40.28% 62.% 64.0% 6.00% 94.55% 9.6% 94.9% 67.28% 62.8% 65.6% 02.6% 97.06% 00.00%
Table 15 GMS: Cost of Medicines by Gender within Age Groups continued
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Table 16 GMS: Number of Prescription Forms and Items 
Health Service 
Executive
Number of Forms Number of Items Items per Form
2005 2004 2005 2004 2005 2004
East Coast Area 9,277 875,458 2,700,20 2,52,586 2.96 2.87
South Western Area ,546,259 ,520,809 4,47,74 4,8,805 2.86 2.75
Northern Area ,94,802 ,50,966 4,066,787 ,799,59 2.92 2.8
Midland 875,4 82,797 2,5,68 2,4,854 2.89 2.8
Mid-Western ,22,8 ,70,705 ,508,6 ,249,094 2.87 2.78
North Eastern ,44,99 ,28,888 ,256,4 ,086,769 2.85 2.7
North Western 924,074 889,0 2,67,62 2,20,424 2.56 2.5
South Eastern ,654,962 ,594,88 4,629, 4,0,59 2.80 2.70
Southern 2,50,99 2,079,929 6,080,556 5,707,29 2.8 2.74
Western ,40,790 ,50,67 ,869,66 ,606,282 2.76 2.67
National 13,227,483 12,793,867 37,427,774 35,030,253 2.83 2.74
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Table 16.1 GMS: Payment to Pharmacists in Respect of Prescriptions
Health Service 
Executive
Cost Cost per Form Cost per Item Ingredient Cost  
per Item
2005  

2004  

2005  

2004  

2005  

2004  

2005  

2004  

East Coast Area 58,772,807 55,704,275 64.49 6.6 2.77 22.7 7.22 6.5
South Western Area 94,586,690 89,28,749 6.7 58.6 2.4 2.0 7.08 6.4
Northern Area 9,07,58 84,60,798 65.46 62.64 22.45 22.27 8.0 7.4
Midland 56,622,978 50,888,26 64.70 6. 22.7 2.7 7.96 7.24
Mid-Western 75,207,0 67,77,452 6.55 57.86 2.44 20.85 7.5 6.4
North Eastern 70,656,822 65,06,476 6.74 57.67 2.70 2.09 7.6 6.62
North Western 5,04,24 46,475,50 55.2 52.27 2.56 20.84 7.0 6.6
South Eastern 99,276,0 89,89,56 59.99 56.7 2.45 20.85 7.08 6.6
Southern 2,492,99 20,76,97 6.60 58.06 2.79 2.6 7.48 6.67
Western 86,46,468 77,579,052 6.5 57.45 22. 2.5 7.98 7.7
National €816,303,561 €747,905,846 €61.71 €58.46 €21.81 €21.35 €17.45 €16.70
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Table 16.2 GMS: Number of Items on Prescription Forms
Prescription forms having:-
2005 2004
No. of Forms % of  Total No. of Forms % of  Total
One Item 5,4,900 8.8 5,082,7 9.69
Two Items 2,668,577 20.5 2,68,48 20.60
Three Items ,555,997 .75 ,527,06 .9
Four Items ,074,998 8.2 ,06,789 8.0
Five Items 849,40 6.4 797,055 6.22
Six Items 74,87 5.62 672,768 5.25
Seven Items 794,6 6.00 675,874 5.28
Eight or more Items 4,29 .2 75,047 2.9
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Table 16.3 DP: Number of Items on Claim Forms
Claim forms having:-
2005 2004
No. of Forms % of  Total No. of Forms % of  Total
One Item ,859,7 4.6 ,798,756 44.06
Two Items 908,87 2.2 888,59 2.76
Three Items 54,544 2.75 526,847 2.90
Four Items 54,705 8.2 2,7 8.5
Five Items 20,24 5.40 20,40 5.5
Six Items 4,48 .7 28,989 .6
Seven Items 88,445 2.08 79,595 .95
Eight or more Items ,694 .4 7,0 2.87
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Table 16.4 LTI: Number of Items on Claim Forms  
Claim forms having:-
2005 2004
No. of Forms % of  Total No. of Forms % of  Total
One Item 279,0 9.8 272,408 4.
Two Items 42,00 9.96 9,90 2.05
Three Items 90,294 2.67 86,89 .04
Four Items 67,28 9.44 59,500 8.98
Five Items 50,49 7.0 4,492 6.26
Six Items 5,2 4.95 27,56 4.5
Seven Items 22,55 .4 6,907 2.55
Eight or more Items 25,95 .64 8,685 2.82
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Table 17 GMS: Number of Dispensing Doctors* and Persons for whom they Dispense
Health Service Executive 2005 2004
No. of Doctors No. of Persons No. of Doctors No. of Persons
Eastern Areas  55  604 
Midland  4,94  4,929 
Mid-Western 0 2,58  2,956 
North Eastern 6 ,75 7 ,587 
North Western 5 6,592 4 ,556 
South Eastern 24 8,7 24 8,96 
Southern  ,266  ,408 
Western 7 7,859 40 20,62 
National 135 53,808 143 54,338 
* In rural areas where a Doctor has a centre of practice 3 miles or more from the nearest retail pharmacy the Doctor dispenses for persons served from that centre who opt to be dispensed to. 
The Doctor is paid a dispensing fee for each such person.  A Doctor’s medicine requirements are obtained on a Stock Order from a retail pharmacy - the stock ordered is approved in advance 
by a HSE Area.
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Table 18 GMS: Advance Payments to Pharmacists
Health Service Executive
Amount Advanced to Pharmacists as at 31st December:-
2005  
1
2004  
1
Eastern Areas ,946,702 4,479,652
Midland 97,85 990,56
Mid-Western ,204,48 ,299,459
North Eastern ,66,09 ,760,065
North Western ,252,4 ,04,286
South Eastern ,972,56 2,054,50
Southern 2,260,880 2,47,057
Western ,980,845 2,28,44
National 115,171,582 116,487,668
68 69
Table 19 GMS: Notes on Some of the More Commonly Prescribed Products
AMOXICILLIN 
AMOXICILLIN AND  
ENZYME INHIBITOR
FUROSEMIDE 
FUROSEMIDE WITH 
POTASSIUM SPARING 
DIURETICS
SALBUTAMOL
DICLOFENAC
ATORVASTATIN AND 
PRAVASTATIN
Amoxicillin, alone or potentiated by an 
inhibitor of bacterial enzymes is a broad 
spectrum Penicillin antibiotic indicated 
for the treatment of a wide range of 
infections. 
Salbutamol is a beta-adrenergic 
stimulant used mainly in the treatment 
of chronic asthma and chronic 
bronchitis.
Diclofenac is a Non-Steroidal Anti-
inflammatory Drug (NSAID) mainly 
used to treat pain and inflammation 
associated with muscular conditions 
and rheumatoid arthritis.
Atorvastatin and Pravastatin are 
indicated, in combination with dietary 
measures, for lowering cholesterol 
levels.
The diuretic Furosemide, alone 
or in combination with potassium 
- sparing diuretics, is used to treat 
hypertension.
OMEPRAZOLE
LANSOPRAZOLE
BECLOMETASONE
AMLODIPINE
ACETYLSALICYLIC ACID 
- ASPIRIN
ATENOLOL
Beclometasone is a potent steroid 
having an anti-inflammatory action 
within the lungs. It is used mainly 
by inhalation for the treatment of 
bronchial asthma.
Amlodipine is a calcium - channel 
blocker (similar to nifedipine) 
with peripheral and coronary 
vasodilator properties. It is given 
by mouth in the management 
of hypertension and of angina 
pectoris.
Acetylsalicylic Acid - Aspirin has 
anti-inflammatory and additionally 
analgesic and antipyretic (body 
temperature lowering) action. 
Acetylsalicylic Acid - Aspirin also has 
action against thrombosis or clot 
formation by inhibition of platelet 
cell aggregretion in the blood.
Atenolol is a beta blocker. 
Members of this class of drugs 
are used in the treatment of 
hypertension, angina pectoris and 
cardiac arrythmias.
Omeprazole and Lansoprazole 
are proton pump inhibitors which 
prevent secretion of gastric acid. 
They are used in the treatment 
of reflux oesophagitis and peptic 
ulceration.
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Table 19.1 GMS: The Top 100 Most Commonly Prescribed Products in the Order of their Prescribing Frequency
Name Prescribing Frequency % of Scheme Total Ingredient Cost E % of Scheme Total
 Acetylsalicylic Acid - Aspirin (Antithrombotic) ,929,054 5.4 4,09,892 0.65
2 Atorvastatin 97,280 2.59 6,47,497 5.48
 Levothyroxine Sodium 586,88 .56 ,259,947 0.9
4 Pravastatin 582,74 .55 24,2,944 .64
5 Salbutamol (Inhaled) 58,877 .55 ,257,50 0.49
6 Atenolol 574,7 .5 ,055,492 0.46
7 Amoxicillin and Enzyme Inhibitor 52,670 .9 4,850,50 0.7
8 Furosemide 59,949 .8 622,899 0.09
9 Amlodipine 52,76 .6 0,50,65 .58
0 Warfarin 502,94 .4 ,284,099 0.9
 Ramipril 494,247 .2 8,065,45 .2
2 Omeprazole 482,572 .28 2,66,509 .56
 Calcium, Combinations 46,64 .2 ,786,6 0.57
4 Bisoprolol 452,4 .20 4,68,298 0.69
5 Diclofenac (Systemic) 44,9 .0 4,90,929 0.74
6 Diazepam 4,677 .0 294,67 0.04
7 Paracetamol 4,6 .0 58,685 0.08
8 Lansoprazole 404, .08 5,652,447 2.5
9 Clinical Nutritional Products 89,596 .04 28,762,507 4.
20 Prednisolone (Systemic) 87,0 .0 509,595 0.08
2 Bendrofluazide 86,920 .0 6,799 0.09
22 Dextropropoxyphene Combs. excl. Psycholeptics 52,40 0.94 60,759 0.09
2 Amoxicillin 50,48 0.9 ,679,49 0.25
24 Zopiclone 22,8 0.86 ,289,64 0.49
25 Nimesulide 2,587 0.86 5,472,259 0.82
26 Esomeprazole 9,52 0.85 ,289,470 2.00
27 Digoxin 09,794 0.82 264,950 0.04
28 Metformin 05,442 0.8 99,47 0.5
29 Paracetamol Combs. excl. Psycholeptics 288,420 0.77 ,874,6 0.28
0 Perindopril 287,77 0.76 5,752,828 0.87
 Alprazolam 28,50 0.75 ,20,950 0.7
2 Clopidogrel 282,54 0.75 5,64,62 2.
 Diagnostic Products 275,247 0.7 0,846,49 .6
4 Pantoprazole 270,560 0.72 9,56,77 .8
5 Bendroflumethazide and Potassium 269,64 0.72 57,082 0.09
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Table 19.1 GMS: The Top 100 Most Commonly Prescribed Products in the Order of their Prescribing Frequency continued
Name Prescribing Frequency % of Scheme Total Ingredient Cost E % of Scheme Total
6 Alendronic Acid 268,68 0.7 9,508,652 .4
7 Lactulose 264,024 0.70 ,50,96 0.2
8 Beclometasone (Inhaled) 262,4 0.70 5,079,849 0.76
9 Salmeterol and other drugs for obstructive airway diseases 25,08 0.67 7,927,868 2.70
40 Salbutamol and other drugs for obstructive airway diseases 252,6 0.67 6,97,46 .04
4 Carbocisteine 250,259 0.67 ,,96 0.20
42 Furosemide and Potassium-Sparing Agents 246,57 0.66 ,257,595 0.9
4 Doxazosin 244,626 0.65 7,585,694 .4
44 Isosorbide Mononitrate 242,09 0.65 ,2, 0.50
45 Lisinopril 24,40 0.64 ,82,700 0.58
46 Alginic Acid 24,6 0.64 ,290,8 0.9
47 Citalopram 2,86 0.62 6,62,577 0.9
48 Temazepam 227,582 0.6 488,96 0.07
49 Gliclazide 224,924 0.60 2,0,656 0.5
50 Zolpidem 22,8 0.59 ,5,22 0.2
5 Tramadol 22,750 0.59 ,2,99 0.50
52 Artificial Tears and other indifferent preparations 20,247 0.56 842,4 0.
5 Diclofenac (Topical) 207,02 0.55 ,24,24 0.9
54 Venlafaxine 97,868 0.5 8,55,022 .29
55 Folic Acid 97,8 0.5 20,864 0.0
56 Domperidone 88,48 0.50 ,022,244 0.5
57 Ferrous Fumarate 87,487 0.50 ,596 0.05
58 Clarithromycin 78,8 0.47 ,495,865 0.5
59 Flurazepam 7,964 0.46 ,89,54 0.8
60 Ibuprofen 58,42 0.42 606,58 0.09
6 Mefenamic Acid 52,29 0.4 762,68 0.
62 Metoprolol 5,22 0.40 496,958 0.07
6 Glyceryl Trinitrate 49,847 0.40 ,625,8 0.24
64 Escitalopram 46,85 0.9 4,08,09 0.65
65 Cefaclor 40,75 0.7 ,58,4 0.7
66 Allopurinol 8,805 0.7 98,84 0.5
67 Rabeprazole 7,702 0.7 4,25,49 0.64
68 Olanzapine 7,4 0.7 6,,69 2.4
69 Tolterodine 6,46 0.6 6,50,9 0.96
70 Betamethasone (Topical) 5,646 0.6 68,87 0.09
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Table 19.1 GMS: The Top 100 Most Commonly Prescribed Products in the Order of their Prescribing Frequency continued
Name Prescribing Frequency % of Scheme Total Ingredient Cost E % of Scheme Total
7 Simvastatin 5,566 0.6 4,786,960 0.72
72 Acetylsalicylic Acid - Aspirin (Anti-inflammatory) 5,444 0.6 75,46 0.0
7 Flucloxacillin ,290 0.5 ,64,940 0.8
74 Risedronic acid 0,69 0.5 4,757,48 0.72
75 Fluoxetine 27,49 0.4 ,72,626 0.56
76 Paroxetine 27,8 0.4 ,945,62 0.59
77 Risperidone 26,88 0.4 7,992,067 .20
78 Carbamazepine 25,679 0. 878,695 0.
79 Betahistine 25,605 0. ,926,056 0.29
80 Rosuvastatin 24,766 0. ,649,28 0.55
8 Diltiazem 22,95 0. ,797,4 0.27
82 Tiotropium Bromide 2,840 0.2 6,088,689 0.92
8 Needles/Syringes/Lancets 2,075 0.2 ,59,06 0.2
84 Latanoprost 20,202 0.2 2,95,947 0.44
85 Tamsulosin 8,66 0.2 ,65,70 0.54
86 Bromazepam 6,605 0. 652,207 0.0
87 Losartan 4,827 0. ,46,40 0.47
88 Amitriptyline 4,574 0. ,806 0.02
89 Captopril 4,500 0.0 2,066,470 0.
90 Nifedipine 4,4 0.0 ,478,05 0.22
9 Prochlorperazine 2,472 0.0 0,28 0.05
92 Sodium Valproate 2,205 0.0 ,225,0 0.8
9 Ranitidine 09,082 0.29 2,69,9 0.4
94 Glucosamine 08,25 0.29 ,487,67 0.52
95 Ispaghula (Psylla Seeds) 07,580 0.29 467,50 0.07
96 Levonorgestrel and Estrogen (Fixed Combination Contraceptives) 06,88 0.28 46,600 0.06
97 Drosperinone and Estrogen 06,044 0.28 7,62 0.
98 Codeine Combs. excl. Psycholeptics 05,705 0.28 867,780 0.
99 Sertraline 04,8 0.28 5,06,44 0.75
00 Dothiepin 0,566 0.28 572,68 0.09
Total 26,789,001 71.30% 451,229,837 67.86%
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Table 19.2 GMS: The Top 100 Products of Highest Cost in the Order of their Total Ingredient Cost 
Name Ingredient Cost E  % of Scheme Total Prescribing Frequency  % of Scheme Total 
 Atorvastatin 6,47,497 5.48 97,280 2.59
2 Clinical Nutritional Products 28,762,507 4. 89,596 .04
 Pravastatin 24,2,944 .64 582,74 .55
4 Omeprazole 2,66,509 .56 482,572 .28
5 Salmeterol and other drugs for obstructive airway diseases 7,927,868 2.70 25,08 0.67
6 Olanzapine 6,,69 2.4 7,4 0.7
7 Lansoprazole 5,652,447 2.5 404, .08
8 Clopidogrel 5,64,62 2. 282,54 0.75
9 Esomeprazole ,289,470 2.00 9,52 0.85
0 Diagnostic Products 0,846,49 .6 275,247 0.7
 Amlodipine 0,50,65 .58 52,76 .6
2 Alendronic Acid 9,508,652 .4 268,68 0.7
 Pantoprazole 9,56,77 .8 270,560 0.72
4 Ostomy Appliances 8,70,282 . 80,82 0.22
5 Venlafaxine 8,55,022 .29 97,868 0.5
6 Donepezil 8,54,86 .28 72,407 0.9
7 Ramipril 8,065,45 .2 494,247 .2
8 Risperidone 7,992,067 .20 26,88 0.4
9 Doxazosin 7,585,694 .4 244,626 0.65
20 Salbutamol and other drugs for obstructive airway diseases 6,97,46 .04 252,6 0.67
2 Tolterodine 6,50,9 0.96 6,46 0.6
22 Citalopram 6,62,577 0.9 2,86 0.62
2 Tiotropium Bromide 6,088,689 0.92 2,840 0.2
24 Perindopril 5,752,828 0.87 287,77 0.76
25 Nimesulide 5,472,259 0.82 2,587 0.86
26 Budesonide (Inhaled) 5,28,67 0.80 72,46 0.9
27 Beclometasone (Inhaled) 5,079,849 0.76 262,4 0.70
28 Sertraline 5,06,44 0.75 04,8 0.28
29 Diclofenac (Systemic) 4,90,929 0.74 44,9 .0
0 Amoxicillin and Enzyme Inhibitor 4,850,50 0.7 52,670 .9
 Simvastatin 4,786,960 0.72 5,566 0.6
2 Risedronic Acid 4,757,48 0.72 0,69 0.5
 Bisoprolol 4,68,298 0.69 452,4 .20
4 Formoterol and other drugs for obstructive airway diseases 4,44,04 0.66 76,58 0.20
5 Acetylsalicylic Acid - Aspirin (Antithrombotic) 4,09,892 0.65 ,929,054 5.4
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Table 19.2 GMS: The Top 100 Products of Highest Cost in the Order of their Total Ingredient Cost continued
Name Ingredient Cost E  % of Scheme Total Prescribing Frequency % of Scheme Total 
6 Escitalopram 4,08,09 0.65 46,85 0.9
7 Rabeprazole 4,25,49 0.64 7,702 0.7
8 Paroxetine ,945,62 0.59 27,8 0.4
9 Lamotrigine ,904,866 0.59 65,507 0.7
40 Lisinopril ,82,700 0.58 24,40 0.64
4 Gabapentin ,796,064 0.57 7,76 0.20
42 Fentanyl ,79,597 0.57 0,829 0.08
4 Calcium, Combinations ,786,6 0.57 46,64 .2
44 Fluoxetine ,72,626 0.56 27,49 0.4
45 Rosuvastatin ,649,28 0.55 24,766 0.
46 Tamsulosin ,65,70 0.54 8,66 0.2
47 Clarithromycin ,495,865 0.5 78,8 0.47
48 Glucosamine ,487,67 0.52 08,25 0.29
49 Tramadol ,2,99 0.50 22,750 0.59
50 Isosorbide Mononitrate ,2, 0.50 242,09 0.65
5 Quetiapine ,0,970 0.50 5,96 0.4
52 Zopiclone ,289,64 0.49 22,8 0.86
5 Salbutamol (Inhaled) ,257,50 0.49 58,877 .55
54 Losartan ,46,40 0.47 4,827 0.
55 Nicotine (Replacement Therapy) ,060,78 0.46 98,56 0.26
56 Atenolol ,055,492 0.46 574,7 .5
57 Urinary Appliances ,004,86 0.45 4, 0.
58 Fluticasone (Inhaled) 2,982,904 0.45 49,662 0.
59 Latanoprost 2,95,947 0.44 20,202 0.2
60 Anastrazole 2,75,725 0.4 25,98 0.07
6 Ranitidine 2,69,9 0.4 09,082 0.29
62 Mirtazapine 2,69,888 0.40 86,79 0.2
6 Valsartan 2,448,227 0.7 0,77 0.27
64 Pregabalin 2,9,26 0.5 25,790 0.07
65 Gliclazide 2,0,656 0.5 224,924 0.60
66 Sildenafil 2,29,0 0. 6,08 0.6
67 Ondansetron 2,94,468 0. ,02 0.04
68 Celecoxib (Anti-inflammatory) 2,29,0 0.2 65,220 0.7
69 Orlistat 2,28,964 0.2 2,826 0.09
70 Montelukast 2,22,642 0.2 54,207 0.4
74 75
Table 19.2 GMS: The Top 100 Products of Highest Cost in the Order of their Total Ingredient Cost continued
Name Ingredient Cost E  % of Scheme Total Prescribing Frequency % of Scheme Total 
7 Captopril 2,066,470 0. 4,500 0.0
72 Candesartan ,952,74 0.29 84,29 0.22
7 Betahistine ,926,056 0.29 25,605 0.
74 Insulin (Human), Comb. Intermediate/Fast Acting ,924,0 0.29 4,925 0.09
75 Mesalazine ,908,705 0.29 2,072 0.09
76 Paracetamol Combs. excl. Psycholeptics ,874,6 0.28 288,420 0.77
77 Rosiglitazone ,860,057 0.28 5,056 0.09
78 Insulin Glargine ,85,596 0.27 24,529 0.07
79 Diltiazem ,797,4 0.27 22,95 0.
80 Levetiracetam ,728,272 0.26 7,75 0.05
8 Alfuzosin ,688,857 0.25 55,664 0.5
82 Amoxicillin ,679,49 0.25 50,48 0.9
8 Glyceryl Trinitrate ,625,8 0.24 49,847 0.40
84 Ciprofloxacin ,592,055 0.24 80,28 0.2
85 Etoricoxib ,57,96 0.24 45,92 0.2
86 Terbinafine (Systemic) ,57,76 0.24 27,09 0.07
87 Oxycodone ,56,580 0.24 40,50 0.
88 Other Osmotically Acting Laxatives ,562,706 0.24 96,8 0.26
89 Needles/Syringes/Lancets ,59,06 0.2 2,075 0.2
90 Zolpidem ,5,22 0.2 22,8 0.59
9 Telmisartan ,58,777 0.2 59,40 0.6
92 Lactulose ,50,96 0.2 264,024 0.70
9 Nifedipine ,478,05 0.22 4,4 0.0
94 Sevelamer ,46,488 0.22 8,245 0.02
95 Carbocisteine ,,96 0.20 250,259 0.67
96 Valsartan and Diuretics ,29,04 0.9 52,044 0.4
97 Alginic Acid ,290,8 0.9 24,6 0.64
98 Warfarin ,284,099 0.9 502,94 .4
99 Calcipotriol, combinations ,276,489 0.9 4,7 0.04
00 Levothyroxine Sodium ,259,947 0.9 586,88 .56
Total 524,388,722 78.87% 21,142,646 56.27%
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Table 19.3 DP: The Top 100 Most Commonly Prescribed Products in the Order of their Prescribing Frequency
Name Prescribing Frequency % of Scheme Total Ingredient Cost E % of Scheme Total
 Acetylsalicylic Acid - Aspirin (Antithrombotic) 494,875 4.68 ,54,92 0.50
2 Atorvastatin 424,7 4.0 7,04,98 7.4
 Salbutamol (Inhaled) 27,50 2.24 ,25,20 0.52
4 Pravastatin 200,750 .90 8,864,909 .80
5 Levothyroxine Sodium 97,459 .87 445,55 0.9
6 Atenolol 75,02 .65 98,928 0.42
7 Amoxicillin and Enzyme Inhibitor 7,79 .64 ,664,95 0.7
8 Omeprazole 67,750 .59 9,267,98 .97
9 Diclofenac (Systemic) 65,857 .57 2,006,450 0.86
0 Bisoprolol 48,762 .4 ,590,544 0.68
 Esomeprazole 46,54 .8 6,505,98 2.79
2 Amlodipine 44,94 .7 ,020,78 .0
 Calcium, Combinations 44,57 .7 ,289,9 0.55
4 Salmeterol and other drugs for obstructive airway diseases 44,89 .6 9,989,96 4.28
5 Ramipril 25,067 .8 2,28,42 0.9
6 Prednisolone (Systemic) 24,89 .8 206,506 0.09
7 Lansoprazole 7,769 . 4,925,00 2.
8 Nimesulide 4,88 .08 ,900,979 0.82
9 Venlafaxine 98,960 0.94 4,626,27 .98
20 Clarithromycin 94,65 0.89 2,00,85 0.86
2 Clinical Nutritional Products 9,425 0.86 ,82,96 .64
22 Bendrofluazide 89,24 0.84 40,066 0.06
2 Warfarin 86,94 0.82 25,446 0.0
24 Beclometasone (Inhaled) 82, 0.78 ,57,965 0.68
25 Alendronic Acid 8,9 0.77 2,900,968 .24
26 Clopidogrel 78,27 0.74 4,24,58 .85
27 Paracetamol Combs. excl. Psycholeptics 78,068 0.74 527,52 0.2
28 Alprazolam 77,67 0.7 24,629 0.4
29 Perindopril 77,82 0.7 ,667,999 0.72
0 Doxazosin 76,707 0.72 2,449,6 .05
 Zopiclone 76,529 0.72 850,25 0.6
2 Pantoprazole 76,28 0.72 2,755,74 .8
 Rosuvastatin 74,85 0.7 2,22,982 0.96
4 Amoxicillin 72,94 0.69 40,828 0.8
5 Citalopram 72,4 0.68 2,84,524 0.94
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Table 19.3 DP: The Top 100 Most Commonly Prescribed Products in the Order of their Prescribing Frequency continued
Name Prescribing Frequency % of Scheme Total Ingredient Cost E % of Scheme Total
6 Diazepam 66,45 0.6 4,098 0.02
7 Lisinopril 64,75 0.6 ,08,955 0.48
8 Zolpidem 62,5 0.59 462,05 0.20
9 Escitalopram 6,80 0.58 2,08,0 0.87
40 Bendroflumethazide and Potassium 58,286 0.55 2,559 0.05
4 Formoterol and other drugs for obstructive airway diseases 57,607 0.54 ,64,449 .44
42 Dextropropoxyphene Combs. excl. Psycholeptics 56,709 0.54 9,89 0.04
4 Folic Acid 54,607 0.52 62,528 0.0
44 Tramadol 5,762 0.5 858,95 0.7
45 Alginic Acid 5,6 0.48 06,828 0.
46 Simvastatin 5,08 0.48 ,95,796 0.84
47 Glucosamine 50,585 0.48 ,655,72 0.7
48 Fluoxetine 48,577 0.46 ,684,66 0.72
49 Allopurinol 48,94 0.46 9,298 0.7
50 Sertraline 48,265 0.46 2,502,402 .07
5 Paroxetine 48,2 0.46 ,60,74 0.69
52 Carbocisteine 47,852 0.45 27,54 0.2
5 Montelukast 47,65 0.45 ,894,794 0.8
54 Domperidone 47,28 0.45 27,470 0.2
55 Mefenamic Acid 46,72 0.44 27,42 0.0
56 Risedronic Acid 45,67 0.4 ,644,974 0.7
57 Terbinafine (Systemic) 45,57 0.4 2,729,542 .7
58 Furosemide 44,467 0.42 58,728 0.0
59 Cefaclor 44,27 0.42 78,990 0.6
60 Losartan 4,84 0.4 ,29,779 0.5
6 Fluticasone (Nasal) 4,457 0.4 708,58 0.0
62 Estradiol 4,42 0.4 407,96 0.7
6 Valsartan 42,95 0.4 ,052,050 0.45
64 Diclofenac (Topical) 42,464 0.40 27,68 0.2
65 Metoprolol 40,04 0.8 7,44 0.06
66 Betamethasone (Topical) 9,467 0.7 99,74 0.09
67 Artificial Tears and other indifferent preparations 9,2 0.7 99,885 0.09
68 Drosperinone and Estrogen 8,92 0.6 266,6 0.
69 Paracetamol 8,076 0.6 55,4 0.02
70 Cetirizine 7,97 0.5 79,08 0.6
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Table 19.3 DP: The Top 100 Most Commonly Prescribed Products in the Order of their Prescribing Frequency continued
Name Prescribing Frequency % of Scheme Total Ingredient Cost E % of Scheme Total
7 Salbutamol and other drugs for obstructive airway diseases 6,952 0.5 646,99 0.28
72 Mometasone 6,429 0.4 574,498 0.25
7 Fluticasone (Inhaled) 6,28 0.4 ,529,979 0.66
74 Lithium 5,675 0.4 85,44 0.04
75 Candesartan 5,04 0. 820,786 0.5
76 Olanzapine 4,959 0. ,46,568 .44
77 Bromazepam 4,296 0.2 87,80 0.08
78 Mesalazine ,667 0.2 2,47,00 .05
79 Ostomy Appliances ,459 0.2 2,84,5 .22
80 Raloxifene 2,288 0. 98,986 0.42
8 Flucloxacillin 2,226 0.0 07,05 0.
82 Amitriptyline ,7 0.0 6,67 0.02
8 Methotrexate ,24 0.0 07,6 0.05
84 Nebivolol ,04 0.29 468,809 0.20
85 Desloratadine 0,44 0.29 4,58 0.5
86 Diltiazem 29,85 0.28 457,59 0.20
87 Cyproterone and Estrogen 29,89 0.28 98,02 0.08
88 Rabeprazole 28,87 0.27 90,949 0.40
89 Sildenafil 28,86 0.27 977,68 0.42
90 Acetylsalicylic Acid - Aspirin (Anti-inflammatory) 28,500 0.27 4,425 0.02
9 Atenolol and other Diuretics 28,8 0.27 270,40 0.2
92 Levonorgestrel and Estrogen (Fixed Combination Contraceptives) 27,668 0.26 5,258 0.05
9 Telmisartan 27,449 0.26 70,4 0.0
94 Fluconazole 27,64 0.26 564,798 0.24
95 Budesonide (Inhaled) 27,267 0.26 ,20,54 0.52
96 Valsartan and Diuretics 27,05 0.26 679,2 0.29
97 Dothiepin 26,976 0.25 55,555 0.07
98 Antifungal Combs. (Topical) 26,926 0.25 94,277 0.04
99 Minocycline 26,95 0.25 56,762 0.24
00 Ranitidine 25,85 0.24 748,955 0.2
Total 7,454,872 70.45% €160,374,529 68.81%
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Table 19.4 DP: The Top 100 Products of Highest Cost in the Order of their Total Ingredient Cost
Name Ingredient Cost E  % of Scheme Total Prescribing Frequency  % of Scheme Total 
 Atorvastatin 7,04,98 7.4 424,7 4.0
2 Salmeterol and other drugs for obstructive airway diseases 9,989,96 4.28 44,89 .6
 Omeprazole 9,267,98 .97 67,750 .59
4 Pravastatin 8,864,909 .80 200,750 .90
5 Esomeprazole 6,505,98 2.79 46,54 .8
6 Follitropin Beta 5,45,48 2.29 6,568 0.06
7 Lansoprazole 4,925,00 2. 7,769 .
8 Venlafaxine 4,626,27 .98 98,960 0.94
9 Clopidogrel 4,24,58 .85 78,27 0.74
0 Clinical Nutritional Products ,82,96 .64 9,425 0.86
 Formoterol and other drugs for obstructive airway diseases ,64,449 .44 57,607 0.54
2 Olanzapine ,46,568 .44 4,959 0.
 Amlodipine ,020,78 .0 44,94 .7
4 Alendronic Acid 2,900,968 .24 8,9 0.77
5 Ostomy Appliances 2,84,5 .22 ,459 0.2
6 Pantoprazole 2,755,74 .8 76,28 0.72
7 Terbinafine (Systemic) 2,729,542 .7 45,57 0.4
8 Sertraline 2,502,402 .07 48,265 0.46
9 Doxazosin 2,449,6 .05 76,707 0.72
20 Mesalazine 2,47,00 .05 ,667 0.2
2 Rosuvastatin 2,22,982 0.96 74,85 0.7
22 Citalopram 2,84,524 0.94 72,4 0.68
2 Ramipril 2,28,42 0.9 25,067 .8
24 Escitalopram 2,08,0 0.87 6,80 0.58
25 Diclofenac (Systemic) 2,006,450 0.86 65,857 .57
26 Clarithromycin 2,00,85 0.86 94,65 0.89
27 Simvastatin ,95,796 0.84 5,08 0.48
28 Nimesulide ,900,979 0.82 4,88 .08
29 Montelukast ,894,794 0.8 47,65 0.45
0 Fluoxetine ,684,66 0.72 48,577 0.46
 Calcipotriol, combinations ,68,76 0.72 6,644 0.6
2 Orlistat ,677,680 0.72 25,89 0.24
 Perindopril ,667,999 0.72 77,82 0.7
4 Amoxicillin and Enzyme Inhibitor ,664,95 0.7 7,79 .64
5 Glucosamine ,655,72 0.7 50,585 0.48
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Table 19.4 DP: The Top 100 Products of Highest Cost in the Order of their Total Ingredient Cost continued
Name Ingredient Cost E  % of Scheme Total Prescribing Frequency % of Scheme Total 
6 Risedronic acid ,644,974 0.7 45,67 0.4
7 Paroxetine ,60,74 0.69 48,2 0.46
8 Bisoprolol ,590,544 0.68 48,762 .4
9 Beclometasone (Inhaled) ,57,965 0.68 82, 0.78
40 IUCD with Progestogen ,555,64 0.67 2,257 0.2
4 Fluticasone (Inhaled) ,529,979 0.66 6,28 0.4
42 Calcium Combinations ,289,9 0.55 44,57 .7
4 Tiotropium Bromide ,242,9 0.5 24,9 0.24
44 Losartan ,29,779 0.5 4,84 0.4
45 Salbutamol (Inhaled) ,25,20 0.52 27,50 2.24
46 Gabapentin ,209,58 0.52 20,679 0.20
47 Budesonide (Inhaled) ,20,54 0.52 27,267 0.26
48 Acetylsalicylic Acid - Aspirin (Antithrombotic) ,54,92 0.50 494,875 4.68
49 Isotretinoin ,20,85 0.48 6,456 0.6
50 Lisinopril ,08,955 0.48 64,75 0.6
5 Azathioprine ,058,07 0.45 24,924 0.24
52 Valsartan ,052,050 0.45 42,95 0.4
5 Tolterodine ,049,850 0.45 22,08 0.2
54 Risperidone ,04,7 0.45 6,6 0.5
55 Pregabalin ,00,857 0.44 0,660 0.0
56 Anastrazole ,02,5 0.44 9,59 0.09
57 Sibutramine ,02,450 0.44 6,004 0.5
58 Raloxifene 98,986 0.42 2,288 0.
59 Atenolol 98,928 0.42 75,02 .65
60 Sildenafil 977,68 0.42 28,86 0.27
6 Sumatriptan 975,44 0.42 8,200 0.7
62 Tacrolimus (Topical) 94,459 0.40 2,42 0.2
6 Rabeprazole 90,949 0.40 28,87 0.27
64 Famciclovir 920,67 0.9 7,04 0.07
65 Ezetimibe 885,960 0.8 2,77 0.2
66 Celecoxib (Anti-inflammatory) 879,55 0.8 24,09 0.2
67 Tramadol 858,95 0.7 5,762 0.5
68 Zopiclone 850,25 0.6 76,529 0.72
69 Candesartan 820,786 0.5 5,04 0.
70 Lamotrigine 8,44 0.5 7,9 0.7
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Table 19.4 DP: The Top 100 Products of Highest Cost in the Order of their Total Ingredient Cost continued
Name Ingredient Cost E  % of Scheme Total Prescribing Frequency % of Scheme Total 
7 Urinary Appliances 80,094 0.4 7,69 0.07
72 Etoricoxib 786,607 0.4 22,428 0.2
7 Ondansetron 782,974 0.4 5,776 0.05
74 Quetiapine 775,8 0. 0,824 0.0
75 Ranitidine 748,955 0.2 25,85 0.24
76 Calcipotriol 7,56 0. 7,28 0.6
77 Fluticasone (Nasal) 708,58 0.0 4,457 0.4
78 Tadalafil 706,908 0.0 2,29 0.22
79 Telmisartan 70,4 0.0 27,449 0.26
80 Valsartan and Diuretics 679,2 0.29 27,05 0.26
8 Fentanyl 67,77 0.29 ,95 0.04
82 Salbutamol and other drugs for obstructive airway diseases 646,99 0.28 6,952 0.5
8 Tamsulosin 64,627 0.28 20,95 0.20
84 Zolmitriptan 68,782 0.27 4,590 0.4
85 Ciprofloxacin 59,98 0.25 25,48 0.24
86 Mometasone 574,498 0.25 6,429 0.4
87 Fluconazole 564,798 0.24 27,64 0.26
88 Acyclovir (Systemic) 56,886 0.24 6,0 0.06
89 Minocycline 56,762 0.24 26,95 0.25
90 Mirtazapine 556,40 0.24 7,585 0.7
9 Paracetamol Combs. excl. Psycholeptics 527,52 0.2 78,068 0.74
92 Captopril 508,46 0.22 24,984 0.24
9 Valaciclovir 497,857 0.2 5,75 0.05
94 Tinzaparin 48,755 0.2 2,676 0.0
95 Nebivolol 468,809 0.20 ,04 0.29
96 Zolpidem 462,05 0.20 62,5 0.59
97 Candesartan and Diuretics 460,80 0.20 5,6 0.5
98 Diltiazem 457,59 0.20 29,85 0.28
99 Salmeterol 454,90 0.9 2,667 0.2
00 Diagnostic Products 452,42 0.9 2,285 0.2
Total 189,031,805 81.08% 6,132,125 57.99%
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Table 19.5 LTI: The Top 100 Most Commonly Prescribed Products in the Order of their Prescribing Frequency
Name Prescribing Frequency % of Scheme Total Ingredient Cost E % of Scheme Total
 Diagnostic Products 222,207 .52 0,80,528 8.66
2 Metformin 46,262 7.58 505,47 0.87
 Acetylsalicylic Acid - Aspirin (Antithrombotic) 45,04 7.52 40,506 0.59
4 Atorvastatin 00,276 5.20 ,955,457 6.8
5 Needles/Syringes/Lancets 99,507 5.6 ,99,546 2.42
6 Gliclazide 85,509 4.4 96,95 .67
7 Ramipril 54,578 2.8 940,658 .62
8 Insulin Aspart 50,655 2.6 ,008,28 5.20
9 Carbamazepine 44,700 2.2 402,69 0.69
0 Sodium Valproate 4,77 2.27 548,70 0.95
 Pravastatin 6,2 .88 ,59,2 2.75
2 Insulin Glargine ,86 .75 2,567,70 4.44
 Lamotrigine ,292 .7 2,92, 4.
4 Perindopril ,07 .6 74,72 .28
5 Amlodipine 0,45 .57 659,779 .4
6 Clinical Nutritional Products 28,506 .48 ,,225 5.4
7 Phenytoin 24,79 .28 7,5 0.2
8 Insulin (Human), Comb. Intermediate/Fast Acting 2,26 .2 ,25,62 2.0
9 Atenolol 22,62 .7 4,589 0.2
20 Lisinopril 2,425 . 78,87 0.65
2 Rosiglitazone 9,8 .00 ,065,448 .84
22 Insulin (Human), Intermediate Acting 9,2 .00 787,99 .6
2 Insulin (Human), Fast Acting 8,605 0.96 86,9 .44
24 Doxazosin 8,58 0.95 642,095 .
25 Bisoprolol 8,208 0.94 99,865 0.5
26 Glimepiride 4,45 0.75 58,67 0.27
27 Insulin Detemir 4,29 0.7 ,04,97 .9
28 Rosuvastatin ,8 0.58 6,052 0.58
29 Levetiracetam ,047 0.57 ,65,852 2.0
0 Levothyroxine Sodium 0,76 0.56 26,00 0.04
 Phenobarbitone 0,7 0.54 24,824 0.04
2 Losartan 0,22 0.5 00,87 0.52
 Clopidogrel 0,068 0.52 559,806 0.97
4 Furosemide 9,65 0.50 5,76 0.0
5 Bendrofluazide 9,509 0.49 4,54 0.0
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Table 19.5 LTI: The Top 100 Most Commonly Prescribed Products in the Order of their Prescribing Frequency continued
Name Prescribing Frequency % of Scheme Total Ingredient Cost E % of Scheme Total
6 Insulin Lispro 9,89 0.48 524,927 0.9
7 Simvastatin 8,908 0.46 47,069 0.60
8 Folic Acid 8,75 0.45 0,48 0.02
9 Pancreatic Enzymes 8,009 0.42 888,2 .5
40 Valsartan 7,96 0.4 95,588 0.4
4 Glibenclamide 7,546 0.9 62,72 0.
42 Candesartan 6,74 0.5 59,752 0.28
4 Glucagon 6,670 0.5 98,80 0.4
44 Levodopa and Decarboxylase Inhibitor 6,60 0.4 0,070 0.22
45 Metformin and Rosiglitazone 6,572 0.4 ,692 0.57
46 Injection Swabs 5,974 0. 8,4 0.0
47 Topiramate 5,95 0. 47,542 0.82
48 Metoprolol 5,589 0.29 20,858 0.04
49 Captopril 5,5 0.27 5,267 0.20
50 Nebivolol 5,4 0.27 80,59 0.4
5 Warfarin 5,090 0.26 5,564 0.0
52 Bendroflumethazide and Potassium 5,075 0.26 0,928 0.02
5 Gabapentin 5,070 0.26 55,924 0.6
54 Enalapril 5,052 0.26 90,42 0.6
55 Urinary Appliances 4,842 0.25 482,76 0.8
56 Acetylsalicylic Acid - Aspirin (Anti-inflammatory) 4,620 0.24 6,722 0.0
57 Quinapril 4,426 0.2 7,47 0.
58 Omeprazole 4,08 0.22 29,66 0.4
59 Diltiazem 4,25 0.22 66,249 0.
60 Sildenafil 4,22 0.22 ,295 0.2
6 Irbesartan 4,95 0.22 ,022 0.9
62 Selegiline 4,2 0.2 46,585 0.25
6 Telmisartan 4,0 0.2 07,278 0.9
64 Salbutamol (Inhaled) 4,050 0.2 5, 0.06
65 Indapamide 4,05 0.2 ,90 0.06
66 Evening Primrose Oil (Naudicelle) 4,06 0.2 09,864 0.9
67 Vitamin A and D in Combination ,902 0.20 72,898 0.
68 Baclofen ,805 0.20 68,952 0.2
69 Amoxicillin and Enzyme Inhibitor ,625 0.9 46,47 0.08
70 Lisinopril and Diuretics ,525 0.8 69,0 0.2
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Table 19.5 LTI: The Top 100 Most Commonly Prescribed Products in the Order of their Prescribing Frequency continued
Name Prescribing Frequency % of Scheme Total Ingredient Cost E % of Scheme Total
7 Pramipexole ,502 0.8 598,496 .0
72 Isosorbide Mononitrate ,49 0.8 46,404 0.08
7 Nifedipine ,252 0.7 48,466 0.08
74 Diazepam ,4 0.6 9,659 0.02
75 Insulin Infusion Sets ,070 0.6 424,57 0.7
76 Tadalafil 2,887 0.5 87,55 0.5
77 Clobazam 2,85 0.5 6,08 0.0
78 Perindopril and Diuretics 2,788 0.4 72,2 0.2
79 Valsartan and Diuretics 2,74 0.4 69,724 0.2
80 Lansoprazole 2,77 0.4 6,92 0.20
8 Atenolol and other Diuretics 2,598 0. 26,64 0.05
82 Digoxin 2,49 0. 2,09 0.00
8 Tolterodine 2,44 0. 7,60 0.20
84 Flucloxacillin 2,4 0. 62,60 0.
85 Colistin (Parenteral) 2,427 0. 2,697 0.56
86 Paracetamol 2,70 0.2 9,88 0.02
87 Ropinirole 2,49 0.2 27,678 0.47
88 Clonazepam 2,24 0.2 7,85 0.0
89 Furosemide and Potassium-Sparing Agents 2,24 0.2 2,89 0.02
90 Fenofibrate 2,08 0.2 5,006 0.09
9 Insulin (Human), Long Acting 2,292 0.2 56,429 0.0
92 Eprosartan 2,28 0.2 5,78 0.09
9 Olmesartan 2,272 0.2 48,604 0.08
94 Dressings 2,28 0. 69,048 0.2
95 Calcium, Combinations 2,94 0. 20,89 0.04
96 Glyceryl Trinitrate 2,7 0. 8,4 0.0
97 Oxcarbazepine 2,28 0. 65,4 0.
98 Sodium Chloride 2,04 0. 29,42 0.05
99 Primidone 2,07 0. 9,25 0.0
00 Esomeprazole 2,020 0.0 86,6 0.5
Total 1,750,011 90.71% €51,672,246 89.24%
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Table 19.6 LTI:The Top 100 Products of Highest Cost in the Order of their Total Ingredient Cost
Name Ingredient Cost E  % of Scheme Total Prescribing Frequency  % of Scheme Total 
 Diagnostic Products 0,80,528 8.66 222,207 .52
2 Atorvastatin ,955,457 6.8 00,276 5.20
 Clinical Nutritional Products ,,225 5.4 28,506 .48
4 Insulin Aspart ,008,28 5.20 50,655 2.6
5 Insulin Glargine 2,567,70 4.44 ,86 .75
6 Lamotrigine 2,92, 4. ,292 .7
7 Pravastatin ,59,2 2.75 6,2 .88
8 Needles/Syringes/Lancets ,99,546 2.42 99,507 5.6
9 Insulin (Human), Comb. Intermediate/Fast Acting ,25,62 2.0 2,26 .2
0 Levetiracetam ,65,852 2.0 ,047 0.57
 Insulin Detemir ,04,97 .9 4,29 0.7
2 Rosiglitazone ,065,448 .84 9,8 .00
 Gliclazide 96,95 .67 85,509 4.4
4 Ramipril 940,658 .62 54,578 2.8
5 Pancreatic Enzymes 888,2 .5 8,009 0.42
6 Insulin (Human), Fast Acting 86,9 .44 8,605 0.96
7 Insulin (Human), Intermediate Acting 787,99 .6 9,2 .00
8 Perindopril 74,72 .28 ,07 .6
9 Amlodipine 659,779 .4 0,45 .57
20 Doxazosin 642,095 . 8,58 0.95
2 Pramipexole 598,496 .0 ,502 0.8
22 Apomorphine 577,25 .00 774 0.04
2 Clopidogrel 559,806 0.97 0,068 0.52
24 Sodium Valproate 548,70 0.95 4,77 2.27
25 Insulin Lispro 524,927 0.9 9,89 0.48
26 Metformin 505,47 0.87 46,262 7.58
27 Urinary Appliances 482,76 0.8 4,842 0.25
28 Topiramate 47,542 0.82 5,95 0.
29 Insulin Infusion Sets 424,57 0.7 ,070 0.6
0 Carbamazepine 402,69 0.69 44,700 2.2
 Lisinopril 78,87 0.65 2,425 .
2 Gabapentin 55,924 0.6 5,070 0.26
 Simvastatin 47,069 0.60 8,908 0.46
4 Acetylsalicylic Acid - Aspirin (Antithrombotic) 40,506 0.59 45,04 7.52
5 Rosuvastatin 6,052 0.58 ,8 0.58
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Table 19.6 LTI:The Top 100 Products of Highest Cost in the Order of their Total Ingredient Cost continued
Name Ingredient Cost E  % of Scheme Total Prescribing Frequency  % of Scheme Total 
6 Metformin and Rosiglitazone ,692 0.57 6,572 0.4
7 Colistin (Parenteral) 2,697 0.56 2,427 0.
8 Nutritional/Ancillary Devices 09,869 0.54 ,792 0.09
9 Losartan 00,87 0.52 0,22 0.5
40 Ropinirole 27,678 0.47 2,49 0.2
4 Omeprazole 29,66 0.4 4,08 0.22
42 Bisoprolol 99,865 0.5 8,208 0.94
4 Glucagon 98,80 0.4 6,670 0.5
44 Valsartan 95,588 0.4 7,96 0.4
45 Metamfetamine 76,28 0.0 ,7 0.07
46 Candesartan 59,752 0.28 6,74 0.5
47 Glimepiride 58,67 0.27 4,45 0.75
48 Selegiline 46,585 0.25 4,2 0.2
49 Tizanidine 46,285 0.25 ,20 0.07
50 Azithromycin 40,982 0.24 ,94 0.0
5 Atenolol 4,589 0.2 22,62 .7
52 Sildenafil ,295 0.2 4,22 0.22
5 Levodopa and Decarboxylase Inhibitor 0,070 0.22 6,60 0.4
54 Orlistat 29,920 0.22 ,948 0.0
55 Pregabalin 26,590 0.22 ,270 0.07
56 Desmopressin 8,2 0.20 ,827 0.09
57 Tolterodine 7,60 0.20 2,44 0.
58 Lansoprazole 6,92 0.20 2,77 0.4
59 Captopril 5,267 0.20 5,5 0.27
60 Ostomy Appliances ,568 0.9 ,69 0.06
6 Irbesartan ,022 0.9 4,95 0.22
62 Evening Primrose Oil (Naudicelle) 09,864 0.9 4,06 0.2
6 Telmisartan 07,278 0.9 4,0 0.2
64 Insulin (Human), Fast Acting Combinations 96,96 0.7 ,666 0.09
65 Entacapone 9,82 0.6 92 0.05
66 Enalapril 90,42 0.6 5,052 0.26
67 Salmeterol and other drugs for obstructive airway diseases 88,044 0.5 ,7 0.06
68 Tadalafil 87,55 0.5 2,887 0.5
69 Esomeprazole 86,6 0.5 2,020 0.0
70 Meropenem 82,472 0.4 59 0.00
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Table 19.6 LTI: The Top 100 Products of Highest Cost in the Order of their Total Ingredient Cost continued
Name Ingredient Cost E  % of Scheme Total Prescribing Frequency  % of Scheme Total 
7 Nebivolol 80,59 0.4 5,4 0.27
72 Levocarnitine 79,427 0.4 5 0.0
7 Ciprofloxacin 78, 0.4 ,498 0.08
74 Ezetimibe 74,26 0. ,840 0.0
75 Quinapril 7,47 0. 4,426 0.2
76 Vitamin A and D in Combination 72,898 0. ,902 0.20
77 Perindopril and Diuretics 72,2 0.2 2,788 0.4
78 Phenytoin 7,5 0.2 24,79 .28
79 Valsartan and Diuretics 69,724 0.2 2,74 0.4
80 Cabergoline 69,450 0.2 40 0.02
8 Lisinopril and Diuretics 69,0 0.2 ,525 0.8
82 Dressings 69,048 0.2 2,28 0.
8 Baclofen 68,952 0.2 ,805 0.20
84 Alimentary Tract/Metabolism,  Various Products 67,722 0.2 6 0.02
85 Diltiazem 66,249 0. 4,25 0.22
86 Oxcarbazepine 65,4 0. 2,28 0.
87 Risperidone 64,805 0. ,27 0.06
88 Ceftazidime 64,276 0.  0.0
89 Repaglinide 62,98 0. ,886 0.0
90 Modafinil 62,905 0. 406 0.02
9 Glibenclamide 62,72 0. 7,546 0.9
92 Flucloxacillin 62,60 0. 2,4 0.
9 Vigabatrin 60,84 0. 959 0.05
94 Gemfibrozil 59,20 0.0 ,824 0.09
95 I.V.  Administration 57,87 0.0  0.02
96 Insulin (Human), Long Acting 56,429 0.0 2,292 0.2
97 Budesonide (Inhaled) 55,45 0.0 684 0.04
98 Eprosartan 5,78 0.09 2,28 0.2
99 Sodium Phenylbutyrate 5,22 0.09 77 0.00
00 Oxybutynin 52,56 0.09 ,762 0.09
Total €54,177,302 93.56% 1,655,783 85.84%
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Table 20 GMS: Distribution of Medicines and Appliances by Anatomical Therapeutic Chemical Classification
ATC 
Class
Product Category Prescribing 
Frequency
 % of Scheme 
Total 
Ingredient Cost  
E
% of Scheme 
Total 
A Alimentary Tract and Metabolism 4,599,054 12.25 106,131,908 15.96
A01 Stomatological Preparations 8,9 0.22 02,49 0.05
A02 Drugs for Acid Related Disorders 2,06,88 5.49 70,97,52 0.67
A03 Drugs for Functional Gastrointestinal Disorders 4,202 0.89 2,027,789 0.0
A04 Anti-emetics and Anti-nauseants 7,74 0.05 2,575,654 0.9
A05 Bile and Liver Therapy 9,508 0.02 468,40 0.07
A06 Laxatives 50,967 .6 4,68,826 0.6
A07 Antidiarrheals, Intestinal Anti-inflammatory/Anti-infective Agents 9,682 0.52 ,84,800 0.48
A08 Anti-obesity Preparations excl. Diet Products 47,464 0. ,08,45 0.46
A09 Digestives, including Enzymes 8,580 0.02 87,7 0.
A10 Drugs Used in Diabetes 770,88 2.05 ,85,84 2.08
A11 Vitamins 5,0 0.4 67,82 0.09
A12 Mineral Supplements 50,00 .6 4,08,550 0.6
B Blood and Blood Forming Organs 3,299,014 8.78 24,046,352 3.61
B01 Antithrombotic Agents 2,765,44 7.6 22,768,42 .42
B02 Antihemorrhagics 9,60 0.0 20,882 0.02
B03 Anti-anemic Preparations 524,24 .9 ,56,560 0.7
B05 Blood Substitutes and Perfusion Solutions 46 0.00 487 0.00
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Table 20 GMS: Distribution of Medicines and Appliances by Anatomical Therapeutic Chemical Classification continued
ATC 
Class
Product Category Prescribing 
Frequency
% of Scheme 
Total
Ingredient Cost  
E
% of Scheme 
Total
C  Cardiovascular System 9,377,404 24.97 162,026,128 24.36
C01 Cardiac Therapy 870,4 2.2 8,7,9 .22
C02 Antihypertensives 28,70 0.75 7,824,48 .8
C03 Diuretics ,75,246 4.62 4,86,9 0.7
C04 Peripheral Vasodilators 6,098 0.6 99,760 0.5
C05 Vasoprotectives 94,776 0.25 604,25 0.09
C07 Beta Blocking Agents ,526,820 4.07 2,8,405 .82
C08 Calcium Channel Blockers 889,662 2.7 5,545,702 2.4
C09 Agents Acting on the Renin-Angiotensin System ,995,675 5. 9,596,479 5.95
C10 Serum Lipid Reducing Agents ,922,254 5.2 72,4,848 0.88
D  Dermatologicals 1,073,983 2.86 10,448,296 1.57
D01 Antifungals for Dermatological Use 249,96 0.66 ,4,984 0.50
D02 Emollients and Protectives 6,892 0. 29,220 0.05
D03 Preparations for Treatment of  Wounds and Ulcers ,092 0.00 ,725 0.00
D05 Antipsoriatics 47,69 0. 2,22,897 0.
D06 Antibiotics and Chemotherapeutics for Dermatological Use 24,95 0. 992,782 0.5
D07 Corticosteroids, Dermatological Preparations 49,466 . 2,90,478 0.6
D10 Anti-Acne Preparations 2,779 0.09 565,24 0.09
D11 Other Dermatological Preparations 0,26 0.0 579,976 0.09
G Genito Urinary System and Sex Hormones 1,356,355 3.61 25,978,378 3.91
G01 Gynecological Anti-infectives and Antiseptics 2,70 0.06 28,628 0.02
G02 Other Gynecologicals ,4 0.04 ,042,27 0.6
G03 Sex Hormones and Modulators of the Genital System 79,9 2. 6,467,609 0.97
G04 Urologicals 527,28 .40 8,9,868 2.76
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Table 20 GMS: Distribution of Medicines and Appliances by Anatomical Therapeutic Chemical Classification continued
ATC 
Class
Product Category Prescribing 
Frequency
% of Scheme 
Total
Ingredient 
Cost E
% of Scheme 
Total
H  Systemic Hormonal Preparations, Excl. Sex Hormones and Insulins 1,112,257 2.96 3,098,939 0.47
H01  Pituitary, Hypothalamic Hormones and Analogues 2,40 0.0 66,7 0.0
H02  Corticosteroids for Systemic Use 457,09 .22 960,65 0.4
H03  Thyroid Therapy 68,424 .70 ,68,5 0.2
H04  Pancreatic Hormones 4,09 0.0 29,45 0.02
H05  Calcium Homeostasis 82 0.00 ,567 0.00
J  Anti-infectives for Systemic Use 2,048,067 5.45 22,650,990 3.41
J01  Antibacterials for Systemic Use ,974,72 5.26 9,24,974 2.9
J02  Antimycotics for Systemic Use 49,56 0. ,28,954 0.9
J04  Antimycobacterials 2,94 0.0 70,08 0.0
J05  Antivirals for Systemic Use 20,558 0.05 2,0,227 0.0
J07  Vaccines 27 0.00 ,527 0.00
L  Antineoplastic and Immunomodulating Agents 181,340 0.48 6,568,060 0.99
L01  Antineoplastic Agents ,228 0.0 206,24 0.0
L02  Endocrine Therapy 77,80 0.2 4,790, 0.72
L04  Immunosuppressive Agents 90,02 0.24 ,57,686 0.24
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Table 20 GMS: Distribution of Medicines and Appliances by Anatomical Therapeutic Chemical Classification continued
ATC 
Class
Product Category Prescribing 
Frequency
% of Scheme 
Total
Ingredient 
Cost E
% of Scheme 
Total
M  Musculo-Skeletal System 2,451,731 6.53 42,627,684 6.41
M01  Anti-inflammatory and Antirheumatic Products ,486,90 .96 22,554,500 .9
M02  Topical Products for Joint and Muscular Pain 78,58 .0 2,867,56 0.4
M03  Muscle Relaxants ,60 0.08 ,084,088 0.6
M04  Antigout Preparations 8,806 0.7 98,844 0.5
M05  Drugs for treatment of Bone Diseases 45,656 . 5,08,509 2.27
M09  Other Drugs for Disorders of the Musculo-Skeletal System 44 0.00 56,227 0.0
N  Nervous System 7,199,805 19.17 132,866,442 19.98
N01  Anaesthetics ,707 0.0 0,262 0.00
N02  Analgesics ,72,900 4.58 5,900,966 2.9
N03  Anti-epileptics 569,04 .52 5,29,00 2.0
N04  Anti-Parkinson Drugs 94,2 0.52 4,064,560 0.6
N05  Psycholeptics 2,9,524 7.75 4,67,52 6.27
N06  Psychoanaleptics ,54,64 4.0 50,29,97 7.57
N07  Other Nervous System Drugs 260,57 0.69 5,598,55 0.84
P  Antiparasitic Products, Insecticides and Repellents 63,998 0.17 374,641 0.05
P01  Antiprotozoals 8, 0.0 20,0 0.0
P02  Anthelmintics 7,555 0.02 2,4 0.00
P03  Ectoparasiticides, incl. Scabicides, Insecticides and Repellents 8,0 0.05 50,97 0.02
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Table 20 GMS: Distribution of Medicines and Appliances by Anatomical Therapeutic Chemical Classification continued
ATC 
Class
Product Category Prescribing 
Frequency
% of Scheme 
Total
Ingredient 
Cost E
% of Scheme 
Total
R  Respiratory System 2,745,138 7.31 63,292,283 9.52
R01  Nasal Preparations 8,748 0.49 2,8,99 0.2
R02  Throat Preparations 8,757 0.02 9,9 0.00
R03  Drugs for Obstructive Airway Diseases 2,060,68 5.49 57,82,822 8.70
R05  Cough and Cold Preparations 27,56 0.7 ,404,47 0.2
R06  Antihistamines for Systemic Use 27,649 0.58 ,902,22 0.29
R07  Other Respiratory System Products ,05 0.00 2,76 0.00
S  Sensory Organs 955,714 2.54 9,011,839 1.36
S01  Ophthalmologicals 876,405 2. 8,722,888 .
S02  Otologicals 8,66 0.0 80,4 0.0
S03  Ophthalmological and Otological Preparations 40,69 0. 08,58 0.02
V  Various 1,097,208 2.92 55,842,736 8.40
V03  Other Therapeutic Products 9,750 0.0 ,590,669 0.24
V04  Diagnostic Products 275,247 0.7 0,846,49 .6
V06  Clinical Nutritional Products 89,596 .04 28,762,507 4.
V07  All Other Non-Therapeutic Products: 422,65 .2 4,64,2 2.20
 Needles/Syringes/Lancets 121,541 0.32 1,601,234 0.24
 Ostomy Requisites 80,869 0.21 8,704,903 1.31
 Urinary Requisites 41,590 0.11 3,030,816 0.46
 Dressings 25,043 0.07 994,308 0.15
 Miscellaneous 153,572 0.41 311,950 0.04
 Total 37,561,068 100.00% €664,964,676 100.00%
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Table 20.1 DP: Distribution of Medicines and Appliances by Anatomical Therapeutic Chemical Classification
ATC 
Class
Product Category Prescribing 
Frequency
% of Scheme 
Total
Ingredient 
Cost E
% of Scheme 
Total
A Alimentary Tract and Metabolism 1,152,963 10.89 36,135,540 15.50
A01 Stomatological Preparations 22,82 0.2 85,298 0.04
A02 Drugs for Acid Related Disorders 62,675 5.98 25,658,6 .00
A03 Drugs for Functional Gastrointestinal Disorders 92,260 0.87 69,788 0.27
A04 Anti-emetics and Antinauseants 7,96 0.08 904,5 0.9
A05 Bile and Liver Therapy 5,25 0.05 24,825 0.4
A06 Laxatives 58,669 0.55 482,75 0.2
A07 Antidiarrheals, Intestinal Anti-inflammatory/Anti-infective Agents 88,6 0.8 ,220,4 .8
A08 Anti-obesity Preparations excluding Diet Products 4,9 0.9 2,699,29 .6
A09 Digestives, including Enzymes ,99 0.0 78,708 0.0
A10 Drugs used in Diabetes ,276 0. 40,58 0.9
A11 Vitamins 4,08 0.4 26,55 0.0
A12 Mineral Supplements 55,242 .47 ,74,7 0.59
A14 Anabolic Agents for Systemic Use 26 0.00 480 0.00
A16 Other Alimentary Tract/Metabolism Products  0.00  0.00
B Blood and Blood Forming Organs 757,565 7.16 6,705,979 2.87
B01 Antithrombotic Agents 667,6 6. 6,40,77 2.75
B02 Antihemorrhagics ,986 0.04 49,985 0.02
B03 Anti-anemic Preparations 86,28 0.8 244,520 0.0
B05 Blood Substitutes and Perfusion Solutions 25 0.00 757 0.00
Note: The above costs are inclusive of the monthly payment of €85 payable to the Pharmacy by an individual or family.
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Table 20.1 DP: Distribution of Medicines and Appliances by Anatomical Therapeutic Chemical Classification continued
ATC 
Class
Product Category Prescribing 
Frequency
% of Scheme 
Total
Ingredient 
Cost E
% of Scheme 
Total
C Cardiovascular System 2,683,640 25.36 59,916,357 25.69
C01 Cardiac Therapy 0,00 0.97 ,57,9 0.58
C02 Antihypertensives 8,90 0.77 2,50,48 .07
C03 Diuretics 27,24 2.56 87, 0.7
C04 Peripheral Vasodilators ,964 0.04 8,4 0.04
C05 Vasoprotectives 7,00 0.5 220,95 0.09
C07 Beta Blocking Agents 485,044 4.58 4,26,440 .8
C08 Calcium Channel Blockers 229,299 2.7 4,240,798 .82
C09 Agents Acting on the Renin-Angiotensin System 659,869 6.24 4,227,889 6.0
C10 Serum Lipid Reducing Agents 8,027 7.68 2,97,082 .8
D Dermatologicals 447,599 4.23 10,253,147 4.40
D01 Antifungals for Dermatological Use 29,666 .2 ,568,9 .5
D02 Emollients and Protectives 26,44 0.25 94,44 0.04
D03 Preparations for Treatment of Wounds and Ulcers 82 0.00 44,69 0.02
D04 Antipruritics including Antihistamines, Anaesthetics, etc. 592 0.0 9,288 0.0
D05 Antipsoriatics 4,78 0.9 2,706,24 .6
D06 Antibiotics and Chemotherapeutics for Dermatological Use 8,09 0.6 498,64 0.2
D07 Corticosteroids Dermatological Preparations 5,26 .45 856,2 0.7
D08 Antiseptics and Disinfectants 4 0.00 2 0.00
D10 Anti-Acne Preparations 4,7 0.4 ,484,254 0.64
D11 Other Dermatological Preparations ,65 0. 98,707 0.42
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Table 20.1 DP: Distribution of Medicines and Appliances by Anatomical Therapeutic Chemical Classification continued
ATC 
Class
Product Category Prescribing 
Frequency
% of Scheme 
Total
Ingredient 
Cost E
% of Scheme 
Total
G Genito Urinary System and Sex Hormones 523,913 4.95 16,348,331 7.01
G01 Gynecological Anti-infectives and Antiseptics 8,244 0.08 46,282 0.02
G02 Other Gynecologicals 5,885 0.5 ,676,75 0.72
G03 Sex Hormones and Modulators of the Genital System 6,674 .42 9,79,777 4.7
G04 Urologicals 8,0 .0 4,905,557 2.0
H Systemic Hormonal Preparations, Excl. Sex Hormones and Insulins 360,969 3.41 1,247,425 0.54
H01  Pituitary, Hypothalamic Hormones and Analogues 7,078 0.07 424,607 0.8
H02  Corticosteroids for Systemic Use 46,90 .8 9,64 0.5
H03  Thyroid Therapy 207,294 .96 475,849 0.2
H04  Pancreatic Hormones 9 0.00 4,4 0.00
H05  Calcium Homeostasis 68 0.00 2,985 0.00
J  Anti-infectives for Systemic Use 680,997 6.44 10,725,088 4.60
J01  Antibacterials for Systemic Use 626,550 5.92 7,669,9 .29
J02  Antimycotics for Systemic Use ,900 0.2 ,009,880 0.4
J04  Antimycobacterials ,760 0.02 49,27 0.02
J05  Antivirals for Systemic Use 8,67 0.8 ,995,70 0.86
J07  Vaccines 4 0.00 ,070 0.00
L  Antineoplastic and Immunomodulating Agents 85,935 0.81 3,336,871 1.43
L01  Antineoplastic Agents 4,6 0.04 0,697 0.04
L02  Endocrine Therapy 22,807 0.2 ,724,825 0.74
L04  Immunosuppressive Agents 59,02 0.56 ,508,49 0.65
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Table 20.1 DP: Distribution of Medicines and Appliances by Anatomical Therapeutic Chemical Classification continued
ATC 
Class
Product Category Prescribing 
Frequency
% of Scheme 
Total
Ingredient 
Cost E
% of Scheme 
Total
M Musculo-Skeletal System 782,552 7.40 14,905,268 6.39
M01 Anti-inflammatory and Antirheumatic Products 56,97 4.89 8,740,029 .75
M02 Topical Products for Joint and Muscular Pain 75,79 0.7 594,88 0.25
M03 Muscle Relaxants ,978 0.04 4,89 0.06
M04 Antigout Preparations 49,42 0.47 409,56 0.8
M05 Drugs for treatment of Bone Diseases 6,547 .29 4,99,8 2.4
M09 Other Drugs for Disorders of the Musculo-Skeletal System 254 0.00 4,786 0.0
N Nervous System 1,592,540 15.05 35,500,996 15.23
N01 Anaesthetics 65 0.0 92,46 0.04
N02 Analgesics 52,887 . 5,00,955 2.5
N03 Anti-epileptics 95,8 0.9 ,66,254 .55
N04 Anti-Parkinson Drugs 4,640 0.4 74,26 0.6
N05 Psycholeptics 58,584 5.5 8,409,569 .6
N06 Psychoanaleptics 5,6 4.85 7,2,58 7.4
N07 Other Nervous System Drugs ,70 0.0 67,940 0.29
P Antiparasitic Products, Insecticides and Repellents 24,895 0.23 320,006 0.14
P01 Antiprotozoals 22,40 0.2 00,99 0.
P02 Anthelmintics ,0 0.0 4,000 0.00
P03 Ectoparasiticides, incl. Scabicides, Insecticides and Repellents ,454 0.0 5,05 0.0
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Table 20.1 DP: Distribution of Medicines and Appliances by Anatomical Therapeutic Chemical Classification continued
ATC 
Class
Product Category Prescribing 
Frequency
% of Scheme 
Total
Ingredient 
Cost E
% of Scheme 
Total
R Respiratory System 1,086,842 10.27 27,206,227 11.67
R01 Nasal Preparations ,8 .24 ,75,04 0.75
R02 Throat Preparations 2,575 0.0 5,792 0.00
R03 Drugs for Obstructive Airway Diseases 795,004 7.5 24,080,005 0.
R05 Cough and Cold Preparations 5,20 0.50 295,27 0.
R06 Antihistamines for Systemic Use 04,804 0.99 ,072,590 0.46
R07 Other Respiratory System Products 68 0.00 ,470 0.00
S Sensory Organs 214,316 2.03 1,883,646 0.81
S01 Ophthalmologicals 79,95 .70 ,768,689 0.76
S02 Otologicals 4,20 0.4 66,5 0.0
S03 Ophthalmological and Otological Preparations 20,28 0.9 48,424 0.02
V Various 186,963 1.77 8,676,625 3.72
V03 Other Therapeutic Products ,5 0.0 255,0 0.
V04 Diagnostic Products 2,285 0.2 452,42 0.9
V06 Clinical Nutritional Products 9,425 0.87 ,82,96 .65
V07 All Other Non-Therapeutic Products: 8,722 0.77 4,6,694 .77
  Ostomy Appliances 33,541 0.32 2,842,473 1.22
  Needles/Syringes/Lancets 16,399 0.15 77,274 0.03
  Dressings 9,727 0.09 288,940 0.12
  Urinary Appliances 7,704 0.07 812,093 0.35
  Miscellaneous 14,351 0.14 115,914 0.05
Total 10,581,689 100.00% €233,161,506 100.00%
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Table 20.2 LTI: Distribution of Medicines and Appliances by Anatomical Therapeutic Chemical Classification
ATC 
Class
Product Category Prescribing 
Frequency
% of Scheme 
Total
Ingredient 
Cost E
% of Scheme 
Total
A  Alimentary Tract and Metabolism 512,930 26.59 15,730,309 27.17
A01  Stomatological Preparations 729 0.04 ,69 0.0
A02  Drugs for Acid Related Disorders 2,885 0.67 546,482 0.94
A03  Drugs for Functional Gastrointestinal Disorders ,684 0.09 2,005 0.04
A04  Anti-emetics and Antinauseants 679 0.04 48,9 0.08
A05  Bile and Liver Therapy 750 0.04 42,84 0.07
A06  Laxatives 6,925 0.6 68,256 0.2
A07  Antidiarrheals, Intestinal Anti-inflammatory/Anti-infective Agents 945 0.05 25,09 0.04
A08  Anti-obesity Preparations excluding Diet Products 2,52 0. 68,2 0.29
A09  Digestives, including Enzymes 8,02 0.4 90,7 .56
A10  Drugs used in Diabetes 458,46 2.75 ,4,094 2.7
A11  Vitamins 4,70 0.76 246,559 0.4
A12  Mineral Supplements ,65 0.7 ,80 0.05
A13  Tonics 24 0.00 26 0.00
A14  Anabolic Agents for Systemic Use 2 0.00 82 0.00
A16  Other Alimentary Tract and Metabolism Products ,522 0.08 24,29 0.7
B  Blood and Blood Forming Organs 173,408 8.99 981,147 1.69
B01  Antithrombotic Agents 6,274 8.6 95,669 .6
B02  Antihemorrhagics 245 0.0 ,065 0.0
B03  Anti-anemic Preparations ,54 0.60 24,927 0.04
B05  Blood Substitutes and Perfusion Solutions 55 0.02 7,486 0.0
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Table 20.2 LTI: Distribution of Medicines and Appliances by Anatomical Therapeutic Chemical Classification continued
ATC 
Class
Product Category Prescribing 
Frequency
% of Scheme 
Total
Ingredient 
Cost E
% of Scheme 
Total
C Cardiovascular System 508,801 26.37 12,512,986 21.62
C01 Cardiac Therapy 0,277 0.5 5,4 0.20
C02 Antihypertensives 9,262 .00 665,768 .5
C03 Diuretics 4,76 .80 29,958 0.22
C04 Peripheral Vasodilators 654 0.0 ,72 0.02
C05 Vasoprotectives 27 0.0 ,0 0.00
C07 Beta Blocking Agents 59,987 . 54,686 0.94
C08 Calcium Channel Blockers 42,0 2.8 86,55 .45
C09 Agents Acting on the Renin-Angiotensin System 75,56 9.08 ,696,45 6.9
C10 Serum Lipid Reducing Agents 66,452 8.6 6,50,724 .25
D Dermatologicals 7,092 0.37 76,337 0.13
D01 Antifungals for Dermatological Use 2,06 0. 29,695 0.05
D02 Emollients and Protectives ,65 0.09 9,897 0.02
D03 Preparations for Treatment of Wounds and Ulcers 25 0.00 724 0.00
D04 Antipruritics including Antihistamines,  Anaesthetics, etc. 20 0.0 2,284 0.00
D05 Antipsoriatics 262 0.0 ,408 0.02
D06 Antibiotics and Chemotherapeutics for Dermatological Use 497 0.0 ,608 0.0
D07 Corticosteroids, Dermatological Preparations ,509 0.08 7,566 0.0
D08 Antiseptics and Disinfectants 425 0.02 ,664 0.0
D10 Anti-Acne Preparations 06 0.00 ,486 0.00
D11 Other Dermatological Preparations 46 0.02 4,005 0.0
G Genito Urinary System and Sex Hormones 17,477 0.91 574,950 0.99
G01 Gynecological Anti-infectives and Antiseptics 48 0.0 5,877 0.0
G02 Other Gynecologicals 86 0.0 9,98 0.0
G03 Sex Hormones and Modulators of the Genital System 2,07 0. 28,78 0.05
G04 Urologicals 5,6 0.78 520,777 0.90
00 0
Table 20.2 LTI: Distribution of Medicines and Appliances by Anatomical Therapeutic Chemical Classification continued
ATC 
Class
Product Category Prescribing 
Frequency
% of Scheme 
Total
Ingredient 
Cost E
% of Scheme 
Total
H  Systemic Hormonal Preparations, Excl. Sex 23,524 1.22 380,415 0.66
 Hormones and Insulins
H01  Pituitary, Hypothalamic Hormones and Analogues ,856 0.0 0,457 0.2
H02  Corticosteroids for Systemic Use ,68 0.9 2,659 0.04
H03  Thyroid Therapy ,298 0.59 27,775 0.05
H04  Pancreatic Hormones 6,670 0.4 98,80 0.4
H05  Calcium Homeostasis 7 0.00 2,44 0.00
J  Anti-infectives for Systemic Use 20,099 1.04 1,070,028 1.85
J01  Antibacterials for Systemic Use 9,095 0.99 999,400 .7
J02  Antimycotics for Systemic Use 57 0.0 2,896 0.04
J04  Antimycobacterials 52 0.0 6,07 0.0
J05  Antivirals for Systemic Use 26 0.0 2,952 0.04
J06  Immune Sera and Immunoglobulins 4 0.00 7,944 0.0
J07  Vaccines 4 0.00 729 0.00
L  Antineoplastic and Immunomodulating Agents 1,571 0.08 55,044 0.10
L01  Antineoplastic Agents 42 0.02 22,84 0.04
L02  Endocrine Therapy 65 0.0 9,727 0.02
L04  Immunosuppressive Agents 985 0.05 22,476 0.04
00 0
Table 20.2 LTI: Distribution of Medicines and Appliances by Anatomical Therapeutic Chemical Classification continued
ATC 
Class
Product Category Prescribing 
Frequency
% of Scheme 
Total
Ingredient 
Cost E
% of Scheme 
Total
M  Musculo-Skeletal System 15,292 0.79 388,456 0.67
M01  Anti-inflammatory and Antirheumatic Products 5,480 0.28 82,78 0.4
M02  Topical Products for Joint and Muscular Pain 580 0.0 5,742 0.0
M03  Muscle Relaxants 5,28 0.27 22,075 0.8
M04  Antigout Preparations ,89 0.0 5,587 0.0
M05  Drugs for treatment of Bone Diseases ,667 0.09 6,508 0.
M09  Other Drugs for Disorders of the Musculo-Skeletal System 89 0.02 ,806 0.00
N  Nervous System 252,911 13.11 8,719,718 15.06
N01  Anaesthetics 250 0.0 7,52 0.0
N02  Analgesics ,85 0.58 92,445 0.6
N03  Anti-epileptics 89,479 9.82 5,805,646 0.0
N04  Anti-Parkinson Drugs 22,45 .6 ,94,604 .4
N05  Psycholeptics 6,25 0.84 295,885 0.5
N06  Psychoanaleptics 2,48 0.64 540,7 0.9
N07  Other Nervous System Drugs ,07 0.06 4,054 0.07
P  Antiparasitic Products, Insecticides and Repellents 153 0.01 1,654 0.00
P01  Antiprotozoals 29 0.0 ,455 0.00
P02  Anthelmintics 4 0.00 80 0.00
P03  Ectoparasiticides, incl. Scabicides, Insecticides and Repellents 0 0.00 9 0.00
02 0
Table 20.2 LTI: Distribution of Medicines and Appliances by Anatomical Therapeutic Chemical Classification continued
ATC 
Class
Product Category Prescribing 
Frequency
% of Scheme 
Total
Ingredient 
Cost E
% of Scheme 
Total
R  Respiratory System 13,686 0.71 324,411 0.56
R01  Nasal Preparations ,57 0.08 2,00 0.04
R02  Throat Preparations 27 0.00 57 0.00
R03  Drugs for Obstructive Airway Diseases 9,775 0.50 284,282 0.49
R05  Cough and Cold Preparations 87 0.05 5,8 0.0
R06  Antihistamines for Systemic Use ,494 0.08 ,56 0.02
S  Sensory Organs 5,832 0.30 78,765 0.14
S01  Ophthalmologicals 5,48 0.28 77,42 0.4
S02  Otologicals 6 0.0 848 0.00
S03  Ophthalmological and Otological Preparations 88 0.0 485 0.00
V  Various 376,335 19.51 16,993,492 29.36
V03  Other Therapeutic Products 222 0.0 ,267 0.06
V04  Diagnostic Products 222,207 .52 0,80,528 8.66
V06  Clinical Nutritional Products 28,506 .48 ,,225 5.4
V07  All Other Non-Therapeutic Products: 25,400 6.50 ,027,472 5.2
  Needles/Syringes/Lancets/Swabs 108,568 5.63 1,843,046 3.19
  Dressings 2,218 0.11 69,048 0.12
  Urinary Appliances 4,983 0.26 491,615 0.85
  Nutritional/Ancillary Devices 2,501 0.13 371,807 0.64
  Ostomy Appliances 1,073 0.06 105,738 0.18
  Miscellaneous 6,057 0.31 146,218 0.25
 Total 1,929,111 100.00% €57,887,712 100.00%
02 0
Table 21 GMS: Average Payment to Doctors in Panel Ranges
Health 
Service  
Executive
Average Panel Ranges in 2005
0-100
        
101-250
        
251-500
        
501-1,000
        
1,001-1,500
        
1,501-2,000
        
2,001 and Over
        
East Coast Area 24,2 (22) 8,2 (7) 59,768 (49) 259,74 (6) 8,048 () - -
South Western 
Area 22,295 (28) 57,500 (4) 29,070 (46) 227,766 (8) 6,294 (42) 92,45 (4) 459,056 ()
Northern Area 26,625 () 69,07 (22) ,552 (42) 225,660 (7) 7,4 (28) 46,48 (0) 569,490 ()
Midland 72,52 (6) 6,9 (7) 40,78 (22) 270,6 (47) 40,9 (20) - -
Mid-Western 2,6 (0) 77,6 (27) 44,92 () 2,72 (75) 55,889 (8) 8,87 (4) -
North Eastern 5, (6) 57,65 (8) 0,49 (0) 22,455 (8) 2,5 (9) 426,855 () -
North Western ,874 (7) 62,494 (0) 5,6 (2) 28,80 (47) 48,807 (6) 455,707 (7) -
South Eastern 9,57 (7) 70,0 (9) 52,70 (9) 252,908 (2) 5,67 (28) 49,889 (5) -
Southern 25,508 (0) 66,72 (45) 44,998 (79) 249,27 (6) 5,422 (0) 549,759 (2) 44,05 ()
Western 22,44 () 64,5 (29) 25,09 (55) 26,759 (0) 66,60 (28) 499,295 () -
National 2005 25,556 (142) 68,250 (248) 139,553 (416) 244,750 (812) 343,234 (252) 434,176 (34) 476,142 (5)
National 2004 e26,9 (59) e57,689 (228) e0,548 (88) e85,92 (78) e267,7 (262) e4,90 (2) e57,897 (5)
Note: (i) Doctors not in the GMS Scheme for the full year have been excluded from the above table.
 (ii) The number of Doctors in each range is shown in brackets.
 (iii) The average payment to Doctors in each panel range is the gross payments divided by the number of Doctors in that range.
 (iv) Doctors payment is exclusive of superannuation paid to retired DMOs.
04 05
Table 21.1 GMS: Number of Doctors in Payment Ranges
Health 
Service 
Executive
Up to 
€30,000
€30,001 -  
€60,000
 €60,001 - 
 €90,000
€90,001-
€120,000
€120,001 - 
€150,000
€150,001-
€180,000
€180,001-
€210,000
€210,001-
€240,000
€240,001-
€270,000
€270,001-
€370,000
€370,001-
€470,000
€470,001 
and Over
East Coast 
Area 9 (20)  (24) 2 (26) 7 (4) 4 (2) 5 (5)  (7)  (4) 0 (9)  (7) 5 ()  (-)
South 
Western 
Area
29 (27) 20 (26) 8 (25) 5 (29) 2 (26) 2 (25)  (2) 9 (4) 9 (5) 4 (2) 5 (2)  () 
Northern 
Area 0 ()  (20) 9 (4) 5 (2) 7 (5)  (27) 6 (9) 22 ()  (2) 2 (4)  (5) 6 (2) 
Midland 6 (5) 4 (7) 4 (7) 4 (7) 4 (0) 0 () 0 (6) 8 (7) 0 (8) 2 (4) 0 (-) - (-)
Mid-
Western 5 (7) 8 () 9 (6) 2 (20) 7 (28) 2 (6) 4 (7)  (7) 8 (0) 0 () 8 () 2 (-)
North 
Eastern 6 (8) 6 (4) 6 () 6 (8) 5 (5) 8 (24) 6 (9) 24 (20) 4 (8) 27 () 6 (-)  (-)
North 
Western 6 (6) 5 (6) 6 (2) 8 (8) 8 (7) 8 (4) 9 () 0 (9)  () 5 (2) 5 () 5 (-)
South 
Eastern 8 (5) 9 (5) 8 () 2 (20) 4 (29) 9 (28) 9 (29) 2 (24) 28 (20) 5 (20) 6 (2) 5 (-)
Southern 25 (4) 20 (27) 2 () 25 (8) 2 (4) 4 (2) 0 (9) 24 (0) 6 (9) 5 (2) 5 (4) 6 (-)
Western 5 (4) 8 (28) 2 (2) 8 (20) 6 (9) 8 (24) 22 (25) 2 (9) 8 (20) 4 (28) 8 (2) 7 (-)
National 139 (137) 126 (180) 156 (178) 132 (206) 151 (211) 159 (218) 160 (217) 177 (185) 179 (132) 375 (170) 119 (20) 36 (3)
Note: (i) Doctors not in the GMS Scheme for the full year have been excluded from the above table.
 (ii) Above table relates to the payments listed in Table 3 and includes the arrears paid resulting from the implementation of the 2005 LRC Agreement.
 (iii) Doctors payment is exclusive of superannuation paid to retired DMOs.
2005 (2004 in brackets)
04 05
Table 22 GMS: Number of Pharmacists in Dispensing Fee Ranges
Note: Pharmacies that left or entered the Scheme during the year are not included in the above table.
Health 
Service 
Executive
Up to 
€20,000
€20,001-
€40,000
€40,001-
€60,000
€60,001-
€80,000
€80,001-
€100,000
€100,001-
€120,000
€120,001-
€140,000
€140,001-
€160,000
€160,001-
€180,000
€180,001-
€200,000
€200,001-
€220,000
€220,001-
€240,000
€240,001 
and over
East Coast 
Area 5 (6)  (6) 7 (9) 9 () 0 (2)  (5) 9 (7)  (7) 6 (5) 4 (7) 2 (2)  () 2 (6)
South 
Western 
Area
7 (7) 22 (6) 6 (7) 26 (24) 20 (5)  (4) 4 (4) 8 (0) 8 (7) 9 (7) 5 (9) 4 (5)  (5)
Northern 
Area 2 (9) 9 (8) 9 (6) 2 (7) 2 (6) 9 (4) 5 (7) 9 (7)  (7) 7 (6)  (6) 5 () 0 (0)
Midland 2 () 5 (5) 4 () 4 ()  (4) 8 (4) 0 (0) 0 (7) 6 (5)  (4)  ()  (5) 4 (4)
Mid-
Western 2 (2) 2 ()  () 5 () 8 (2) 0 (7) 9 (0) 9 (7) 9 (8) 6 (4) 2 ()  () 5 ()
North 
Eastern 2 (4) 8 (7) 7 (6) 5 (0) 4 (7) 5 (0) 2 () 0 () 4 (6) 4 () 5 () - (2) 5 ()
North 
Western 4 () 2 (4) 6 (4)  (9) 9 () 7 (7) 5 (6) 6 (4)  (4) 5 (4) 2 (4)  (5) 8 (4)
South 
Eastern 6 (6) 5 (4) 7 (7) 6 (0)  () 6 (5) 9 (6) 8 () 2 (9) 8 (9) 4 (4) 4 (4)  (8)
Southern 7 (9)  (8) 8 (2) 4 (2) 2 (20) 26 (22) 2 (7) 5 (4)  (8)  (8) 4 (7)  (5)  (7)
Western 5 (2)  (0) 9 (0) 4 (8) 20 (6) 2 () 2 () 7 (7) 0 (6) 9 (7) 6 (9) 4 () 7 (5)
National 62 (59) 100 (79) 116 (106) 175 (149) 149 (136) 135 (139) 126 (123) 85 (89) 72 (65) 68 (59) 34 (48) 28 (36) 68 (55)
2005 (2004 in brackets)
06 07
Table 23 DP: Number of Eligible Persons and Number and Cost of Pharmacists Claims
Note:  *As at 31st December 2005.
Health Service 
Executive
*Number 
of Persons 
Covered
 Unique 
Number of 
Claimants
Number of 
Items
Cost per Item 
E
Gross Cost
E
Net Cost per 
Claimant  
E 
Paid by HSE 
E 
 Eastern Areas 508,9 85,60 4,5,027 7.67 55,770,98 54.26 00,457,9 
Midland 9,9 2,84 648,992 4.8 22,60,2 429.47 4,05, 
Mid-Western 5,566 48,756 9,744 5.79 ,48,07 425.0 20,726,49 
North Eastern 0,9 49,79 946,459 5.8 ,29,072 4.02 20,564,876 
North Western 64,25 9,026 65,789 6.77 ,448,480 442.68 8,422,499 
South Eastern 5,560 54,692 ,22,97 4.82 9,080,695 48.76 2,996,49 
Southern 248,02 89,48 ,622,59 7.06 60,2,89 47.85 7,7,22 
Western 0,9 45,905 806,922 7.52 0,274,554 40.45 8,84,555 
National 2005 1,478,650 526,052 10,581,689 €36.67 €388,021,077 €464.76 €244,485,938
National 2004 ,469,25 499,664 9,92,64 €5.5 €5,44, €448.22 €22,958,892
06 07
Table 23.1 DP: Number of Pharmacists in Dispensing Fee/Mark-Up Ranges
Note: (i) Pharmacies that entered or left the Scheme during the year are not included in the above table.
 (ii) The above figures do not include the monthly co-payment of €85 payable to the Pharmacy by an individual or family.
2005 (2004 in brackets)
Health 
Service 
Executive
Up to 
€20,000
€20,001 - 
€40,000
€40,001-
€60,000
€60,001-
€80,000
€80,001-
€100,000
€100,001-
€120,000
€120,001-
€140,000
€140,001-
€160,000
€160,001-
€180,000
€180,001-
€200,000
€200,001-
€220,000
€220,001-
€240,000
€240,001 
and over
East Coast 
Area 9 (6) 2 (8) 26 (2) 2 (7) 20 (5) 8 (9) 7 (4) 4 ()  () - () 5 (2) - ()  (-)
South 
Western 
Area
2 (20) 2 (27) 2 () 25 (22) 2 (6)  (0) 6 (7) 2 (9) 0 (9)  () 2 () - 7 (6)
Northern 
Area 7 (4) 25 (25) 7 (20) 2 (22) 9 (9) 20 (7) 0 (6)  (7) 2 (6) 6 (6) 5 (-) 2 () 4 ()
Midland 4 (6)  (2)  (5) 0 () 8 (6) 7 (8) 5 (4) 2 (-) - () 2 ()  (-) - -
Mid-
Western 4 (2) 29 (26) 2 (27) 25 (4) 4 (7) 5 (8) 4 ()  ()  () -  () - -
North 
Eastern 8 (0) 29 (0) 20 (20) 5 () 6 (7) 0 (7)  (6) 5 (4)  (2)  ()  (-) -  (-)
North 
Western 5 (20) 22 (8) 5 (4) 8 (8) 4 () 2 () 2 (-) - () -  () - - -
South 
Eastern 5 () 27 (28)  (29) 20 (24) 4 (8)  (8) 8 (7) 2 () - - - 2 () -
Southern 4 (9) 5 (58) 42 (5) 9 (0) 4 (0)  (0) 8 (7)  (4)  () 2 (4) 2 () 2 ()  ()
Western 28 (26) 0 (5) 2 (2) 6 (6) 0 (0) 0 (5) 5 () 2 ()  ()  (-) - - -
 National 145(144) 272 (277) 233 (233) 193 (177) 111 (91) 97 (85) 58 (47) 36 (29) 23 (24) 16 (19) 17 (5) 6 (6) 14 (10)
08 09
Table 24 LTI: Number of Eligible Persons and Number and Cost of Pharmacists Claims
Note:  *As at 31st December 2005.
Health Service Executive *Number of 
Eligible Persons
Unique Number 
of Claimants
Number of 
Items
Cost per Item 
E
Total  
Cost 
E
Cost per 
Claimant
E
Eastern Areas 52,044 22,520 844,66 5.5 45,06,8 2,000.94
Midland 5,40 ,08 ,245 52.45 5,940,055 ,927.96
Mid-Western 7,00 4,06 9,286 47.08 6,557,278 ,6.90
North Eastern 7,888 4,755 70,74 52.29 8,928,228 ,877.65
North Western 5,492 ,02 06,485 5.98 5,54,647 ,80.85
South Eastern 9,96 5,576 205,67 49.9 0,267,489 ,84.7
Southern 6,852 6,25 225,90 5.46 ,597,622 ,854.7
Western 4,657 ,75 2,664 5.86 6,660,4 ,78.7
National 2005 99,280 53,006 1,929,111 52.12 100,546,643 1,896.89 
National 2004 9,504 50,526 ,674,707 e5.08 e85,55,069 e,69.2 
08 09
Table 24.1 LTI: Number of Pharmacists in Dispensing Fee/Mark-Up Ranges
Note: Pharmacies that entered or left the Scheme during the year are not included in the above table.
2005 (2004 in brackets)
Health Service 
Executive
Up to €10,000 €10,001 - €20,000 €20,001- €30,000 €30,001- €40,000 €40,001- €50,000 €50,001 - €60,000 €60,001 and over
East Coast Area 2 (2) 25 (26) 8 (2)  (0) 4 (4) 7 (4) 6 ()
South Western 
Area
22 (2) 9 (45) 24 (26) 2 (22) 20 (8)  (9) 24 (9)
Northern Area 2 (7) 22 (27) 28 () 2 (24) 2 (5) 2 () 6 ()
Midland  ()  (7) 2 (7) 4 () 7 (7) 4 () 4 (2)
Mid-Western 5 (7) 47 (7) 2 (5) 7 (8) 4 ()  () 4 ()
North Eastern 8 (2) 27 (4) 8 () 20 () 6 (0) 5 () 7 ()
North Western 2 (7) 5 (7) 7 (7)  (7)  (6) 6 (-) 2 (2)
South Eastern 24 (25) 6 (5)  () 9 () 8 (9) 6 (-) 4 (4)
Southern 5 (60) 7 (65) 7 () 9 (4) 9 (7) 5 (2) 2 ()
Western 44 (4) 9 (45) 2 (7) 5 ()  ()  () 2 ()
National 250 (264) 334 (348) 231 (221) 164 (129) 95 (88) 58 (34) 81 (55)
0 
Table 25 EEA: Number and Cost of Pharmacists Claims
Health Service Executive Number of Items Cost per Item  

Total Cost  

East Coast Area ,9 20.6 64,0 
South Western Area 4,742 2.68 2,07 
Northern Area 2,77 22.42 62,92 
Midland ,94 22.84 77,502 
Mid-Western 8,46 22.67 84,670 
North Eastern 4,95 24.6 9,68 
North Western ,2 22.25 249,9 
South Eastern 9,88 24.09 27,992 
Southern 9,02 22.75 42,790 
Western 4,70 2.0 8,257 
National 2005 81,965 €22.93 €1,879,609
National 2004 80,50 €22.25 €,79,527
0 
Table 26 DTS: Number of Treatments
Health Service Executive Above the Line Below the Line Total
Eastern Areas 264,54 26,094 290,248 
Midland 5,924 6,728 58,652 
Mid-Western 82,458 0,8 9,29 
North Eastern 77,27 9,795 87,02 
North Western 75,7 5,29 80,702 
South Eastern 5,584 4,822 0,406 
Southern 78,04 7,445 95,549 
Western 8,22 5,420 ,542 
National 2005 962,936 106,466 1,069,402 
National 2004 968,665 04,850 ,07,55 
2 
Table 26.1 DTS: Number of Dentists in Payment Ranges
Note: Dentists who entered or left the Scheme during the year are not included in the above table.
Health 
Service 
Executive
 Up to 
€10,000 
 €10,001-
€20,000 
 €20,001-
€30,000 
 €30,001-
€40,000 
 €40,001-
€50,000 
 €50,001-
€60,000 
 €60,001-
€70,000 
 €70,001-
€80,000 
 €80,001-
€90,000 
 €90,001-
€100,000 
 €100,001-
€110,000 
 €110,001-
€120,000 
 €120,001 
and over 
Eastern 
Areas 4 (4) 9 (4) 40 (2) 28 (28) 7 (28) 8 (2) 5 (9) 2 (6) 4 (2)  (8) 0 (9) 4 (4) 7 (2)
Midland 4 (5) 4 () 4 (4)  (4) 6 (4) 4 () 5 (5) 4 (6) 2 (5) 2 (2) 4 (2)  ()  ()
Mid-
Western 5 (4) 7 (9) 8 (0) 0 (8)  () 2 (5) 4 (6) 4 (2) 2 (-) 2 (2)  (2)  () 9 (9)
North 
Eastern  (8) 4 (9) 8 (2) 0 (6) 9 (4) 8 (6) 5 () 8 (8)  (6) 6 (7) 4 (2) - ()  ()
North 
Western  (-) - ()  ()  (4)  (8) 4 ()  () 2 (4) 5 (4) 2 (-) 2 () 2 (4) 9 (6)
South 
Eastern 9 (6) 5 (6)  () 4 (9)  (4) 2 (0) 0 (8) 5 (8) 7 (8) 8 ()  (2) 2 (4) 8 (5)
Southern 9 (2) 27 () 7 (28) 26 (28) 25 (20) 0 (8) 2 (7) 4 (0)  (6)  () 8 () - (4) 9 (7)
Western 8 (25) 5 () 8 (0)  (7) 0 ()  (8) 8 (8) 9 (7) 0 (9) 7 ()  (4)  (4) 4 (2)
National 114 (115) 91 (107) 111 (110) 103 (94) 92 (100) 71 (72) 71 (67) 67 (61) 46 (50) 49 (28) 35 (25) 15 (25) 72 (53)
2005 (2004 in brackets)
2 
Table 27 HSE-COS: Number and Cost of Claims 
Health Service Executive Number of  Treatments Cost of Claims
E
Eastern Areas 2,22 4,77,686
Midland 26,4 ,075,79
Mid-Western 7,58 ,409,20
North Eastern ,420 ,225,70
North Western 5,92 ,28,706
South Eastern 59,79 2,98,744
Southern 64,070 2,48,926
Western 8,92 ,40,759
National 2005 417,533 15,833,940
National 2004 44,84 e6,27,620
Note: Optometrists/Ophthalmologists were also paid in respect of: Health (Amendment) Act 1996 €44,541; Optical services for Teenagers €83,210; Optical services for Children €1,038,488.
4 5
Table 27.1 HSE-COS: Number of Optometrists/Ophthalmologists in Payment Ranges
Note: Optometrists/Ophthalmologists who entered or left the Scheme during the year are not included in the above table.
Health 
Service 
Executive
 Up to 
€10,000 
 €10,001-
€20,000 
 €20,001-
€30,000 
 €30,001-
€40,000 
 €40,001-
€50,000 
 €50,001-
€60,000 
 €60,001-
€70,000 
 €70,001-
€80,000 
 €80,001-
€90,000 
 €90,001-
€100,000 
 €100,001-
€110,000 
 €110,001-
€120,000 
 €120,001 
and over 
Eastern 
Areas 48 (49) 4 (5)  (2)  (4) 8 (8) 5 (4)  ()  ()  () - - () 2 (-)  ()
Midland 2 () 6 (7)  () 6 (5)  ()  () - - () - - - () - (-)  (-)
Mid-
Western  (9) 6 (6)  ()  (4) 2 (2) - - -  (-) - () - - 2 (2)
North 
Eastern 7 (4) 0 (6)  (7) 2 ()  (2)  ()  () - - - - - -
North 
Western 6 ()  (2) 4 (5) 2 (2) 2 ()  () 2 (2) - - ()  (-) - - -
South 
Eastern 5 () 6 (7) 4 ()  () 5 (5) 6 (4) 2 ()  ()  (2)  (2)  (-) - () -
Southern 6 (6) 7 (9) 0 () 7 (7) 5 (2)  (5)  (-) - - () - -  (-)  ()
Western 8 (5) 9 (8) 8 (5) 4 (8)  (-) -  () - - ()  (-) - - () -
National 145 (130) 91 (80) 46 (51) 38 (44) 29 (25) 15 (16) 8 (6) 2 (3) 3 (6) 3 (3) 1 (2) 3 (2) 5 (4)
2005 (2004 in brackets)
4 5
Table 28 GMS: Investment in General Practice Development
Note: The above are payments from the Indicative Drug Target Savings.
Health Service Executive 2005
E
2004
E
Eastern Areas ,999,647 4,94, 
Midland 262,648 674,72 
Mid-Western 572,4 ,507,4 
North Eastern 409,79 700,40 
North Western 2,68,2 2,90,467 
South Eastern ,895,60 2,074,580 
Southern 2,85,906 ,848,55 
Western ,258,08 ,68,85 
National €11,932,845 €15,791,624 
6


